
<html lang="en"     class="pb-page"  data-request-id="e263c47a-4731-4649-beaf-630c35d38822"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.5b01522;requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2016.59.issue-1;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants" /></meta><meta name="dc.Creator" content="Hojong  Yoon" /></meta><meta name="dc.Creator" content="Yeonui  Kwak" /></meta><meta name="dc.Creator" content="Seunghye  Choi" /></meta><meta name="dc.Creator" content="Hanna  Cho" /></meta><meta name="dc.Creator" content="Nam Doo  Kim" /></meta><meta name="dc.Creator" content="Taebo  Sim" /></meta><meta name="dc.Description" content="Aberrant RET kinase signaling plays critical roles in several human cancers such as thyroid carcinoma. The gatekeeper mutants (V804L or V804M) of RET are resistant to currently approved RET inhibit..." /></meta><meta name="Description" content="Aberrant RET kinase signaling plays critical roles in several human cancers such as thyroid carcinoma. The gatekeeper mutants (V804L or V804M) of RET are resistant to currently approved RET inhibit..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 22, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01522" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01522" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01522" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01522" /></link>
        
    
    

<title>A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01522" /></meta><meta property="og:title" content="A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0012.jpeg" /></meta><meta property="og:description" content="Aberrant RET kinase signaling plays critical roles in several human cancers such as thyroid carcinoma. The gatekeeper mutants (V804L or V804M) of RET are resistant to currently approved RET inhibitors such as cabozantinib and vandetanib. We, for the first time, report a highly selective and extremely potent RET inhibitor, 6i rationally designed. Compound 6i inhibits strongly RET gatekeeper mutants and other clinically relevant RET mutants as well as wt-RET. This substance also significantly suppresses growth of thyroid cancer-derived TT cell lines and Ba/F3 cells transformed with various RET mutants. Docking studies reveal that the isoxazole moiety in 6i is responsible for binding affinity improvement by providing additional site for H-bonding with Lys758. Also, 6i not only substantially blocks cellular RET autophosphorylation and its downstream pathway, it markedly induces apoptosis and anchorage-independent growth inhibition in TT cell lines while having no effect on normal thyroid Nthy ori-3-1 cells." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01522"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01522">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01522&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01522&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01522&amp;href=/doi/10.1021/acs.jmedchem.5b01522" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 358-373</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01498" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01558" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hojong++Yoon">Hojong Yoon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yeonui++Kwak">Yeonui Kwak</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Seunghye++Choi">Seunghye Choi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hanna++Cho">Hanna Cho</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nam+Doo++Kim">Nam Doo Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Taebo++Sim">Taebo Sim</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Chemical Kinomics Research Center, Korea Institute of Science and Technology (KIST), 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul 136-791, Republic of Korea</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">KU-KIST Graduate School of Converging Science and Technology, Korea University, 145, Anam-ro, Seongbuk-gu, Seoul, 136-713, Republic of Korea</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Daegu-Gyeongbuk Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 706-010, Republic of Korea</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#8afee8f9e3e7cae1e3f9fea4f8efa4e1f8"><span class="__cf_email__" data-cfemail="a3d7c1d0cacee3c8cad0d78dd1c68dc8d1">[email protected]</span></a> or <a href="/cdn-cgi/l/email-protection#641006170d09240f0b1601054a05074a0f16"><span class="__cf_email__" data-cfemail="b0c4d2c3d9ddf0dbdfc2d5d19ed1d39edbc2">[email protected]</span></a>. Phone: +82-2-958-6437.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01522&amp;href=/doi/10.1021%2Facs.jmedchem.5b01522" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 358–373</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 10, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 September 2015</li><li><span class="item_label"><b>Published</b> online</span>22 December 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01522" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01522</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D358%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHojong%2BYoon%252C%2BYeonui%2BKwak%252C%2BSeunghye%2BChoi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D1%26contentID%3Dacs.jmedchem.5b01522%26title%3DA%2BPyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2BDerivative%2BContaining%2Ban%2BIsoxazole%2BMoiety%2BIs%2Ba%2BSelective%2Band%2BPotent%2BInhibitor%2Bof%2BRET%2BGatekeeper%2BMutants%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D373%26publicationDate%3DJanuary%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01522"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2415</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">23</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01522" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hojong&quot;,&quot;last_name&quot;:&quot;Yoon&quot;},{&quot;first_name&quot;:&quot;Yeonui&quot;,&quot;last_name&quot;:&quot;Kwak&quot;},{&quot;first_name&quot;:&quot;Seunghye&quot;,&quot;last_name&quot;:&quot;Choi&quot;},{&quot;first_name&quot;:&quot;Hanna&quot;,&quot;last_name&quot;:&quot;Cho&quot;},{&quot;first_name&quot;:&quot;Nam&quot;,&quot;last_name&quot;:&quot;Doo Kim&quot;},{&quot;first_name&quot;:&quot;Taebo&quot;,&quot;last_name&quot;:&quot;Sim&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;358-373&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01522&quot;},&quot;abstract&quot;:&quot;Aberrant RET kinase signaling plays critical roles in several human cancers such as thyroid carcinoma. The gatekeeper mutants (V804L or V804M) of RET are resistant to currently approved RET inhibitors such as cabozantinib and vandetanib. We, for the first time, report a highly selective and extremely potent RET inhibitor, 6i rationally designed. Compound 6i inhibits strongly RET gatekeeper mutants and other clinically relevant RET mutants as well as wt-RET. This substance also significantly suppresses growth of thyroid cancer-derived TT cell lines and Ba/F3 cells transformed with various RET mutants. Docking studies reveal that the isoxazole moiety in 6i is responsible for binding affinity improvement by providing additional site for H-bonding with Lys758. Also, 6i not only substantially blocks cellular RET autophosphorylation and its downstream pathway, it markedly induces apoptosis and anchorage-independent growth inhibition in TT cell lines while having no effect on normal thyroid Nthy ori-3-1 cells.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01522&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01522" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01522&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01522" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01522&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01522" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01522&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01522&amp;href=/doi/10.1021/acs.jmedchem.5b01522" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01522" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01522" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01522%26sid%3Dliteratum%253Aachs%26pmid%3D26652860%26genre%3Darticle%26aulast%3DYoon%26date%3D2016%26atitle%3DA%2BPyrazolo%255B3%252C4-d%255Dpyrimidin-4-amine%2BDerivative%2BContaining%2Ban%2BIsoxazole%2BMoiety%2BIs%2Ba%2BSelective%2Band%2BPotent%2BInhibitor%2Bof%2BRET%2BGatekeeper%2BMutants%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D1%26spage%3D358%26epage%3D373%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291864" title="Fluorescence resonance energy transfer">Fluorescence resonance energy transfer</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/jmcmar.2016.59.issue-1/20160114/jmcmar.2016.59.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Aberrant RET kinase signaling plays critical roles in several human cancers such as thyroid carcinoma. The gatekeeper mutants (V804L or V804M) of RET are resistant to currently approved RET inhibitors such as cabozantinib and vandetanib. We, for the first time, report a highly selective and extremely potent RET inhibitor, <b>6i</b> rationally designed. Compound <b>6i</b> inhibits strongly RET gatekeeper mutants and other clinically relevant RET mutants as well as wt-RET. This substance also significantly suppresses growth of thyroid cancer-derived TT cell lines and Ba/F3 cells transformed with various RET mutants. Docking studies reveal that the isoxazole moiety in <b>6i</b> is responsible for binding affinity improvement by providing additional site for H-bonding with Lys758. Also, <b>6i</b> not only substantially blocks cellular RET autophosphorylation and its downstream pathway, it markedly induces apoptosis and anchorage-independent growth inhibition in TT cell lines while having no effect on normal thyroid Nthy ori-3-1 cells.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10070" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10070" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">RET (REarranged during Transfection) is a single-pass transmembrane receptor tyrosine kinase that is mainly expressed in both the central and peripheral nervous system.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> This kinase contains Ca<sup>2+</sup>-dependent cell adhesion (cadherin) like domains and a cysteine rich region in its extracellular domain. Moreover, the tyrosine kinase domain of RET activates numerous intracellular signaling cascades in the cytosol.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> RET is activated by a complex of its coreceptors (GFRαs distributed within lipid rafts) and their distinct ligands (GDNF, neurturin, artemin, persephin). The ligand-<i>co</i>-receptor complex recruits monomeric RET and promotes its dimerization and autophosphorylation. After initial autophosphorylation at Y900 and Y905, subsequent autophosphorylations at Y981, Y1015, and Y1062 take place to generate centers that function as specific docking sites for numerous adaptor molecules. Y981 and Y1015 are binding sites for Src and PLCγ, respectively,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> while Y1062 is a binding site for various adaptor proteins, including Shc, ShcC, IRS1/2, FRS2, DOK 1/4/5, Enigma, ERK5, and MAPK. In addition, Y1062 engages in Ras/MAPK and PI3K/AKT signaling, which play roles in cell proliferation and survival.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">The results of several clinical studies show that deregulation of RET signaling can lead to thyroid cancers. For example, medullary thyroid carcinoma (MTC) arises either sporadically (75%) or as a consequence of germline RET mutation (25%). The inherited form of MTC includes multiple endocrine neoplasia type 2A (MEN2A), type 2B (MEN2B), and familial thyroid carcinoma (FMTC), which are characterized by missense mutations that are different in each genotype. RET point mutations in MEN2A take place predominantly at six cysteine residues in the extracellular domain, including C609, C611, C618, C620, C630, and C634.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Predominant among these is the mutation at C634, which accounts for 85% of the cases.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Mutations of the cysteine residues lead to the formation of intramolecular disulfide bonds and constitutive activation of RET kinase. MEN2B is principally characterized by the M918T mutation (95%) with 5% of cases involving the A833F mutation,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> both of which bring about conformational changes that lead to highly increased kinase activities.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In addition to these thyroid carcinomas, which are a consequence of oncogenic point mutations of RET, papillary thyroid carcinoma (PTC) is associated with specific chromosomal rearrangements of RET including, for example, CCDC6, PRKAR1A, NCOA, and TRIM24.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> These chimeric products (RET/PTC) lead to ligand independent dimerization of the kinase domain and constitutive activation. Additionally, several other chimeric RET proteins, containing fusions such as KIF5B-RET, CCDC6-RET, NCOA4-RET, and TRIM33-RET identified in lung adenocarcinoma, result in highly increased RET transcription that leads to tumorigenesis.</div><div class="NLM_p">To date, various small molecules that inhibit RET have been developed for the treatment of RET-deregulated thyroid malignancy and KIF5B-RET fusion-positive NSCLC.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Quinazoline-based vandetanib and quinoline-based cabozantinib are clinically approved for treatment of MTC patients and are in an ongoing phase II clinical trial for treatment of RET-rearranged NSCLC (NCT 01639508 for cabozantinib, NCT 01823068 for vandetanib).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Other small molecule kinase inhibitors are known to have a high binding affinity toward RET. These substances include alectinib, ponatinib, sorafenib, and several pyrazolopyrimidines such as PP1, PP2, and 1-isopropyl-3-(phenylethynyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> (<b>7a</b> reported by Peter Diner et al.) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Although PP1, PP2, and vandetanib effectively inhibit RET kinase activity in HEK293 cells driven by various RET/MEN2 mutants, these inhibitors are seldom able to inhibit gatekeeper mutants (V804M and V804L) of RET,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> which are frequently identified in familial and sporadic MTC in certain regions.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> V804 of RET is a gatekeeper residue that corresponds to specific codons, such as T315 in Bcr-Abl, V561 in FGFR1, T338 in Src, and T790 in EGFR, in which point mutations are crucial for drug resistance. The Bcr-Abl T315I is a mutation that leads to secondary acquired resistance to imatinib in Bcr-Abl positive CML patients,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and EGFR-T790M causes resistance to gefitinib in NSCLC patients.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The observations that the RET-V804G mutation leads to improved sensitivities to PP1 and PP2 while methionine mutations at these positions result in resistance to these drugs suggest that substitution of codon 804 with bulky residues causes steric hindrance with the inhibitors. In addition, the findings indicate that V804M and V804L mutations cause primary or secondary resistance in vandetanib-treated MTC patients.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">Recently, a few RET inhibitors that overcome inhibition blocking caused by the V804 mutation have been discovered. For example, the established ALK inhibitor, alectinib, was demonstrated to be efficacious in RET fusion protein-driven NSCLC and to have the ability to overcome KIF5B-RET V804L/V804M.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Ponatinib, reported to be a Bcr-Abl T315I inhibitor, also displays a potent activity against RET-V804M.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Finally, Pz-1, which was reported to be a dual pan-RET/VEGFR2 inhibitor, also exhibits kinase inhibitory activity on RET-V804M.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> It is important to note that none of the RET inhibitors described above possess high kinase selectivities and that most, including vandetanib and cabozantinib, display several adverse effects such as QTc prolongation, proteinuria, and high blood pressure, especially a consequence of strong VEGFR2 inhibition.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p">In the study described below, we devised a new strategy for the design of RET inhibitors. Based on the known crystal structure of the RET kinase domain (KD) complexed with PP1 and an analysis of the results of studies in which the previously described substance <b>7a</b> is docked with RET KD,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> we devised a novel strategy for the design of RET KD inhibitors. Specifically, we envisioned that inhibitor activity would be enhanced by replacement of the alkynyl group of <b>7a</b> with a small heterocyclic moiety, which can participate in hydrogen bonding interactions with RET KD. We selected the isoxazole ring for this purpose based on the hypothesis that this moiety would form a hydrogen bond with the ε-amino group of Lys758 that is positioned in the ATP binding site. In addition, we believed that like the alkyne moiety in <b>7a</b>, the isoxazole group would function as a rigid linker. Utilizing this strategy, we identified <b>6i</b> as a lead compound. The results of initial studies showed that this substance has strong kinase inhibitory activities against RET-V804M (IC<sub>50</sub> = 4 nM) and V804L (IC<sub>50</sub> = 21 nM) as well as on RET-wild type (IC<sub>50</sub> = 1.4 nM) and that it significantly suppresses growth of Ba/F3 cells transformed with RET-V804M (GI<sub>50</sub> = 320 nM) and RET-V804L mutants (GI<sub>50</sub> = 500 nM). The results of this effort are described below.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Representative RET inhibitors. (B) Rational design of novel isoxazole-containing RET inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16654" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16654" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">The routes used to synthesize the 3-(isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amines explored in this investigation are presented in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. In one pathway, the pyrazole ring in 3-bromo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>1</b>) was <i>N</i>-alkylated using 2-bromopropane in the presence of potassium carbonate in DMF. The bromo group in <b>2</b>, the product produced in this process, was replaced by a vinyl group to form <b>3</b> using a Stille coupling reaction with tributyl(vinyl)tin and Pd(PPh<sub>3</sub>)<sub>4</sub>. Dihydroxylation of <b>3</b> with OsO<sub>4</sub> and NMO, followed by oxidative cleavage using NaIO<sub>4</sub> produced the corresponding aldehyde <b>4</b>. Subsequent independent condensations of the aldehyde group in <b>4</b> with hydroxylamine and <i>O</i>-benzylhydroxylamine yielded the key oximes <b>5a</b> and <b>5b</b>. Oxime <b>5a</b> was used to optimize the nitrile oxide cycloaddition (NOC) reaction promoted by NBS/TEA, NaOCl, or <i>t</i>-BuOCl. Reaction of <b>5a</b> using NBS failed to bring about bromination and treatment of this substance with either NaOCl or <i>t</i>-BuOCl results in formation of only trace amounts of desired isoxazole product. Jawalekar et al. reported earlier that phenyliodine-bis(trifluoroacetate) (PIFA) promotes NOC reactions that generate isoxazoles or isoxazolines with excellent yields and levels of regioselectivity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> By utilizing this methodology, the desired NOC reactions of <b>5a</b> occur in moderate yields to form the corresponding isoxazole derivatives <b>6a</b>–<b>l</b>. Treatment of <b>6l</b> with cesium fluoride then affords the isoxazole ring unsubstituted analogue <b>7</b>.</div><div class="NLM_p">Another route developed for preparation of 3-(isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amines began with cyclopropyl ketone <b>8</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Reaction of <b>8</b> with diethyl oxalate in the presence of sodium hydride produced diketo-ester <b>9</b>, which reacted with hydroxylamine to form isoxazole <b>10</b>. Subsequent hydrolysis of the ester moiety in <b>10</b> formed the carboxylic acid <b>11</b>, which was transformed to the corresponding acid chloride by treatment with oxalyl chloride. Subsequent addition of malononitrile followed by methylation produced <b>14</b> in a 63% yield over three steps. Reaction of <b>14</b> with hydrazine yielded pyrazole <b>15</b>, which upon treatment with formamide at 160 °C generated pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine <b>16</b>. Preparation of the <i>N</i>-alkyl derivatives <b>17a</b>–<b>f</b> was accomplished by using Mitsunobu reactions with selected alcohols or by alkylation with alkyl halides in basic media.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Inhibitors <b>5a</b>–<b>b</b>, <b>6a</b>–<b>l</b>, and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagent and condition: (a) 2-bromopropane, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 69%; (b) tributyl(vinyl)tin, Pd(PPh<sub>3</sub>)<sub>4</sub>, toluene, reflux, 82%; (c) (i) OsO<sub>4</sub>, NMO, THF/H<sub>2</sub>O, 0 °C to rt; (ii) NaIO<sub>4</sub>, THF/H<sub>2</sub>O, 0 °C to rt; (d) hydroxylamine hydrochloride or benzyloxyamine hydrochloride, NaOAc, EtOH, rt, 72–89% over two steps; (e) styrene or various acetylenes, phenyliodine bis(trifluoroacetate), MeOH/H<sub>2</sub>O, rt, 17–32%; (f) <b>6l</b>, CsF, MeCN/EtOH, rt, 43%.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Inhibitors <b>16</b> and <b>17a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagent and condition: (a) diethyl oxalate, NaH, THF, 0 °C to rt, 92%; (b) hydroxylamine hydrochloride, MeOH, reflux, 88%; (c) NaOH, EtOH, rt, 100%; (d) oxalyl chloride, cat. DMF, CH<sub>2</sub>Cl<sub>2</sub>, rt; (e) malononitrile, DIPEA, THF, 0 °C; (f) dimethylsulfate, THF, reflux, 63% over three steps; (g) hydrazine dihydrochloride, TEA, EtOH, rt, 72%; (h) formamide, 160 °C, 82%; (g) a) R<sub>2</sub>-X (X = Br, I) or 2,2-dimethoxyoxirane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C or b) R<sub>2</sub>–OH, DIAD, PPh<sub>3</sub>, THF, rt, 32–81%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Structure–Activity Relationships</h3><div class="NLM_p"><i>In vitro</i> biochemical kinase assays with recombinant RET kinase were used to assess the kinase-inhibitory activities of the isoxazole derivatives prepared in the manner described above. The results show that <b>6b</b> has an IC<sub>50</sub> value of 0.190 μM against RET-wild type (WT) but that it displays no inhibitory activity against the RET-V804M gatekeeper mutant (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In addition, the oxime derivatives <b>5a</b> and <b>5b</b> have low inhibitory activities, which is consistent with the previous report that rigidity of linker is essential for this activity. Moreover, replacement of isoxazole ring in <b>6b</b> with an isoxazoline ring (<b>6a</b>) and the phenyl group in <b>6b</b> with a benzyl (<b>6c</b>) or 4-fluorophenyl (<b>6d</b>) group have no distinctive effects on inhibitory activity. Introduction of pyridine ring (<b>6e</b>) leads to a 5-fold decrease in activity (IC<sub>50</sub> = 0.910 μM) compared with that of <b>6b</b>, which could be a consequence of the existence of a highly hydrophobic back pocket in the kinase that accommodates the R<sub>1</sub> group.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">In contrast to the observation that replacements by several aromatic groups at R<sub>1</sub> do not alter activity, incorporation of small alkyl substituents at the R<sub>1</sub> position was found to lead to enhanced inhibitory activities. For example, introduction of small alkyl groups such as ethyl (<b>6f</b>) and isopropyl (<b>6g</b>) caused remarkable increases in activity. In contrast, introduction of the bulky <i>t</i>-butyl group (<b>6h</b>) at this position resulted in poor activity (IC<sub>50</sub> = 0.210 μM). Compared to the activity difference between <b>6g</b> and <b>6h</b>, the cyclopropyl group containing substance <b>6i</b> has excellent kinase-inhibitory activities against both RET-WT (IC<sub>50</sub> = 0.0014 μM) and V804M gatekeeper mutant (IC<sub>50</sub> = 0.004 μM). Encouraged by these observations, we explored kinase inhibition by cyclopentyl (<b>6j</b>, IC<sub>50</sub> = 0.241 μM) and cyclohexyl (<b>6k</b>, IC<sub>50</sub> = 0.910 μM) derivatives related to <b>6i</b>. The results show that these substances have activities that decrease as the size of ring increases. Finally, studies with <b>7</b>, in which the R<sub>1</sub> group is hydrogen, indicate that it has mediocre activity (IC<sub>50</sub> = 0.213 μM). This observation suggests that hydrophobic interaction between the R<sub>1</sub> group and a hydrophobic site in the kinase is essential for RET inhibitory activity. In summary, the combined results of this effort show that the cyclopropyl group containing isoxazole derivative <b>6i</b> has optimal kinase inhibitory activity.</div><div class="NLM_p">Our attention next turned to an evaluation of the effects on kinase inhibitory activity of changing the <i>N</i>-isopropyl group in <b>6i</b> to other <i>N</i>-alkyl groups (R<sub>2</sub>). The results show that elimination (<b>16</b>, IC<sub>50</sub> = 0.052 μM) or substitution of the <i>N</i>-isopropyl group with the relatively small methyl group (<b>17a</b>, IC<sub>50</sub> = 0.027 μM) leads to a lower activity than that of <b>6i</b>. Also, introduction of bulkier groups such as benzyl (<b>17b</b>), heptyl (<b>17c</b>), and 2,2-dimethyl propanol (<b>17d</b>) causes a decrease in activity. Even though substances containing cyclic substituents, like <b>17e</b> and <b>17f</b>, display higher activities (IC<sub>50</sub> = 0.002 and 0.005 μM, respectively) than their bulky acyclic analogues and exhibit comparable potency to <b>6i</b> on RET-WT, they are slightly less potent on RET-V804M gatekeeper mutant than <b>6i</b>, which contains an isopropyl group at the R<sub>2</sub> position.</div><div class="NLM_p">Encouraged by the excellent kinase inhibitory activities observed using the biochemical kinase assay, we next assessed the capability of the 3-(isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amines to inhibit RET in the two human-driven thyroid cell lines, TT and Nthy ori-3-1. TT cells are RET-dependent human thyroid cancer cells harboring a MEN2A-type mutation in the form of a C634W point mutation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Nthy ori-3-1 cells are a normal thyroid cell line, which are used as a control to assess the differential cytotoxicity of the RET inhibitors. As the data displayed in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> shows, GI<sub>50</sub> values of the 3-(isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amines against TT thyroid cancer cells range between 0.24 μM to over 10 μM. In addition, the trend observed in growth-inhibitory activities of the inhibitors on these cell lines well-matches with the trends seen in the enzymatic assay data. For example, <b>6i</b>, which showed the highest potency in the enzyme assay, is also highly potent against TT cells (GI<sub>50</sub> = 0.24 μM). However, the cellular activity of <b>6i</b> is slightly less than that of cabozantinib (GI<sub>50</sub> = 0.12 μM). It should be noted that cabozantinib blocks the growth of normal thyroid cells, Nthy ori-3-1, to a greater extent (GI<sub>50</sub> = 4.9 μM) than does <b>6i</b> (GI<sub>50</sub> = 13.7 μM), which suggests that the strong growth inhibitory effect of cabozantinib might be explained in part by off-target effects of cabozantinib, a multitargeted kinase inhibitor. The results show that the optimized oxazole derivative <b>6i</b> possesses remarkable potency against TT thyroid cancer cells and an excellent differential cytotoxicity (over 50-fold, TT GI<sub>50</sub> = 0.24 μM, Nthy ori-3-1 GI<sub>50</sub> = 13.7 μM). Meanwhile, among other tested substances, <b>17e</b> exhibited the greatest selectivity for TT thyroid cancer cells (GI<sub>50</sub> = 0.29 μM) over normal thyroid cells (GI<sub>50</sub> = 32.5 μM).</div><div class="NLM_p">In order to estimate kinase activity-dependent cellular activities of the new RET inhibitor in an accurate and efficient fashion, several engineered-Ba/F3 cell lines transformed with various RET mutations along with wild-type RET were constructed. The antiproliferative activities of the inhibitors on Ba/F3 cell lines transformed with wild-type and gatekeeper mutants (V804M) of RET were determined first. As expected, the trend in growth inhibitory activities of the inhibitors against these Ba/F3 cell lines closely matches the kinase-inhibitory trend observed in the biochemical kinase assay data. Compared with activities against RET-WT Ba/F3 cells, all the inhibitors except <b>6e</b> and <b>6k</b> are less potent against RET-V804M Ba/F3 cells. This observation is consistent with the results emanating from the biochemical kinase assays. Using the Ba/F3 cell based assay, we showed that the optimized substance <b>6i</b> has excellent potencies against RET-WT Ba/F3 (GI<sub>50</sub> = 0.08 μM) and RET-V804M Ba/F3 (GI<sub>50</sub> = 0.32 μM), which demonstrates that this substance has a remarkable inhibitory effect on RET-WT and RET-V804M at the cellular level.</div><div class="NLM_p">The results of studies designed to assess the <i>in vitro</i> microsomal stability and toxicity properties of <b>6i</b> (Tables S1 and S2 and Figure S1 in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) show that this substance has a moderate level of metabolic stability in human liver microsome (<i>T</i><sub>1/2</sub> = 13 min). Also, the four cytochrome P450 enzymes, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, are not inhibited by <b>6i</b> (IC<sub>50</sub> > 30 μM), while CYP1A2 is influenced to some extent (IC<sub>50</sub> = 2 μM). Moreover, no inhibition occurs even at 100 μM in the herg patch clamp assay, indicating that <b>6i</b> is free from cardiac toxicity caused by QT-interval prolongation.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Results of Biochemical Assays of the Inhibitory Activities of the 3-(Isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amines against RET-WT and RET-V804M</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0009.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">RET-WT</th><th class="colsep0 rowsep0" align="center">RET-V804M</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">4.90</td><td class="colsep0 rowsep0" align="left">3.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="center">benzyl</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="left">8.33</td><td class="colsep0 rowsep0" align="left">inactive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="center">phenyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.583</td><td class="colsep0 rowsep0" align="left">5.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="center">phenyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.190</td><td class="colsep0 rowsep0" align="left">inactive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="center">benzyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.241</td><td class="colsep0 rowsep0" align="left">1.99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="center">4-fluorophenyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.150</td><td class="colsep0 rowsep0" align="left">inactive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="center">2-pyridinyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.910</td><td class="colsep0 rowsep0" align="left">5.88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6f</b></td><td class="colsep0 rowsep0" align="center">ethyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.041</td><td class="colsep0 rowsep0" align="left">0.531</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6g</b></td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.041</td><td class="colsep0 rowsep0" align="left">0.355</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6h</b></td><td class="colsep0 rowsep0" align="center"><i>t</i>-butyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.210</td><td class="colsep0 rowsep0" align="left">2.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6i</b></td><td class="colsep0 rowsep0" align="center">cyclopropyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.0014</td><td class="colsep0 rowsep0" align="left">0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6j</b></td><td class="colsep0 rowsep0" align="center">cyclopentyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.241</td><td class="colsep0 rowsep0" align="left">1.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6k</b></td><td class="colsep0 rowsep0" align="center">cyclohexyl</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.910</td><td class="colsep0 rowsep0" align="left">inactive</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">isopropyl</td><td class="colsep0 rowsep0" align="left">0.213</td><td class="colsep0 rowsep0" align="left">0.903</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center">cyclopropyl</td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="left">0.052</td><td class="colsep0 rowsep0" align="left">0.354</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="center">cyclopropyl</td><td class="colsep0 rowsep0" align="center">methyl</td><td class="colsep0 rowsep0" align="left">0.027</td><td class="colsep0 rowsep0" align="left">0.182</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17b</b></td><td class="colsep0 rowsep0" align="center">cyclopropyl</td><td class="colsep0 rowsep0" align="center">benzyl</td><td class="colsep0 rowsep0" align="left">0.074</td><td class="colsep0 rowsep0" align="left">0.557</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17c</b></td><td class="colsep0 rowsep0" align="center">cyclopropyl</td><td class="colsep0 rowsep0" align="center"><i>n</i>-heptyl</td><td class="colsep0 rowsep0" align="left">0.096</td><td class="colsep0 rowsep0" align="left">0.927</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17d</b></td><td class="colsep0 rowsep0" align="center">cyclopropyl</td><td class="colsep0 rowsep0" align="center">2-methyl-propan-2-ol-1-yl</td><td class="colsep0 rowsep0" align="left">0.068</td><td class="colsep0 rowsep0" align="left">0.217</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17e</b></td><td class="colsep0 rowsep0" align="center">cyclopropyl</td><td class="colsep0 rowsep0" align="center">cyclohexyl</td><td class="colsep0 rowsep0" align="left">0.002</td><td class="colsep0 rowsep0" align="left">0.014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17f</b></td><td class="colsep0 rowsep0" align="center">cyclopropyl</td><td class="colsep0 rowsep0" align="center">tetrahydropyran-4-yl</td><td class="colsep0 rowsep0" align="left">0.005</td><td class="colsep0 rowsep0" align="left">0.041</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Radiometric biochemical kinase assay.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">“Inactive” means that the kinase activity was inhibited by less than 50% even at 10 μM concentration of the compound.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferation Activities of 3-(Isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amines against Various Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">GI<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">Ba/F3 cell lines</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">TT</th><th class="colsep0 rowsep0" align="center">Nthy ori-3-1</th><th class="colsep0 rowsep0" align="center">parental</th><th class="colsep0 rowsep0" align="center">RET-WT</th><th class="colsep0 rowsep0" align="center">RET-V804M</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cabozantinib</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.02</td><td class="colsep0 rowsep0" align="left">4.93 ± 0.49</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.05 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.89 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="left">2.54 ± 0.89</td><td class="colsep0 rowsep0" align="left">3.58 ± 0.88</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.61 ± 0.06</td><td class="colsep0 rowsep0" align="left">2.60 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">107 ± 14.1</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">9.27 ± 1.97</td><td class="colsep0 rowsep0" align="left">9.85 ± 1.59</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">7.41 ± 1.31</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">18.9 ± 1.21</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">6.24 ± 0.34</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">5.72 ± 2.06</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">3.46 ± 0.35</td><td class="colsep0 rowsep0" align="left">4.97 ± 1.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6c</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">21.5 ± 3.69</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6d</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">9.77 ± 5.82</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="left">9.26 ± 1.26</td><td class="colsep0 rowsep0" align="left">1.63 ± 0.12</td><td class="colsep0 rowsep0" align="left">5.30 ± 1.64</td><td class="colsep0 rowsep0" align="left">1.11 ± 0.35</td><td class="colsep0 rowsep0" align="left">0.70 ± 0.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6f</b></td><td class="colsep0 rowsep0" align="left">2.61 ± 0.09</td><td class="colsep0 rowsep0" align="left">28.6 ± 3.22</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">1.56 ± 0.52</td><td class="colsep0 rowsep0" align="left">5.77 ± 1.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6g</b></td><td class="colsep0 rowsep0" align="left">5.13 ± 0.07</td><td class="colsep0 rowsep0" align="left">23.7 ± 1.81</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">2.40 ± 0.61</td><td class="colsep0 rowsep0" align="left">5.90 ± 0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6h</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">24.7 ± 1.27</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">6.12 ± 0.62</td><td class="colsep0 rowsep0" align="left">7.31 ± 0.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6i</b></td><td class="colsep0 rowsep0" align="left">0.24 ± 0.05</td><td class="colsep0 rowsep0" align="left">13.7 ± 0.42</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.08 ± 0.00</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6j</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">11.5 ± 2.13</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">7.12 ± 1.67</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6k</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">4.11 ± 0.53</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">9.50 ± 1.49</td><td class="colsep0 rowsep0" align="left">4.73 ± 1.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">7.92 ± 1.15</td><td class="colsep0 rowsep0" align="left">18.6 ± 1.95</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">3.21 ± 0.05</td><td class="colsep0 rowsep0" align="left">8.94 ± 2.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.51 ± 0.04</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">5.34 ± 0.45</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="left">3.51 ± 0.04</td><td class="colsep0 rowsep0" align="left">28.7 ± 6.85</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">2.67 ± 0.69</td><td class="colsep0 rowsep0" align="left">5.56 ± 0.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17b</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">39.6 ± 1.95</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17c</b></td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">31.6 ± 4.01</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17d</b></td><td class="colsep0 rowsep0" align="left">4.25 ± 0.73</td><td class="colsep0 rowsep0" align="left">2.82 ± 0.50</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">1.77 ± 0.19</td><td class="colsep0 rowsep0" align="left">6.75 ± 1.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17e</b></td><td class="colsep0 rowsep0" align="left">0.29 ± 0.06</td><td class="colsep0 rowsep0" align="left">32.5 ± 7.16</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.52 ± 0.11</td><td class="colsep0 rowsep0" align="left">2.00 ± 0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17f</b></td><td class="colsep0 rowsep0" align="left">0.94 ± 0.19</td><td class="colsep0 rowsep0" align="left">32.9 ± 6.30</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">0.44 ± 0.30</td><td class="colsep0 rowsep0" align="left">1.93 ± 0.32</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">GI<sub>50</sub> represents the concentration at which a compound causes half-maximal growth inhibition. GI<sub>50</sub> values for Nthy ori-3-1 and transformed Ba/F3 cell lines were determined with SD values arising from three independent data sets, while those for TT cells and parental Ba/F3 cells were determined in a duplicate mode.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Inhibitory Activities of <b>6i</b> against Clinically Relevant RET Mutants</h3><div class="NLM_p">The next phase of this investigation was designed to gain more detailed information about the inhibitory activities of <b>6i</b> and two reference compounds, cabozantinib and <b>7a</b>, against other oncogenic RET mutants as well as the V804M gatekeeper mutant. For this purpose, the activities of these substances against clinically relevant RET mutants (G691S, Y791F, V804L, V804M, S891A, and M918T) were determined using an <i>in vitro</i> biochemical kinase assays. As shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, <b>6i</b> has excellent kinase inhibitory activities against all of the clinically relevant RET mutants, with IC<sub>50</sub> values ranging from 1.4 to 21 nM. Moreover, <b>6i</b> is much more potent than <b>7a</b> against all of the RET mutants tested. In particular, <b>6i</b> has a several hundred-fold higher (over 600-fold for V804M and over 100-fold for V804L) potency against RET gatekeeper mutants relative to that of <b>7a</b>. Furthermore, <b>6i</b> also displays a 10- to 90-fold greater kinase-inhibitory activity against V804L/M gatekeeper mutants as compared to cabozantinib. Both <b>7a</b> and cabozantinib are much less active against RET gatekeeper mutants compared to RET-WT, while <b>6i</b> is highly potent against both RET gatekeeper mutants and RET-WT.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Activities of <b>6i</b>, Cabozantinib, and <b>7a</b> against Clinically Relevant RET Mutants</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>6i</b></th><th class="colsep0 rowsep0" align="center">cabozantinib</th><th class="colsep0 rowsep0" align="center"><b>7a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center"><b>Enzyme assay (IC</b><sub><b>50</b></sub>, <b>nM)</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-WT</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-G691S</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-Y791F</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-V804L</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">230</td><td class="colsep0 rowsep0" align="left">3130</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-V804M</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">358</td><td class="colsep0 rowsep0" align="left">2650</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-S891A</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-M918T</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="center"><b>Ba/F3 Cell Assay (GI</b><sub><b>50</b></sub>, <b>μM)</b><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Parental</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">16.1 ± 5.98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-WT</td><td class="colsep0 rowsep0" align="left">0.08 ± 0.00</td><td class="colsep0 rowsep0" align="left">0.05 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.61 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-V804L</td><td class="colsep0 rowsep0" align="left">0.50 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.91 ± 0.03</td><td class="colsep0 rowsep0" align="left">5.43 ± 0.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-V804M</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.89 ± 0.03</td><td class="colsep0 rowsep0" align="left">2.60 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET-S891A</td><td class="colsep0 rowsep0" align="left">0.09 ± 0.26</td><td class="colsep0 rowsep0" align="left">0.01 ± 0.00</td><td class="colsep0 rowsep0" align="left">0.35 ± 0.03</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Radiometric kinase assay.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">All GI<sub>50</sub> values, except those for parental and RET-V804M Ba/F3 cells, were determined in a duplicate mode.</p></div></div></div><div class="NLM_p last">The growth inhibitory activities of <b>6i</b>, cabozantinib, and <b>7a</b> on parental Ba/F3 and three different Ba/F3 cell lines transformed with RET mutations, including gatekeeper mutations, were also determined (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). None of the three compounds was observed to suppress significantly the proliferation of parental Ba/F3 cells. Inhibitor <b>6i</b> exhibits profound antiproliferative activities on RET-WT Ba/F3 and three Ba/F3 cells harboring three RET point-mutations (V804L, V804M, or S891A), and more significantly, it blocks proliferation of Ba/F3 cells harboring gatekeeper mutations to a greater extent than does cabozantinib. Cabozantinib and <b>6i</b> have double-digit nanomolar potencies against Ba/F3 cells transformed with RET-WT and RET-S891A. Finally, the antiproliferative activities of <b>7a</b> against Ba/F3 cells transformed with gatekeeper mutations (V804L and V804M) is low, a finding that is consistent with its low inhibition activities against gatekeeper mutants in biochemical kinase assays.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Molecular Docking Study of <b>6i</b></h3><div class="NLM_p">To gain a better understanding of the source of the activity differences between <b>6i</b>, cabozantinib, and <b>7a</b> against RET-WT and its gatekeeper mutants, docking studies were performed using the Schrödinger docking program, Glide. Analysis of the binding mode predicted using this docking method shows that <b>6i</b> forms hydrogen bonds with both Glu805 and Ala807 in the hinge region. In addition, the cyclopropyl group in <b>6i</b> occupies a hydrophobic back pocket in the ATP binding site and the oxygen atom of isoxazole moiety acts as hydrogen bond acceptor for interaction with the ammonium group of Lys758 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A,B). The additional hydrogen bonding interaction caused by the presence of the isoxazole group and H-bonding contacts to the kinase hinge appear to be the major contributing factors making <b>6i</b> a more potent RET inhibitor than <b>7a</b>. In addition, the hydrogen bonding interactions with the isoxazole moiety might also be the reason why <b>6i</b> has a high affinity for RET gatekeeper mutants. Furthermore, the relatively small cyclopropyl group in <b>6i</b> seems to be sterically less affected by the bulky groups present in the gatekeeper point mutants, M804 and L804.</div><div class="NLM_p">We also carried out docking studies on complexes between the two reference compounds, <b>7a</b> and cabozantinib, and the RET-V804M gatekeeper mutant. The goal was to understand why these substances are much less potent inhibitors of the gatekeeper mutant as compared to RET-WT. Based analysis of the docking model of the complex, the phenyl group of <b>7a</b> is located in the hydrophobic pocket of the kinase where it is involved in a steric interaction with the bulky group that is present in M804 but not in V804. This interaction might be the cause of the substantially lower activity of <b>7a</b> against the V804M mutant (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C,D). The results of the docking studies show that cabozantinib binds to the DFG-out inactive conformation, which is characteristic of a type II kinase inhibitor, and decreased activity of cabozantinib against V804M might be a consequence of a steric interaction between the bridge phenyl ring and a bulky group in the V804M mutant (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>E,F).</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking models of (A,B) <b>6i</b>, (C,D) <b>7a</b>, and (E,F) cabozantinib bound to RET kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV">2IVV</a> for <b>6i</b> and <b>7a</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8">3LQ8</a> for cabozantinib). Hydrogen bonds are depicted as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Kinase Selectivity Profile of <b>6i</b></h3><div class="NLM_p">The inhibition selectivity of <b>6i</b> was assessed using a panel of 332 kinases [Reaction Biology, USA] and an <i>in vitro</i> biochemical autophosphorylation assay at a single concentration of 1 μM. The results show that <b>6i</b> displays an excellent kinase selectivity with a 0.02 selectivity score S<sub>10</sub> value, defined as the percentage of the kinases showing >90% inhibition out of the total (332) number of kinases profiled (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). The kinases, which are inhibited by <b>6i</b> (1 μM) to an extent of >80%, are RET, p70S6K, PKA, FLT4, MEK2, FGR, VEGFR2, MEK1, HCK, and RSK1. IC<sub>50</sub> values of <b>6i</b> against these 10 kinases were determined in order to assess its selectivity for RET (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B). The IC<sub>50</sub> values for the 10 kinases are in the range of 23–311 nM, showing that <b>6i</b> possesses an approximately 16–200-fold selectivity for RET (IC<sub>50</sub> = 1.4 nM).</div><div class="NLM_p">It has recently been reported that cabozantinib and vandetanib cause VEGFR2-related adverse effects such as high blood pressure and proteinuria in patients with thyroid cancer.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> As a result, a significant effort is being given to the discovery of inhibitors that are more selective for RET over other kinases including VEGFR2. From this perspective, <b>6i</b> is advantageous because it is a much less potent inhibitor of VEGFR2 (IC<sub>50</sub> = 96 nM) relative to RET (IC<sub>50</sub> = 1.4 nM). We further demonstrated that this selectivity exists at the cellular level using VEGFR2 Ba/F3 cells (<a class="ref internalNav" href="#notes-1" aria-label="Figure S2">Figure S2</a>). In a manner that is different from the high potency of cabozantinib (GI<sub>50</sub> = 3 nM), <b>6i</b> exhibits only a moderate antiproliferative activity on VEGFR2-Ba/F3 cells (GI<sub>50</sub> = 3 μM). This result suggests that <b>6i</b> might have an important pharmacological advantage in that it may not trigger VEGFR2-driven adverse effects.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) KinomeScanTreeSpot description of the <b>6i</b> selectivity profile. <b>6i</b> was screened against a 332 kinase panel at a concentration of 1 μM. Scores for primary screen hits are reported as a percent of the DMSO control (% control). (B) Biochemical IC<sub>50</sub>s of <b>6i</b> measured with selected kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Inhibition of RET Signaling in Cancer Cell Lines by <b>6i</b></h3><div class="NLM_p">The capability of <b>6i</b> to block RET signaling in a cellular context was evaluated. First, the effects of <b>6i</b>, <b>7a</b>, and cabozantinib on RET phosphorylation and its downstream signaling on Ba/F3 cell lines transformed with several RET variants (WT, V804M, V804L, and S891A) were determined. In its phosphorylated state, Y905 located in the A-loop enables the RET kinase domain to exist in the active conformation, and Y1062 plays a role as a docking site for multiple adaptor molecules.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In agreement with <i>in vitro</i> assay data, <b>6i</b> and cabozantinib effectively inhibit the level of phosphorylation of RET and its adaptor molecules such as PLCγ and Shc in RET-WT Ba/F3 and RET-S891A Ba/F3 cells. In contrast, <b>7a</b> is a less effective inhibitor of phosphorylation (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A,B). More importantly, <b>6i</b> and cabozantinib suppress RET phosphorylation in RET-V804L/V804M Ba/F3 cells in a dose-dependent manner (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C,D). Notably, <b>6i</b> more effectively blocks RET phosphorylation in RET-V804M Ba/F3 cells than does cabozantinib, an observation that is consistent with the results of <i>in vitro</i> biochemical kinase assays. In contrast to <b>6i</b> and cabozantinib, <b>7a</b> is unable to block RET signaling in RET-V804L/V804M Ba/F3 cells even at a high concentration of 10 μM.</div><div class="NLM_p">In order to investigate further their abilities to abrogate autophosphorylatoin of RET kinase and its downstream signaling, the effects of <b>6i</b>, cabozantinib, and <b>7a</b> on TT cells harboring RET-C634W mutation were evaluated (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>E). Autophosphorylation of RET at Y905 and Y1062 is effectively attenuated by 1 μM <b>6i</b> and cabozantinib, while <b>7a</b> does not exhibit significant inhibition at this concentration. Phosphorylation of RET downstream molecules, such as PLCγ, AKT, and ERKs, is also much more effectively blocked by <b>6i</b> and cabozantinib than by <b>7a</b>. In addition, <b>6i</b> much more strongly suppresses cellular phosphorylation of S6 than does cabozantinib. This observation is consistent with the finding that <b>6i</b> inhibits p70S6K, a direct upstream regulator of S6, with an IC<sub>50</sub> value of 23 nM in the biochemical kinase assay (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B).</div><div class="NLM_p">The cellular activity of <b>6i</b> against GDNF-induced phosphorylation of ERK1/2 in MCF-7 breast cancer cells was explored (<a class="ref internalNav" href="#notes-1" aria-label="Figure S3">Figure S3</a>). GDNF (glial cell derived neurotrophic Factor) is known<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> to induce RET-dependent phosphorylation of ERK1/2. In accordance with the previous report,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> addition of GDNF results in an increase in ERK1/2 phosphorylation. Importantly, <b>6i</b> effectively inhibits GDNF-induced phosphorylation of ERK1/2 even at a 100 nM concentration.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Autophosphorylation of RET and its downstream signaling are blocked by <b>6i</b>. The effect of <b>6i</b> on autophosphorylation of RET in (A) RET-WT Ba/F3, (B) RET-S891A Ba/F3, (C) RET-V804L Ba/F3, and (D) RET-V804M Ba/F3. (A–D) Ba/F3 cells, stably transformed with the indicated constructs, were treated for 1 h with gradually increasing concentrations of <b>7a</b>, cabozantinib, and <b>6i</b> (0–10 μM) and then lysed. Protein extracts were immunoblotted with antibodies specific for the Y905 and Y1062 phosphorylated forms of RET. Actin was used as loading control. (E) TT cells were treated with <b>6i</b> (0.1, 1, and 10 μM), cabozantinib, and <b>7a</b> (1 and 10 μM) for 4 h. Cell lysates were immunoblotted with the indicated antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Effects of <b>6i</b> on Apoptosis and Cell Cycle Arrest in TT and Nthy ori-3-1 Cell Lines</h3><div class="NLM_p">The effects of <b>6i</b>, cabozantinib, and <b>7a</b> on apoptosis induction and cell cycle arrest in both TT and Nthy ori-3-1 cell lines were determined. The results show that <b>6i</b> and cabozantinib do not induce cell cycle arrest, but they do promote increased apoptosis in TT cells (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A,C). Apoptosis induction caused by <b>6i</b> was also confirmed by immunoblotting apoptosis markers, which showed an increase in cleaved PARP1/2 and the increased amount of PUMA, a pro-apoptotic marker (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>E). It is worthwhile to note that cabozantinib at a concentration of 10 μM also causes cell cycle arrest in the G2 phase and apoptosis in the normal thyroid cell line, Nthy ori-3-1 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B,D), while <b>6i</b> at 10 μM does not. This observation indicates that <b>6i</b> has appreciable selectivity for thyroid cancer cells over normal cells while cabozantinib does not. Meanwhile, <b>7a</b> does not cause significant cell cycle arrest and apoptosis in either TT or Nthy ori-3-1 cells.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>6i</b> induces apoptosis in TT cells but not in Nthy ori-3-1. Effects of <b>7a</b>, <b>6i</b>, and cabozantinib on cell cycle arrest of (A) TT cells and (B) Nthy ori-3-1 cells. TT cells and Nthy ori-3-1 cells were incubated with the indicated compounds for 48 and 24 h, respectively. Cells, fixed with 70% ethanol, were stained with propidium iodide and analyzed by using flow cytometry. (A,B) The left panel contains a representative image obtained from the flow cytometric analysis of cell cycle arrest. Bar graphs in the right panel contain means ± SDs for three independent experiments on Nthy ori-3-1 cells and for two independent sets on TT cells. Effects of <b>7a</b>, <b>6i</b>, and cabozantinib on apoptosis of (C) TT cells and (D) Nthy ori-3-1 cells. The indicated concentrations of the compounds were incubated with TT cells for 96 h and Nthy ori-3-1 cells for 48 h. Cells were harvested and incubated in a binding buffer containing propidium iodide and annexin V and then analyzed by using flow cytometry. (C,D) The left panel contains a representative image of the flow cytometric analysis of apoptosis. In the right panel are bar graphs that indicate the mean ± SDs for three independent experiments. **<i>p</i> < 0.01, ***<i>p</i> < 0.001, one way ANOVA tested. (E) Treatment with <b>6i</b> for 96 h induces cleavage of PARP1/2, while increasing the expression of PUMA in TT cells. Actin was used as the loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Inhibition of Anchorage-Independent Growth of TT Cells by <b>6i</b></h3><div class="NLM_p">In the final phase of this effort, we investigated the antitumor effect of <b>6i</b> by utilizing the soft agar assay (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Incubation with <b>7a</b> at two different concentrations (0.3 and 1 μM) for 30 days does not suppress anchorage-independent growth with a mean value of 150 colonies. On the contrary, incubation with either <b>6i</b> or cabozantinib causes TT cells to form in significantly lower numbers (# < 3) and in smaller colonies in soft agar (<i>p</i> < 0.001). Treatment with 0.3 μM <b>6i</b> also leads to prevention of RET-driven oncogenic transformation of TT cells. The effect caused by 0.3 μM <b>6i</b> is comparable to that promoted by 1 μM cabozantinib, indicating that <b>6i</b> is more effective in inhibiting anchorage-independent growth of TT cells.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Anchorage independent growth of TT cells is suppressed by treatment with <b>6i</b>. (A–G) Effects of <b>7a</b>, <b>6i</b>, and cabozantinib on anchorage-independent growth of TT cells in soft agar. (A–F) A representative colony under each indicated condition was photographed after crystal violet staining at 400× magnification. Bar = 0.2 mm. (G) Soft agar assays were performed three times. Total colonies in each well were automatically counted using ImageJ software. The average number of colonies (<i>n</i> = 3) are presented with ± SD, ***<i>p</i> < 0.001, one way ANOVA tested.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70860" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70860" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In the investigation described above, we rationally designed and synthesized a series of novel 3-(isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amines containing an isoxazole moiety, and carried out a biological evaluation of their RET kinase inhibitor activities and selectivities. The strategy employed to design these substances arose from an analysis of important interactions that exist in the crystal structure of RET kinase domain complexed with PP1 and a model obtained by docking of <b>7a</b> (reported by Peter Diner et al.) in the RET kinase domain. The results of an SAR study, led to the identification of the 3-(isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine <b>6i</b> as an optimal RET inhibitor. The results of biochemical kinase assays show that this substance has single-digit nanomolar IC<sub>50</sub> values against V804M gatekeeper mutant (IC<sub>50</sub> = 4 nM) and RET-WT (IC<sub>50</sub> = 1.4 nM). In addition, <b>6i</b> has a high potency against Ba/F3 cells transformed with RET-V804M. The results of molecular docking studies suggest that hydrogen bonding interaction between the isoxazole ring in <b>6i</b> and the Lys758 ammonium group in the kinase is important in causing the high inhibitory activities of <b>6i</b>. Kinome-wide selectivity profiling, using 332 kinases, revealed that <b>6i</b> displays an excellent selectivity (five ones of 332 kinases are inhibited over 90% by 1 μM of <b>6i</b>) for RET over other kinases including VEGFR2, whose inhibition is thought to be the main cause of the adverse effects of vandetanib and cabozantinib. Considering the fact that no selective RET inhibitor that is capable of blocking RET gatekeeper mutant has been uncovered to date, observations made in studies with <b>6i</b> are significant. Also, we observed that <b>6i</b> substantially suppresses proliferation of thyroid cancer-derived TT cells harboring the C634W-RET mutant and significantly blocks RET autophosphorylation and downstream signaling. A remarkable level of apoptosis is promoted by <b>6i</b> and this substance is a more effective than cabozantinb as a selective inhibitor on TT cell lines over noncancerous thyroid Nthy ori-3-1 cells. Moreover, <b>6i</b> is more effective in inhibiting anchorage-independent growth of TT cells rather than cabozantinb. Taken together, the capability of <b>6i</b> to inhibit both RET-wild type and its gatekeeper mutant in a highly potent and selective manner highlights its potential therapeutic value for treatment of RET mutation-driven diseases. Finally, the isoxazole ring containing pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine <b>6i</b> provides insight into structural features and functionality that need to be considered when designing selective and potent RET inhibitors capable of overcoming RET gatekeeper mutations.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Compounds</h3><div class="NLM_p last">All the compounds used in this research were synthesized except cabozantinb, which was purchased from ChemScene LLC. Every compound was diluted in 100% DMSO stock, and diluted compound was directly treated to cells by adapting final DMSO concentration to 0.5% (v/v).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Cell Culture</h3><div class="NLM_p last">TT cells were grown in RPMI media supplemented with 15% FBS and 1% antibiotics. Parental Ba/F3 cells were grown in RPMI supplemented with 10% FBS in the presence of IL-3, and all RET-WT, RET-V804L, RET-V804M, RET-S891A, and VEGFR2 transformed Ba/F3 cell lines were cultured in IL-3-free RPMI media supplemented with 10% FBS and 1% antibiotics. Nthy ori-3-1 cells were grown in RPMI1640 media supplemented with 10% FBS, 2 mM glutamine, and 1% antibiotics.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Kinase Profiling and Kinase Assay</h3><div class="NLM_p last">Biochemical kinase assay and kinome profiling were performed by Reaction Biology Corp. (San Diego, CA). In biochemical kinase assay, test compounds were tested with ATP (10 μM) and RET enzymes (RET-WT, 2 nM; RET-G691S, 90 nM; RET-Y791F, 1.5 nM; RET-V804L, 2.5 nM; RET-V804M, 60 nM; RET-S891A, 3 nM) in a 10-dose IC<sub>50</sub> mode with 3-fold serial dilution starting at 10 μM. In kinase profiling, <b>6i</b> (1 μM) was tested at a concentration of 10 μM ATP against 332 recombinant human kinases in duplicate mode.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Growth Inhibition of Thyroid Cell Lines</h3><div class="NLM_p last">TT cells were seeded at a density of 10,000 cells/well in a 96-well plate. The next day, compound (0.5% DMSO) was treated to the cells in a 10-dose GI<sub>50</sub> mode with 1:3 serial dilution in DMSO. Ten days later, growth of compound-treated TT cells relative to DMSO-treated one was measured using MTT assay kit (Promega, USA). Dose–response curve was fit utilizing Graphpad prism 5.0 software. GI<sub>50</sub> values on Nthy ori-3-1 cells were determined 3 days after compound treatment in the same way as TT cells and SD values were determined by replicating each assay three times independently.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Site-Directed Mutagenesis (SDM)</h3><div class="NLM_p">Point mutations of RET were generated by site direct mutagenesis using QuickChange kit (Stratagene) and the following primers.</div><div class="NLM_p last">After Dpn I digestion, competent <i>E. coli</i> cells were transformed with the point-mutated plasmids and spread on an ampicilin-positive LB agar plate. After inoculation and shaking incubation (200 rpm, 37 °C), plasmid DNA was isolated using plasmid DNA miniprep Kit (Qiagen). Intended mutation was confirmed by sequencing open reading frame of RET.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Construction of Stable Ba/F3 Cells Expressing RET-TEL Kinases and Ba/F3 Cell Viability Assay</h3><div class="NLM_p last">RET-TEL gene was introduced into Ba/F3 cells using Platinum-A (Plat-A) retroviral packaging system. Plat-A cells were transfected with the pBabe-puro plasmid DNA encoding RET-TEL fusion gene using lipofectamine 2000. Eighteen hours later, supernatant above transfected-plat-A cells was harvested and filtered through 0.22 μm filter. RET-TEL transformed Ba/F3 cells were generated using retroviral infection to parental Ba/F3 cells. Cells were selected in growth media containing 3 μg/mL puromycin and 10 ng/mL IL-3 for 5 days, followed by the incubation without IL-3 supplement for another 5 days. To generate RET mutants, V804M, V804L, and S891A were introduced into RET-TEL plasmid using site-directed mutagenesis. Each RET, RET-V804M, RET-V804L, or RET-S891A transformed Ba/F3 cells were seeded in a 96-well plate at a density of 10000/well and after stabilization of a few hours, treated with each concentration of the compounds on the same day. After 48 h, cells were assessed by MTT assay. The GI<sub>50</sub> values were calculated using Graphpad Prism version 5.0 (Graphpad Software Inc.).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Cell Cycle Arrest and Apoptosis Analysis</h3><div class="NLM_p last">The day after cells were plated to 100 mm<sup>2</sup> dishes, compounds (0.5% DMSO) were treated to medullar thyroid cancer TT cells expressing C634W RET mutant and normal thyroid Nthy ori-3-1 cells. Two days later, Nthy ori-3-1 cells were harvested by trypsinization, incubated with annexin V (1:500 diluted in ice-cold annexin V binding buffer) for 30 min, and PI (1:200) solution was added right before flow cytometry analysis. TT cells were analyzed 4 days after compound treatment as were Nthy ori-3-1. For cell cycle arrest analysis, cells were harvested by trypsinization and fixed with 70% ethanol overnight at −20 °C. The next day, cells were harvest by centrifugation at 1000 × <i>g</i> and washed with ice-cold DPBS at 500 × <i>g</i>. The supernatant was removed out, and the remaining pellet was suspended in RNase/PI solution (Cell Signaling, #4087)</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Soft Agar Assay</h3><div class="NLM_p last">Top agar (0.5%) containing 7000 cells/1 mL was plated on presolidified 0.7% base agar per well. Compound-added media were fed onto top agar after the complete solidification of top agar and refreshed twice a week. Spheroids were fixed and stained using 0.005% crystal violet in 4% formaldehyde for over 1 h and washed with DPBS for several times. Spheroid was magnified 400× and photographed. Colonies in each well were counted using threshold function of image J software.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Western Blot</h3><div class="NLM_p last">TT cells were seeded in 60 mm<sup>2</sup> dishes and treated with compounds for 4 h, while Ba/F3 cell lines were treated with the indicated compounds for 1 h. After brief washing with ice-cold PBS twice, cells were lysed in a buffer (50 mM HEPES, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl) containing 1× protease inhibitor (Roche) and 1× phosphatase inhibitor (Roche). All primary antibodies used for phospho-form of RET (Y905, #3221), PLCγ (Y783 #2821), AKT (T308, #9275), AKT (S473, #9171), ERK1/2 (T202/Y204, #4370), and VEGFR2 (Y1175, #3770) and total form of RET (#3220), AKT (#9272), ERK (#9102), VEGFR2 (#2479), and PUMA (#12450) were purchased from Cell Signaling Technologies. Anti-TEL (H-214, sc-11382), anti-PARP 1/2 (H-250, sc-7150), and antiactin (C4, sc-47778) primary antibodies as well as antirabbit and antimouse HRP-conjugated secondary antibodies were products of Santa Cruz. Antiphospho-RET (Y1062, ab51103) antibody was purchased from Abcam. Western blot analysis was conducted after loading and separation of equal amount of protein by SDS-PAGE gel and transfer to PVDF membrane. All primary antibodies were uniformly prediluted in TBS-T at 1:1000 (v/v) except for actin (1:5000), while all secondary antibodies were prediluted in 1% skim milk (in TBS-T) at 1:3000.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Molecular Modeling</h3><div class="NLM_p last">The crystal structure of type I RET kinase from Protein Data Bank (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV">2IVV</a>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> a complex with the inhibitor PP1) was used for docking simulations. The currently available, type II RET kinase structure has not been reported. Therefore, the type II model of RET kinase was constructed using the homology modeling method based on the RET sequence and the c-MET kinase structure (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8">3LQ8</a><a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>) as template with BIOVIA Discovery Studio 4.5. The gatekeeper mutant model structure of RET kinase was constructed using the rapid torsion scan tool in Maestro. Models of RET kinase inhibitors were constructed using Maestro build panel and minimized using the Impact module of Maestro in the Schrödinger suite program. The initial structures of the RET kinase were further modified for docking. The protein structure was minimized using the Protein Preparation Wizard by applying an OPLS force field. After complete preparation of the ligands and protein for docking, receptor-grid files were generated. Ligand docking into the ATP binding site of RET kinase was carried out using the Schrödinger docking program, Glide. The energy minimized RET kinase inhibitors were docked into the prepared receptor grid. The best-docked pose was selected as the lowest Glide score. The molecular graphics for the inhibitor binding pocket and refined docking model for the selected inhibitors were generated using PyMol (<a href="http://www.pymol.org" class="extLink">http://www.pymol.org</a>).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Chemistry</h3><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Information</h4><div class="NLM_p">Unless otherwise described, all commercial reagents and solvents were purchased from commercial suppliers and used without further purification. All reactions were performed under N<sub>2</sub> atmosphere in flame-dried glassware. Reactions were monitored by TLC with 0.25 mm E. Merck precoated silica gel plates (60 F254). Reaction progress was monitored by TLC analysis using a UV lamp, ninhydrin, or <i>p</i>-anisaldehyde stain for detection purposes. All solvents were purified by standard techniques. Purification of reaction products was carried out by silica gel column chromatography using Kieselgel 60 Art. 9385 (230–400 mesh). The purity of all compounds was over 95%, and mass spectra and purity of all compounds was analyzed using Waters LCMS system (Waters 2998 Photodiode Array Detector, Waters 3100 Mass Detector, Waters SFO System Fluidics Organizer, Water 2545 Binary Gradient Module, Waters Reagent Manager, Waters 2767 Sample Manager) using SunFireTM C18 column (4.6 × 50 mm, 5 μm particle size): solvent gradient = 60% (or 95%) A at 0 min, 1% A at 5 min. Solvent A = 0.035% TFA in H<sub>2</sub>O; Solvent B = 0.035% TFA in MeOH; flow rate 3.0 (or 2.5) mL/min. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained using a Bruker 400 MHz FT-NMR (400 MHz for <sup>1</sup>H, and 100 MHz for <sup>13</sup>C) spectrometer. Standard abbreviations are used for denoting the signal multiplicities.</div><div id="sec4_11_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 3-Bromo-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>2</b>)</h5><div class="NLM_p last">To a solution of 3-bromo-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine-4-amine (5.0 g, 23.36 mmol) in dry DMF (80 mL) was added K<sub>2</sub>CO<sub>3</sub> (12.91 g, 93.44 mmol) and 2-bromopropane (2.41 mL, 25.7 mmol) at room temperature. The reaction mixture was then stirred for 12 h at 80 °C, quenched with H<sub>2</sub>O, and diluted with EtOAc. The organic layer was washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (30% EtOAc/hexane) to afford <b>2</b> (4.13 g, 69%) as a white solid. <i>R</i><sub>f</sub> = 0.4 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.26 (s, 1H), 5.05 (sep, <i>J</i> = 6.8 Hz, 1H), 1.50 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 157.65, 155.97, 153.02, 116.91, 100.21, 49.34, 21.87.</div></div><div id="sec4_11_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 1-Isopropyl-3-vinyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>3</b>)</h5><div class="NLM_p last">To a solution of <b>2</b> (3.99 g, 15.58 mmol) in dry toluene (156 mL) was added Pd(PPh<sub>3</sub>)<sub>4</sub> (1.8 g, 1.56 mmol) and tributyl(vinyl)tin (5.47 mL, 18.7 mmol) at room temperature. The reaction mixture was refluxed for 4 h and cooled to ambient temperature. Afterward, the mixture was diluted with EtOAc and extracted with 1 N HCl solution. The pH of water layer was adjusted to a value of 10 with saturated sodium bicarbonate solution, extracted with DCM. The organic layer was washed with brine, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (50% EtOAc/hexane) to afford <b>3</b> (2.59 g, 82%) as a yellow solid. <i>R</i><sub>f</sub> = 0.4 (66% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.28 (s, 1H), 6.95 (dd, <i>J</i> = 11.2 Hz, 18.0 Hz, 1H), 6.41 (bs, 2H), 5.91 (dd, <i>J</i> = 1.2 Hz, 17.6 Hz, 1H), 5.59 (dd, <i>J</i> = 1.2 Hz, 11.6 Hz, 1H), 5.09 (sep, <i>J</i> = 6.8 Hz, 1H), 1.51 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.23, 155.07, 153.19, 141.62, 129.14, 119.98, 98.35, 48.67, 21.84.</div></div><div id="sec4_11_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine-3-carbaldehyde Oxime (<b>5a</b>)</h5><div class="NLM_p last">To a solution of <b>3</b> (2.07 g, 10.19 mmol) in THF/H<sub>2</sub>O (3:1, 136 mL) was added 4-methylmorpholine <i>N</i>-oxide (50% solution in H<sub>2</sub>O, 4.77 mL, 20.38 mmol) and OsO<sub>4</sub> (4% solution in H<sub>2</sub>O, 6.5 mL, 1.02 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 3 h. The reaction was quenched with saturated Na<sub>2</sub>SO<sub>3</sub> solution and extracted with mixed solution of CHCl<sub>3</sub>/IPA (4:1). The organic phase was washed with water and brine, dried over MgSO<sub>4</sub> and concentrated under reduced pressure to afford crude diol. Then the diol was dissolved in THF/H<sub>2</sub>O (3:1, 136 mL), NaIO<sub>4</sub> (4.36 g, 20.38 mmol) was added, and the mixture was stirred for 2 h at room temperature. The suspended mixture was filtered through Celite pad and extracted with EtOAc. The organic phase was washed with water and brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure to afford the crude aldehyde. To a solution of the crude aldehyde in EtOH (16 mL) was added hydroxylamine hydrochloride (841 mg, 25.48 mmol) and NaOAc (2.01 g, 24.46 mmol) at room temperature. The reaction mixture was stirred for 6 h and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (66% EtOAc/hexane to 100% EtOAc) to afford <b>5a</b> (1.99 g, 89% over 3 steps) as a white solid. <i>R</i><sub>f</sub> = 0.3 (10% CH<sub>2</sub>Cl<sub>2</sub>/MeOH); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.78 (s, 1H), 8.26 (s, 1H), 8.18 (s, 1H), 8.15 (bs, 1H), 8.03 (bs, 1H), 4.99 (sep, <i>J</i> = 6.8 Hz, 1H), 1.43 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 158.40, 156.37, 153.47, 144.13, 138.02, 97.63, 48.31, 21.59. LRMS (ESI) <i>m</i>/<i>z</i> 221.14 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>9</sub>H<sub>13</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 221.1151. Found: 221.1166.</div></div><div id="sec4_11_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 4-Amino-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine-3-carbaldehyde <i>O</i>-Benzyl Oxime (<b>5b</b>)</h5><div class="NLM_p last">Compound <b>3</b> (100 mg, 0.49 mmol) was converted to the target compound using the same procedure of <b>5a</b> as described above. The crude product was purified by flash column chromatography on silica gel (25% EtOAc/hexane) to afford <b>5b</b> (109 mg, 72%) as a white solid. <i>R</i><sub>f</sub> = 0.3 (25% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.36 (s, 1H), 8.26 (s, 1H), 7.84 (bs, 1H), 7.40–7.33 (m, 5H), 5.39 (bs, 1H), 5.21 (s, 2H), 5.09 (sep, <i>J</i> = 6.8 Hz, 1H), 1.52 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.21, 156.36, 153.89, 145.49, 137.35, 137.09, 128.64, 128.37, 128.28, 98.58, 76.46, 48.97, 21.80. LRMS (ESI) <i>m</i>/<i>z</i> 311.19 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>19</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 311.1620. Found: 311.1625.</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> General Procedure A for the Synthesis of Compounds <b>6a</b>–<b>l</b></h4><div class="NLM_p">To a solution of <b>5a</b> (1 equiv) and phenylacetylene (1.5 equiv) in MeOH/H<sub>2</sub>O (5:1, 0.1 M) was added [Bis(trifluoroacetoxy)iodo]benzene (PIFA) in four portions (0.5 equiv × 4) every 2 h. After 6 h stirring, the reaction mixture was diluted with EtOAc. The organic layer was washed with 1 N NaOH solution and brine, dried over MgSO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel.</div><div id="sec4_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 1-Isopropyl-3-(5-phenylisoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6b</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (33% EtOAc/hexane) to afford <b>6b</b> (46 mg, 32%) as a white solid. <i>R</i><sub>f</sub> = 0.5 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.26 (s, 1H), 8.16 (bs, 1H), 8.14 (bs, 1H), 8.05–8.03 (m, 2H), 7.62 (s, 1H), 7.58–7.56 (m, 3H), 5.10 (sep, <i>J</i> = 6.8 Hz, 1H), 1.52 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.84, 158.45, 157.96, 156.43, 153.66, 132.22, 131.00, 129.33, 126.18, 126.01, 98.45, 97.98, 48.87, 21.65. LRMS (ESI) <i>m</i>/<i>z</i> 321.19 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>17</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 321.1464. Found: 321.1472.</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 1-Isopropyl-3-(5-phenyl-4,5-dihydroisoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6a</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (33% EtOAc/hexane) to afford <b>6a</b> (42 mg, 29%) as a white solid. <i>R</i><sub>f</sub> = 0.5 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.42 (bs, 1H), 8.33 (s, 1H), 7.41–7.33 (m, 5H), 5.81 (bs, 1H), 5.78 (dd, <i>J</i> = 8.4 Hz, 11.2 Hz, 1H), 5.11 (sep, <i>J</i> = 6.8 Hz, 1H), 3.98 (dd, <i>J</i> = 10.8 Hz, 17.6 Hz, 1H), 5.78 (dd, <i>J</i> = 8.4 Hz, 17.6 Hz, 1H), 1.52 (t, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.18, 156.48, 154.02, 153.79, 140.12, 134.12, 128.83, 128.44, 125.86, 98.90, 82.75, 49.16, 42.53, 21.80. LRMS (ESI) <i>m</i>/<i>z</i> 323.20 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>19</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 323.1620. Found: 323.1634.</div></div><div id="sec4_12_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 3-(5-Benzylisoxazol-3-yl)-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6c</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (33% EtOAc/hexane) to afford <b>6c</b> (49 mg, 32%) as a white solid. <i>R</i><sub>f</sub> = 0.5 (40% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.60 (bs, 1H), 8.33 (s, 1H), 7.39–7.31 (m, 5H), 6.61 (s, 1H), 6.07 (bs, 1H), 5.13 (sep, <i>J</i> = 6.8 Hz, 1H), 4.16 (s, 2H), 1.54 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 172.27, 158.13, 158.06, 156.18, 153.82, 135.38, 133.16, 128.86, 128.81, 127.28, 100.39, 98.71, 49.09, 33.08, 21.82. LRMS (ESI) <i>m</i>/<i>z</i> 335.20 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>19</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 335.1620. Found: 335.1637.</div></div><div id="sec4_12_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 3-(5-(4-Fluorophenyl)isoxazol-3-yl)-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6d</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (33% EtOAc/hexane) to afford <b>6d</b> (40 mg, 26%) as a white solid. <i>R</i><sub>f</sub> = 0.5 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.60 (bs, 1H), 8.36 (s, 1H), 7.87 (dd, <i>J</i> = 5.2 Hz, 8.4 Hz, 2H), 7.22 (t, <i>J</i> = 8.4 Hz, 2H), 7.16 (s, 1H), 5.83 (bs, 1H), 5.19 (sep, <i>J</i> = 6.8 Hz, 1H), 1.60 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.07, [165.27, 162.77, <i>J</i> = 250 Hz], 158.70, 158.14, 156.38, 154.02, 133.01, [128.13, 128.05, <i>J</i> = 8 Hz], [123.32, 123.29, <i>J</i> = 3 Hz], [116.51, 116.29, <i>J</i> = 22 Hz], 98.85, 97.72, 49.25, 21.96. LRMS (ESI) <i>m</i>/<i>z</i> 339.41 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>16</sub>FN<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 339.1370. Found: 339.1377.</div></div><div id="sec4_12_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 1-Isopropyl-3-(5-(pyridin-2-yl)isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6e</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (66% EtOAc/hexane) to afford <b>6e</b> (28 mg, 19%) as an ivory solid. <i>R</i><sub>f</sub> = 0.3 (66% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.75 (dq, <i>J</i> = 0.8 Hz, 4.8 Hz, 1H), 8.55 (bs, 1H), 8.34 (s, 1H), 7.94 (dt, <i>J</i> = 0.8 Hz, 7.6 Hz, 1H), 7.87 (td, <i>J</i> = 1.6 Hz, 7.6 Hz, 1H), 7.58 (s, 1H), 7.39 (ddd, <i>J</i> = 1.2 Hz, 4.8 Hz, 7.2 Hz, 1H), 5.98 (bs, 1H), 5.17 (sep, <i>J</i> = 6.8 Hz, 1H), 1.59 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.18, 158.89, 158.11, 156.26, 153.96, 150.27, 146.11, 137.07, 132.79, 124.76, 120.97, 100.84, 98.82, 49.17, 21.93. LRMS (ESI) <i>m</i>/<i>z</i> 322.38 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>16</sub>N<sub>7</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 322.1416. Found: 322.1432.</div></div><div id="sec4_12_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-(5-Ethylisoxazol-3-yl)-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6f</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (40% EtOAc/hexane) to afford <b>6f</b> (27 mg, 22%) as a white solid. <i>R</i><sub>f</sub> = 0.4 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.64 (bs, 1H), 8.33 (s, 1H), 6.66 (s, 1H), 5.90 (bs, 1H), 5.15 (sep, <i>J</i> = 6.8 Hz, 1H), 2.85 (q, <i>J</i> = 7.6 Hz, 2H), 1.57 (d, <i>J</i> = 6.8 Hz, 6H), 1.38 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 175.07, 158.18, 157.99, 156.24, 153.89, 133.39, 98.76, 98.74, 49.13, 21.88, 20.13, 11.59. LRMS (ESI) <i>m</i>/<i>z</i> 273.17 [M + H]<sup>+</sup>.</div></div><div id="sec4_12_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 1-Isopropyl-3-(5-isopropylisoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6g</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (40% EtOAc/hexane) to afford <b>6g</b> (35 mg, 27%) as a white solid. <i>R</i><sub>f</sub> = 0.4 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.65 (bs, 1H), 8.33 (s, 1H), 6.64 (s, 1H), 6.03 (bs, 1H), 5.15 (sep, <i>J</i> = 6.8 Hz, 1H), 3.15 (sep, <i>J</i> = 6.8 Hz, 1H), 1.57 (d, <i>J</i> = 6.8 Hz, 6H), 1.39 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.96, 158.20, 157.82, 156.18, 153.87, 133.48, 98.76, 97.60, 49.13, 27.14, 21.88, 20.78. LRMS (ESI) <i>m</i>/<i>z</i> 287.47 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>14</sub>H<sub>19</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 287.1620. Found: 287.1632.</div></div><div id="sec4_12_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 3-(5-(<i>tert</i>-Butyl)isoxazol-3-yl)-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6h</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (33% EtOAc/hexane) to afford <b>6g</b> (32 mg, 24%) as a white solid. <i>R</i><sub>f</sub> = 0.5 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.67 (bs, 1H), 8.33 (s, 1H), 6.63 (s, 1H), 5.90 (bs, 1H), 5.16 (sep, <i>J</i> = 6.8 Hz, 1H), 1.58 (d, <i>J</i> = 6.8 Hz, 6H), 1.42 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 181.41, 158.18, 157.66, 156.17, 153.80, 133.46, 98.70, 96.93, 49.06, 32.76, 28.71, 21.83. LRMS (ESI) <i>m</i>/<i>z</i> 301.41 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>15</sub>H<sub>21</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 301.1777. Found: 301.1790.</div></div><div id="sec4_12_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 3-(5-Cyclopropylisoxazol-3-yl)-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6i</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (40% EtOAc/hexane) to afford <b>6i</b> (32 mg, 25%) as a white solid. <i>R</i><sub>f</sub> = 0.4 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.72 (bs, 1H), 8.27 (s, 1H), 6.86 (bs, 1H), 6.52 (s, 1H), 5.11 (sep, <i>J</i> = 6.8 Hz, 1H), 2.11–2.04 (m, 1H), 1.53 (d, <i>J</i> = 6.8 Hz, 6H), 1.13–0.99 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 175.35, 157.95, 157.55, 155.03, 153.54, 133.74, 98.70, 97.01, 49.29, 21.91, 8.64, 8.02. LRMS (ESI) <i>m</i>/<i>z</i> 285.46 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>14</sub>H<sub>17</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 285.1464. Found: 285.1476.</div></div><div id="sec4_12_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 3-(5-Cyclopentylisoxazol-3-yl)-1-isopropyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6j</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (33% EtOAc/hexane) to afford <b>6j</b> (42 mg, 30%) as a white solid. <i>R</i><sub>f</sub> = 0.5 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.67 (bs, 1H), 8.33 (s, 1H), 6.64 (s, 1H), 5.93 (bs, 1H), 5.15 (sep, <i>J</i> = 6.4 Hz, 1H), 3.27 (quin, <i>J</i> = 7.2 Hz, 1H), 2.18–2.12 (m, 2H), 1.82–1.72 (m, 6H), 1.57 (d, <i>J</i> = 6.4 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.84, 158.24, 157.86, 156.29, 153.93, 98.81, 97.97, 49.16, 37.37, 31.87, 25.31, 21.92. LRMS (ESI) <i>m</i>/<i>z</i> 313.44 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>21</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 313.1777. Found: 313.1787.</div></div><div id="sec4_12_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 3-(5-Cyclohexylisoxazol-3-yl)-1-isopropyl-1H-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6k</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (100 mg, 0.454 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (33% EtOAc/hexane) to afford <b>6k</b> (41 mg, 28%) as a white solid. <i>R</i><sub>f</sub> = 0.5 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.67 (bs, 1H), 8.33 (s, 1H), 6.62 (s, 1H), 5.94 (bs, 1H), 5.15 (sep, <i>J</i> = 6.8 Hz, 1H), 2.85 (tt, <i>J</i> = 3.6 Hz, 10.8 Hz, 1H), 2.14–2.11 (m, 2H), 1.85 (dt, <i>J</i> = 3.6 Hz, 9.6 Hz, 2H), 1.77–1.73 (m, 1H), 1.58 (d, <i>J</i> = 6.8 Hz, 6H), 1.56–1.25 (m, 5H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.11, 158.20, 157.79, 156.19, 153.90, 133.58, 98.80, 97.66, 49.18, 36.25, 31.10, 25.77, 25.62, 21.92. LRMS (ESI) <i>m</i>/<i>z</i> 328.23 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>23</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 327.1933. Found: 327.1948.</div></div><div id="sec4_12_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 1-Isopropyl-3-(5-(trimethylsilyl)isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>6l</b>)</h5><div class="NLM_p last">Compound <b>5a</b> (200 mg, 0.908 mmol) was converted to the target compound using general procedure A. The crude product was purified by flash column chromatography on silica gel (50% EtOAc/hexane) to afford <b>6g</b> (48 mg, 17%) as a white solid. <i>R</i><sub>f</sub> = 0.3 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.75 (bs, 1H), 8.33 (s, 1H), 7.11 (s, 1H), 6.07 (bs, 1H), 5.16 (sep, <i>J</i> = 6.8 Hz, 1H), 1.58 (d, <i>J</i> = 6.8 Hz, 6H), 0.41 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.52, 158.05, 156.25, 155.89, 153.89, 133.31, 111.01, 98.90, 49.18, 21.88, −2.00.</div></div><div id="sec4_12_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 1-Isopropyl-3-(isoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>7</b>)</h5><div class="NLM_p last">To a solution of <b>6l</b> (47 mg, 0.148 mmol) in acetonitrile/EtOH (10:1, 1.65 mL) was added cesium fluoride (45 mg, 0.297 mmol) at room temperature. The reaction mixture was then stirred for 30 min at 90 °C and cooled to ambient temperature. Afterward, EtOAc was added to the mixture, which was washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (50% EtOAc/hexane) to afford <b>7 </b>(15 mg, 42%) as a white solid. <i>R</i><sub>f</sub> = 0.3 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.55 (bs, 1H), 8.47 (d, <i>J</i> = 1.6 Hz, 1H), 8.35 (s, 1H), 7.03 (d, <i>J</i> = 1.6 Hz, 1H), 6.01 (bs, 1H), 5.17 (sep, <i>J</i> = 6.8 Hz, 1H), 1.58 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 158.38, 158.19, 157.30, 156.33, 154.03, 132.81, 103.12, 98.86, 49.26, 21.92. LRMS (ESI) <i>m</i>/<i>z</i> 245.35 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>11</sub>H<sub>13</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 245.1151. Found: 245.1178.</div></div><div id="sec4_12_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> Ethyl (<i>Z</i>)-4-cyclopropyl-4-hydroxy-2-oxobut-3-enoate (<b>9</b>)</h5><div class="NLM_p last">To a solution of 1-cyclopropylethan-1-one (12 mL, 128.39 mmol) in THF (250 mL) was added sodium hydride (7.7 g, 192.58 mmol) at 0 °C. The reaction mixture was then stirred for 30 min at room temperature, and diethyl oxalate (21 mL, 154.00 mmol) was added. The reaction mixture was then stirred for 12 h, diluted with EtOAc, and quenched with H<sub>2</sub>O. The organic layer was washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (11% EtOAc/hexane) to afford <b>9</b> (24.7 g, 92%) as a pale yellow liquid. <i>R</i><sub>f</sub> = 0.3 (14% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 14.43 (bs, 1H), 6.36 (s, 1H), 4.22 (q, <i>J</i> = 7.2 Hz, 2H), 1.82–1.76 (m, 1H), 1.24 (t, <i>J</i> = 7.2 Hz, 3H), 1.10–1.06 (m, 2H), 0.97–0.95 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 204.36, 162.84, 161.92, 101.84, 61.99, 20.37, 13.69, 11.87. LRMS (ESI) <i>m</i>/<i>z</i> 185.04 [M + H]<sup>+</sup>.</div></div><div id="sec4_12_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> Ethyl 5-cyclopropylisoxazole-3-carboxylate (<b>10</b>)</h5><div class="NLM_p last">To a solution of <b>9</b> (24.7 g, 118.21 mmol) in MeOH (250 mL) was added hydroxylamine hydrochloride (9.03 g, 130.03 mmol) at room temperature. The reaction mixture was refluxed for 2 h, and then concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (10% EtOAc/hexane) to afford <b>10</b> (18.85 g, 88%) as a colorless oil. <i>R</i><sub>f</sub> = 0.5 (14% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.14 (s, 1H), 4.23 (q, <i>J</i> = 7.2 Hz, 2H), 1.96–1.89 (m, 1H), 1.21 (t, <i>J</i> = 7.2 Hz, 3H), 0.97–0.90 (m, 2H), 0.88–0.82 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 176.37, 159.59, 155.94, 98.75, 61.43, 13.61, 8.29, 7.61. LRMS (ESI) <i>m</i>/<i>z</i> 182.60 [M + H]<sup>+</sup>.</div></div><div id="sec4_12_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 5-Cyclopropylisoxazole-3-carboxylic Acid (<b>11</b>)</h5><div class="NLM_p last">To a solution of <b>10</b> (18.2 g, 100.45 mmol) in EtOH (200 mL) was added sodium hydroxide (40 g, 1 mol) at 0 °C. The reaction mixture was stirred for 2 h, diluted with EtOAc, and quenched with conc. HCl for adjusting the pH to a value of 2. The mixture was then extracted with EtOAc, washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford <b>11</b> (15.38 g, 100%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.51 (s, 1H), 2.49–2.13 (m, 1H), 1.10–1.05 (m, 2H), 0.94–0.90 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 176.79, 161.03, 157.02, 99.29, 8.61, 7.65. LRMS (ESI) <i>m</i>/<i>z</i> 154.22 [M + H]<sup>+</sup>.</div></div><div id="sec4_12_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 2-((5-Cyclopropylisoxazol-3-yl) (methoxy)methylene)malononitrile (<b>14</b>)</h5><div class="NLM_p last">To a solution of <b>11</b> (2.02 g, 13.19 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was added oxalyl chloride (2.8 mL, 32.98 mol) and DMF (0.07 mL). The reaction mixture was stirred for 2 h and concentrated under reduced pressure. To the resulting solid was added malononitrile (1.05 g, 15.83 mmol) and THF (25 mL). After cooling to 0 °C, DIPEA (5.7 mL, 32.98 mmol) was added dropwise, and the reaction was allowed to warm to room temperature and proceed for 2 h. Afterward, dimethyl sulfate (3.8 mL, 39.57 mmol) was added, and the temperature was raised to 70 °C for 6 h. After the reaction was over, the mixture was cooled to room temperature and quenched with H<sub>2</sub>O. The aqueous layer was extracted with EtOAc. The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (25% EtOAc/hexane) to afford <b>14</b> (1.8 g, 63% over 3 steps) as a colorless oil. <i>R</i><sub>f</sub> = 0.3 (33% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.31 (s, 1H), 4.14 (s, 3H), 2.17–2.10 (m, 1H), 1.23–1.14 (m, 2H), 1.11–1.07 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.81, 172.72, 153.14, 111.81, 110.62, 70.18, 61.95, 9.38, 8.32. LRMS (ESI) <i>m</i>/<i>z</i> 216.12 [M + H]<sup>+</sup></div></div><div id="sec4_12_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 5-Amino-3-(5-cyclopropylisoxazol-3-yl)-1<i>H</i>-pyrazole-4-carbonitrile (<b>15</b>)</h5><div class="NLM_p last">To a solution of <b>14</b> (1.63 g, 7.57 mmol) in EtOH (22 mL) was added hydrazine dihydrochloride (874 mg, 8.33 mmol) and TEA (4.2 mL, 30.29 mmol) at room temperature. The reaction mixture was stirred for 30 min and diluted with EtOAc. The organic layer was washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was washed with 20% EtOH/ether to afford <b>15</b> (1.17 g, 72%) as a white solid. <i>R</i><sub>f</sub> = 0.2 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.47 (bs, 1H), 6.55 (bs, 2H), 6.43 (s, 1H), 2.21–2.14 (m, 1H), 1.08–1.06 (m, 2H), 0.93–0.92 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.92, 157.06, 155.47, 142.75, 114.40, 97.33, 73.21, 8.65, 8.34. LRMS (ESI) <i>m</i>/<i>z</i> 216.12 [M + H]<sup>+</sup>.</div></div><div id="sec4_12_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 3-(5-Cyclopropylisoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>16</b>)</h5><div class="NLM_p last">Compound <b>15</b> (1 g, 4.65 mmol) was dissolved in formamide (9 mL). The reaction mixture was stirred for 16 h at 160 °C and then cooled to room temperature. The resulting solid was washed with H<sub>2</sub>O, ether, MeOH, acetone, and CH<sub>2</sub>Cl<sub>2</sub> to afford <b>16</b> (923 mg, 82%) as an ivory-light brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.94 (bs, 1H), 8.20 (s, 1H), 8.06 (bs, 1H), 7.99 (bs, 1H), 6.77 (s, 1H), 2.27–2.21 (m, 1H), 1.15–1.10 (m, 2H), 1.03–0.99 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 175.82, 158.03, 157.87, 156.66, 156.24, 133.67, 97.19, 96.98, 8.64, 7.62. LRMS (ESI) <i>m</i>/<i>z</i> 243.35 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>11</sub>H<sub>11</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 243.0994. Found: 243.1009.</div></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> General Procedure B</h4><div class="NLM_p">To a solution of <b>16</b> (1 equiv) in DMF (0.3 M) was added cesium carbonate (2 equiv) and alkyl halide or 2,2-dimethoxyoxirane (1.2 equiv) at room temperature. The reaction mixture was then stirred for 2 h at 70 °C, cooled to room temperature and diluted with EtOAc. The organic layer was washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel.</div><div id="sec4_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 3-(5-Cyclopropylisoxazol-3-yl)-1-methyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>17a</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.413 mmol) was converted to the target compound with iodomethane using general procedure B. The crude product was purified by flash column chromatography on silica gel (66% EtOAc/hexane) to afford <b>17a</b> (66 mg, 62%) as a white solid. <i>R</i><sub>f</sub> = 0.2 (66% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.60 (bs, 1H), 8.32 (s, 1H), 6.48 (s, 1H), 6.31 (bs, 1H), 4.02 (s, 3H), 2.14–2.05 (m, 1H), 1.14–1.03 (m, 2H), 1.02–1.01 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 175.49, 158.6, 157.70, 156.60, 154.81, 133.74, 98.55, 96.73, 34.06, 8.70, 8.01. LRMS (ESI) <i>m</i>/<i>z</i> 257.38 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>12</sub>H<sub>13</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 257.1151. Found: 257.1160.</div></div><div id="sec4_13_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 1-Benzyl-3-(5-cyclopropylisoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>17b</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.413 mmol) was converted to the target compound with benzyl bromide using general procedure B. The crude product was purified by flash column chromatography on silica gel (50% EtOAc/hexane) to afford <b>17b</b> (111 mg, 81%) as a white solid. <i>R</i><sub>f</sub> = 0.4 (66% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.64 (bs, 1H), 8.37 (s, 1H), 7.34–7.26 (m, 5H), 6.52 (s, 1H), 5.87 (bs, 1H), 5.60 (s, 2H), 2.13–2.07 (m, 1H), 1.16–1.05 (m, 2H), 1.05–1.00 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 175.32, 158.24, 157.75, 156.75, 154.85, 136.21, 134.23, 128.56, 127.78, 98.61, 96.94, 50.79, 8.58, 7.93. LRMS (ESI) <i>m</i>/<i>z</i> 333.17 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>17</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 333.1464. Found: 333.1483.</div></div><div id="sec4_13_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 3-(5-Cyclopropylisoxazol-3-yl)-1-heptyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>17c</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.413 mmol) was converted to the target compound with heptyl bromide using general procedure B. The crude product was purified by flash column chromatography on silica gel (33% EtOAc/hexane) to afford <b>17c</b> (101 mg, 72%) as a white solid. <i>R</i><sub>f</sub> = 0.6 (66% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.63 (bs, 1H), 8.33 (s, 1H), 6.52 (s, 1H), 6.10 (bs, 1H), 4.39 (t, <i>J = </i> 7.2 Hz, 2H), 2.16–2.08 (m, 1H), 1.92 (quin, <i>J = </i> 7.2 Hz, 2H), 1.33–1.24 (m, 8H), 1.15–1.12 (m, 2H), 1.04–1.02 (m, 2H), 0.85 (t, <i>J = </i> 6.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 175.42, 158.18, 157.88, 156.37, 154.57, 133.61, 98.54, 96.88, 47.45, 31.63, 29.60, 28.78, 26.55, 22.50, 14.00, 8.66, 8.01. LRMS (ESI) <i>m</i>/<i>z</i> 341.24 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>18</sub>H<sub>25</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 341.2090. Found: 341.2094.</div></div><div id="sec4_13_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 1-(4-Amino-3-(5-cyclopropylisoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)-2-methylpropan-2-ol (<b>17d</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.413 mmol) was converted to the target compound with 2,2-dimethoxyoxirane using general procedure B. The crude product was purified by flash column chromatography on silica gel (80% EtOAc/hexane) to afford <b>17d</b> (42 mg, 32%) as a white solid. <i>R</i><sub>f</sub> = 0.15 (66% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.33 (s, 1H), 6.73 (s, 1H), 4.45 (s, 2H), 2.29–2.22 (m, 1H), 1.29 (s, 6H), 1.24–1.18 (m, 2H), 1.08–1.05 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 177.97, 158.72, 156.93, 155.39, 152.93, 136.87, 99.38, 97.97, 71.96, 59.06, 27.64, 9.24, 8.72. LRMS (ESI) <i>m</i>/<i>z</i> 315.34 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>15</sub>H<sub>19</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 315.1569. Found: 315.1574.</div></div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> General Procedure C</h4><div class="NLM_p">To a solution of <b>16</b> (1 equiv), triphenyl phosphine (1.5 euqiv) and alcohol (2 equiv) in THF (0.1 M) was added DIAD (1.5 equiv) at room temperature. The reaction mixture was then stirred for 12 h at room temperature and quenched with H<sub>2</sub>O. The organic layer was washed with H<sub>2</sub>O, dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel.</div><div id="sec4_14_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 1-Cyclohexyl-3-(5-cyclopropylisoxazol-3-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>17e</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.413 mmol) was converted to the target compound using general procedure C. The crude product was purified by flash column chromatography on silica gel (40% EtOAc/hexane) to afford <b>17e</b> (60 mg, 45%) as a white solid. <i>R</i><sub>f</sub> = 0.3 (50% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.62 (bs, 1H), 8.32 (s, 1H), 6.54 (s, 1H), 5.89 (bs, 1H), 4.78–4.70 (m, 1H), 2.14–2.07 (m, 1H), 2.05–1.99 (m, 3H), 1.94–1.91 (m, 1H), 1.76 (dt, <i>J</i> = 3.2 Hz, 12.8 Hz, 1H), 1.56–1.45 (m, 2H), 1.34 (tt, <i>J</i> = 3.2 Hz, 12.8 Hz, 1H), 1.28–1.25 (m, 1H), 1.16–1.11 (m, 2H), 1.08–1.02 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 175.19, 158.19, 158.10, 156.12, 153.91, 133.24, 98.68, 96.99, 56.44, 32.21, 25.48, 25.26, 8.54, 7.96. LRMS (ESI) <i>m</i>/<i>z</i> 325.19 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>21</sub>N<sub>6</sub>O<sup>+</sup> [M + H]<sup>+</sup>: 325.1777. Found: 325.1783.</div></div><div id="sec4_14_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 3-(5-Cyclopropylisoxazol-3-yl)-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-4-amine (<b>17f</b>)</h5><div class="NLM_p last">Compound <b>16</b> (100 mg, 0.413 mmol) was converted to the target compound using general procedure C. The crude product was purified by flash column chromatography on silica gel (60% EtOAc/hexane) to afford <b>17f</b> (54 mg, 45%) as a white solid. <i>R</i><sub>f</sub> = 0.15 (66% EtOAc/hexane); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.62 (bs, 1H), 8.31 (s, 1H), 6.52 (s, 1H), 6.15 (bs, 1H), 4.97 (tt, <i>J</i> = 4.0 Hz, 11.6 Hz, 1H), 4.13 (dd, <i>J</i> = 4.0 Hz, 11.2 Hz, 2H), 3.63 (td, <i>J</i> = 2.0 Hz, 12.0 Hz, 2H), 2.39 (qd, <i>J</i> = 4.4 Hz, 12.0 Hz, 2H), 2.16–2.09 (m, 1H), 1.96 (dq, <i>J</i> = 2.0 Hz, 12.4 Hz, 2H), 1.17–1.11 (m, 2H), 1.09–1.04 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 175.31, 158.24, 157.95, 156.28, 154.14, 133.73, 98.74, 97.01, 67.00, 53.26, 32.08, 8.59, 7.99. LRMS (ESI) <i>m</i>/<i>z</i> 327.45 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>19</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 327.1569. Found: 327.1584.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01522">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13157" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13157" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01522" class="ext-link">10.1021/acs.jmedchem.5b01522</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><i>In vitro</i> ADME and toxicity properties of <b>6i</b>; kinase selectivity profile of <b>6i</b>; inhibitory activity of <b>6i</b> against VEGFR2 Ba/F3 cell lines; inhibitory activity of <b>6i</b> against GDNF-induced phosphorylation of ERK1/2 in MCF-7 breast cancer cell lines; NMR spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01522/suppl_file/jm5b01522_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES data (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01522/suppl_file/jm5b01522_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01522/suppl_file/jm5b01522_si_001.pdf">jm5b01522_si_001.pdf (5.02 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01522/suppl_file/jm5b01522_si_002.csv">jm5b01522_si_002.csv (2.33 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01522" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22046" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22046" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taebo Sim</span> - <span class="hlFld-Affiliation affiliation">Chemical
Kinomics Research Center, Korea Institute
of Science and Technology (KIST), 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul 136-791, Republic of Korea</span>; 
    <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, Korea University, 145,
Anam-ro, Seongbuk-gu, Seoul, 136-713, Republic of Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#423620312b2f02292b31366c30276c2930623620312b2f02292d3027236c23216c2930"><span class="__cf_email__" data-cfemail="681c0a1b01052803011b1c461a0d46031a">[email protected]</span> <span class="__cf_email__" data-cfemail="7d091f0e14103d16120f181c531c1e53160f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hojong Yoon</span> - <span class="hlFld-Affiliation affiliation">Chemical
Kinomics Research Center, Korea Institute
of Science and Technology (KIST), 5, Hwarang-ro 14-gil, Seongbuk-gu, Seoul 136-791, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yeonui Kwak</span> - <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, Korea University, 145,
Anam-ro, Seongbuk-gu, Seoul, 136-713, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seunghye Choi</span> - <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, Korea University, 145,
Anam-ro, Seongbuk-gu, Seoul, 136-713, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hanna Cho</span> - <span class="hlFld-Affiliation affiliation">KU-KIST
Graduate School of Converging Science and Technology, Korea University, 145,
Anam-ro, Seongbuk-gu, Seoul, 136-713, Republic of Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nam Doo Kim</span> - <span class="hlFld-Affiliation affiliation">Daegu-Gyeongbuk
Medical Innovation Foundation, 2387 dalgubeol-daero, Suseong-gu, Daegu 706-010, Republic of Korea</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>H.Y. and Y.K. contributed equally to this work. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2362e5110-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by Korea Institute of Science and Technology (KIST), the KU-KIST Graduate School of Converging Science and Technology Program, Creative/Challenging Research Program (2011-0028676) of the National Research Foundation of Korea (NRF, and a grant (D33400) of Korea Basic Science Institute.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i65" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i65"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i66" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i66"> ABBREVIATIONS USED</h2><tr><td class="NLM_term">RET</td><td class="NLM_def"><p class="first last">rearranged during transfection</p></td></tr><tr><td class="NLM_term">MTC</td><td class="NLM_def"><p class="first last">medullary thyroid carcinoma</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">KIF5B</td><td class="NLM_def"><p class="first last">kinesin family member 5B</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">NMO</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl morpholine <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">NaOAc</td><td class="NLM_def"><p class="first last">sodium acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">trimethylamine</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type</p></td></tr><tr><td class="NLM_term">GDNF</td><td class="NLM_def"><p class="first last">glial cell line-derived neurotrophic factor</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41153" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41153" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 26 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Attie-Bitach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abitbol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delezoide, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachnis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munnich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vekemans, M.</span><span> </span><span class="NLM_article-title">Expression of the RET proto-oncogene in human embryos</span> <span class="citation_source-journal">Am. J. Med. Genet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.1002/(SICI)1096-8628(19981228)80:5<481::AID-AJMG8>3.0.CO;2-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1002%2F%28SICI%291096-8628%2819981228%2980%3A5%3C481%3A%3AAID-AJMG8%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=9880212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A280%3ADyaK1M%252FpsVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1998&pages=481-486&issue=5&author=T.+Attie-Bitachauthor=M.+Abitbolauthor=M.+Gerardauthor=A.+L.+Delezoideauthor=J.+Augeauthor=A.+Peletauthor=J.+Amielauthor=V.+Pachnisauthor=A.+Munnichauthor=S.+Lyonnetauthor=M.+Vekemans&title=Expression+of+the+RET+proto-oncogene+in+human+embryos&doi=10.1002%2F%28SICI%291096-8628%2819981228%2980%3A5%3C481%3A%3AAID-AJMG8%3E3.0.CO%3B2-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the RET proto-oncogene in human embryos</span></div><div class="casAuthors">Attie-Bitach T; Abitbol M; Gerard M; Delezoide A L; Auge J; Pelet A; Amiel J; Pachnis V; Munnich A; Lyonnet S; Vekemans M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-6</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">The patterns of RET proto-oncogene expression in mouse, rat, and chicken and the anomalies observed in targeted RET mutants suggest that RET plays a major role in development of mouse enteric nervous system and in kidney organogenesis.  Here, we report on in situ hybridization studies describing the pattern of RET proto-oncogene expression during early development of human embryos between 23 and 42 days.  We show that the RET gene is expressed in the developing kidney (nephric duct, mesonephric tubules, and ureteric bud), the presumptive enteric neuroblasts of the developing enteric nervous system, cranial ganglia (VII+VIII, IX, and X) and in the presumptive motor neurons of the spinal cord.  Yet, despite the high level of RET gene expression in the kidney and in the motor neurons of the developing central nervous system in human embryos, only rare cases with renal agenesis have been reported in Hirschsprung disease patients, and no clinical evidence of spinal cord involvement has been shown in patients carrying RET germline mutations (i.e., multiple endocrine neoplasia syndromes and Hirschsprung disease).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA7WHZRXiaJQxyojvcjibhfW6udTcc2eabHQaWc2RXurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FpsVyhsw%253D%253D&md5=b290f70327e19be3290d83f6fe2a19c7</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-8628%2819981228%2980%3A5%3C481%3A%3AAID-AJMG8%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-8628%252819981228%252980%253A5%253C481%253A%253AAID-AJMG8%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DAttie-Bitach%26aufirst%3DT.%26aulast%3DAbitbol%26aufirst%3DM.%26aulast%3DGerard%26aufirst%3DM.%26aulast%3DDelezoide%26aufirst%3DA.%2BL.%26aulast%3DAuge%26aufirst%3DJ.%26aulast%3DPelet%26aufirst%3DA.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DPachnis%26aufirst%3DV.%26aulast%3DMunnich%26aufirst%3DA.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DVekemans%26aufirst%3DM.%26atitle%3DExpression%2520of%2520the%2520RET%2520proto-oncogene%2520in%2520human%2520embryos%26jtitle%3DAm.%2520J.%2520Med.%2520Genet%26date%3D1998%26volume%3D80%26issue%3D5%26spage%3D481%26epage%3D486%26doi%3D10.1002%2F%28SICI%291096-8628%2819981228%2980%3A5%3C481%3A%3AAID-AJMG8%3E3.0.CO%3B2-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Durbec, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LarssonBlomberg, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchardt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachnis, V.</span><span> </span><span class="NLM_article-title">Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts</span> <span class="citation_source-journal">Development</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1996&pages=349-358&author=P.+L.+Durbecauthor=L.+B.+LarssonBlombergauthor=A.+Schuchardtauthor=F.+Costantiniauthor=V.+Pachnis&title=Common+origin+and+developmental+dependence+on+c-ret+of+subsets+of+enteric+and+sympathetic+neuroblasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurbec%26aufirst%3DP.%2BL.%26aulast%3DLarssonBlomberg%26aufirst%3DL.%2BB.%26aulast%3DSchuchardt%26aufirst%3DA.%26aulast%3DCostantini%26aufirst%3DF.%26aulast%3DPachnis%26aufirst%3DV.%26atitle%3DCommon%2520origin%2520and%2520developmental%2520dependence%2520on%2520c-ret%2520of%2520subsets%2520of%2520enteric%2520and%2520sympathetic%2520neuroblasts%26jtitle%3DDevelopment%26date%3D1996%26volume%3D122%26spage%3D349%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Arighi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrello, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sariola, H.</span><span> </span><span class="NLM_article-title">RET tyrosine kinase signaling in development and cancer</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2005.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1016%2Fj.cytogfr.2005.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=15982921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVCnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=441-467&author=E.+Arighiauthor=M.+G.+Borrelloauthor=H.+Sariola&title=RET+tyrosine+kinase+signaling+in+development+and+cancer&doi=10.1016%2Fj.cytogfr.2005.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">RET tyrosine kinase signaling in development and cancer</span></div><div class="casAuthors">Arighi, Elena; Borrello, Maria Grazia; Sariola, Hannu</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">441-467</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The variety of diseases caused by mutations in RET receptor tyrosine kinase provides a classic example of phenotypic heterogeneity.  Gain-of-function mutations of RET are assocd. with human cancer.  Gene rearrangements juxtaposing the tyrosine kinase domain to heterologous gene partners have been found in sporadic papillary carcinomas of the thyroid (PTC).  These rearrangements generate chimeric RET/PTC oncogenes.  In the germline, point mutations of RET are responsible for multiple endocrine neoplasia type 2 (MEN 2A and 2B) and familial medullary thyroid carcinoma (FMTC).  Both MEN 2 mutations and PTC gene rearrangements potentiate the intrinsic tyrosine kinase activity of RET and, ultimately, activate the RET downstream targets.  Loss-of-function mutations of RET cause Hirschsprung's disease (HSCR) or colonic aganglionosis.  A deeper understanding of the mol. signaling of normal vs. abnormal RET activity in cancer will enable the development of potential new treatments for patients with sporadic and inherited thyroid cancer or MEN 2 syndrome.  We now review the role and mechanisms of RET signaling in development and carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozw_crTv66LbVg90H21EOLACvtfcHk0lhtWwYuW0BPwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVCnu7s%253D&md5=8f664352542b6034d0ca001b9c1c4f16</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2005.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2005.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DArighi%26aufirst%3DE.%26aulast%3DBorrello%26aufirst%3DM.%2BG.%26aulast%3DSariola%26aufirst%3DH.%26atitle%3DRET%2520tyrosine%2520kinase%2520signaling%2520in%2520development%2520and%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2005%26volume%3D16%26spage%3D441%26epage%3D467%26doi%3D10.1016%2Fj.cytogfr.2005.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Encinas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milbrandt, J.</span><span> </span><span class="NLM_article-title">Critical and distinct roles for key RET tyrosine docking sites in renal development</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.1101/gad.1387206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1101%2Fgad.1387206" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=321-333&author=S.+Jainauthor=M.+Encinasauthor=E.+M.+Johnsonauthor=J.+Milbrandt&title=Critical+and+distinct+roles+for+key+RET+tyrosine+docking+sites+in+renal+development&doi=10.1101%2Fgad.1387206"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1101%2Fgad.1387206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1387206%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%26aulast%3DEncinas%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DMilbrandt%26aufirst%3DJ.%26atitle%3DCritical%2520and%2520distinct%2520roles%2520for%2520key%2520RET%2520tyrosine%2520docking%2520sites%2520in%2520renal%2520development%26jtitle%3DGenes%2520Dev.%26date%3D2006%26volume%3D20%26spage%3D321%26epage%3D333%26doi%3D10.1101%2Fgad.1387206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lundgren, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakahata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebellato, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlen, P.</span><span> </span><span class="NLM_article-title">RET PLCgamma phosphotyrosine binding domain regulates Ca2+ signaling and neocortical neuronal migration</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e31258</span><span class="refDoi"> DOI: 10.1371/journal.pone.0031258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1371%2Fjournal.pone.0031258" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e31258&author=T.+K.+Lundgrenauthor=K.+Nakahataauthor=N.+Fritzauthor=P.+Rebellatoauthor=S.+Zhangauthor=P.+Uhlen&title=RET+PLCgamma+phosphotyrosine+binding+domain+regulates+Ca2%2B+signaling+and+neocortical+neuronal+migration&doi=10.1371%2Fjournal.pone.0031258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0031258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0031258%26sid%3Dliteratum%253Aachs%26aulast%3DLundgren%26aufirst%3DT.%2BK.%26aulast%3DNakahata%26aufirst%3DK.%26aulast%3DFritz%26aufirst%3DN.%26aulast%3DRebellato%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DUhlen%26aufirst%3DP.%26atitle%3DRET%2520PLCgamma%2520phosphotyrosine%2520binding%2520domain%2520regulates%2520Ca2%252B%2520signaling%2520and%2520neocortical%2520neuronal%2520migration%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De31258%26doi%3D10.1371%2Fjournal.pone.0031258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Mulligan, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsdon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mole, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papi, L.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span><span class="refDoi"> DOI: 10.1038/363458a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2F363458a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=1993&pages=458-460&author=L.+M.+Mulliganauthor=J.+B.+Kwokauthor=C.+S.+Healeyauthor=M.+J.+Elsdonauthor=C.+Engauthor=E.+Gardnerauthor=D.+R.+Loveauthor=S.+E.+Moleauthor=J.+K.+Mooreauthor=L.+Papi&title=Germ-line+mutations+of+the+RET+proto-oncogene+in+multiple+endocrine+neoplasia+type+2A&doi=10.1038%2F363458a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F363458a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F363458a0%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26aulast%3DKwok%26aufirst%3DJ.%2BB.%26aulast%3DHealey%26aufirst%3DC.%2BS.%26aulast%3DElsdon%26aufirst%3DM.%2BJ.%26aulast%3DEng%26aufirst%3DC.%26aulast%3DGardner%26aufirst%3DE.%26aulast%3DLove%26aufirst%3DD.%2BR.%26aulast%3DMole%26aufirst%3DS.%2BE.%26aulast%3DMoore%26aufirst%3DJ.%2BK.%26aulast%3DPapi%26aufirst%3DL.%26atitle%3DGerm-line%2520mutations%2520of%2520the%2520RET%2520proto-oncogene%2520in%2520multiple%2520endocrine%2520neoplasia%2520type%25202A%26jtitle%3DNature%26date%3D1993%26volume%3D363%26spage%3D458%26epage%3D460%26doi%3D10.1038%2F363458a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Eng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuffenecker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenoir, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Amstel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lips, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishisho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takai, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank-Raue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raue, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noll, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zedenius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordenskjold, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komminoth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendy, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, L. M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">1575</span><span class="NLM_x">–</span> <span class="NLM_lpage">1579</span><span class="refDoi"> DOI: 10.1001/jama.276.19.1575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1001%2Fjama.276.19.1575" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1996&pages=1575-1579&author=C.+Engauthor=D.+Claytonauthor=I.+Schuffeneckerauthor=G.+Lenoirauthor=G.+Coteauthor=R.+F.+Gagelauthor=H.+K.+van+Amstelauthor=C.+J.+Lipsauthor=I.+Nishishoauthor=S.+I.+Takaiauthor=D.+J.+Marshauthor=B.+G.+Robinsonauthor=K.+Frank-Raueauthor=F.+Raueauthor=F.+Xueauthor=W.+W.+Nollauthor=C.+Romeiauthor=F.+Paciniauthor=M.+Finkauthor=B.+Niederleauthor=J.+Zedeniusauthor=M.+Nordenskjoldauthor=P.+Komminothauthor=G.+N.+Hendyauthor=L.+M.+Mulligan&title=The+relationship+between+specific+RET+proto-oncogene+mutations+and+disease+phenotype+in+multiple+endocrine+neoplasia+type+2.+International+RET+mutation+consortium+analysis&doi=10.1001%2Fjama.276.19.1575"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.276.19.1575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.276.19.1575%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DC.%26aulast%3DClayton%26aufirst%3DD.%26aulast%3DSchuffenecker%26aufirst%3DI.%26aulast%3DLenoir%26aufirst%3DG.%26aulast%3DCote%26aufirst%3DG.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3Dvan%2BAmstel%26aufirst%3DH.%2BK.%26aulast%3DLips%26aufirst%3DC.%2BJ.%26aulast%3DNishisho%26aufirst%3DI.%26aulast%3DTakai%26aufirst%3DS.%2BI.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DFrank-Raue%26aufirst%3DK.%26aulast%3DRaue%26aufirst%3DF.%26aulast%3DXue%26aufirst%3DF.%26aulast%3DNoll%26aufirst%3DW.%2BW.%26aulast%3DRomei%26aufirst%3DC.%26aulast%3DPacini%26aufirst%3DF.%26aulast%3DFink%26aufirst%3DM.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DZedenius%26aufirst%3DJ.%26aulast%3DNordenskjold%26aufirst%3DM.%26aulast%3DKomminoth%26aufirst%3DP.%26aulast%3DHendy%26aufirst%3DG.%2BN.%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26atitle%3DThe%2520relationship%2520between%2520specific%2520RET%2520proto-oncogene%2520mutations%2520and%2520disease%2520phenotype%2520in%2520multiple%2520endocrine%2520neoplasia%2520type%25202.%2520International%2520RET%2520mutation%2520consortium%2520analysis%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D1996%26volume%3D276%26spage%3D1575%26epage%3D1579%26doi%3D10.1001%2Fjama.276.19.1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Mulligan, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuffenecker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zedenius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lips, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takai, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noll, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium</span> <span class="citation_source-journal">J. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">238</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span><span class="refDoi"> DOI: 10.1111/j.1365-2796.1995.tb01208.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1111%2Fj.1365-2796.1995.tb01208.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=7595170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A280%3ADyaK28%252FmvFKmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=238&publication_year=1995&pages=343-346&author=L.+M.+Mulliganauthor=D.+J.+Marshauthor=B.+G.+Robinsonauthor=I.+Schuffeneckerauthor=J.+Zedeniusauthor=C.+J.+Lipsauthor=R.+F.+Gagelauthor=S.+I.+Takaiauthor=W.+W.+Nollauthor=M.+Fink&title=Genotype-phenotype+correlation+in+multiple+endocrine+neoplasia+type+2%3A+report+of+the+International+RET+Mutation+Consortium&doi=10.1111%2Fj.1365-2796.1995.tb01208.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium</span></div><div class="casAuthors">Mulligan L M; Marsh D J; Robinson B G; Schuffenecker I; Zedenius J; Lips C J; Gagel R F; Takai S I; Noll W W; Fink M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of internal medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">238</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">343-6</span>
        ISSN:<span class="NLM_cas:issn">0954-6820</span>.
    </div><div class="casAbstract">The International RET Mutation Consortium was first convened as part of the Fifth International Workshop on Multiple Endocrine Neoplasia, Stockholm, Sweden, in an attempt to analyse the relationship of RET mutation and disease phenotype in the autosomal dominantly inherited multiple endocrine neoplasia type 2 (MEN 2) syndromes.  Out of 361 families studied, 41% had MEN 2A, 17.7% MEN 2B, 6.4% FMTC and the remaining subjects were unclassified.  RET mutations were detected in 87.3% of families overall.  Over 93% of MEN 2B families had the RET 918 ATG-->ACG mutation, while the most frequent mutation detected in MEN 2A families was cysteine codon 634 (87% of all mutations).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS24qPZJh1PEmGmni0r9GoKfW6udTcc2eZiBJfiphaBLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FmvFKmsg%253D%253D&md5=7f0c721ba5775850ba95d9cd00b5c67b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2796.1995.tb01208.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2796.1995.tb01208.x%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DSchuffenecker%26aufirst%3DI.%26aulast%3DZedenius%26aufirst%3DJ.%26aulast%3DLips%26aufirst%3DC.%2BJ.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DTakai%26aufirst%3DS.%2BI.%26aulast%3DNoll%26aufirst%3DW.%2BW.%26aulast%3DFink%26aufirst%3DM.%26atitle%3DGenotype-phenotype%2520correlation%2520in%2520multiple%2520endocrine%2520neoplasia%2520type%25202%253A%2520report%2520of%2520the%2520International%2520RET%2520Mutation%2520Consortium%26jtitle%3DJ.%2520Intern.%2520Med.%26date%3D1995%26volume%3D238%26spage%3D343%26epage%3D346%26doi%3D10.1111%2Fj.1365-2796.1995.tb01208.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Cranston, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carniti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakhill, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radzio-Andzelm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallion, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mondellini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bongarzone, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponder, B. A.</span><span> </span><span class="NLM_article-title">RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">10179</span><span class="NLM_x">–</span> <span class="NLM_lpage">10187</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1158%2F0008-5472.CAN-06-0884" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=10179-10187&author=A.+N.+Cranstonauthor=C.+Carnitiauthor=K.+Oakhillauthor=E.+Radzio-Andzelmauthor=E.+A.+Stoneauthor=A.+S.+McCallionauthor=S.+Hodgsonauthor=S.+Clarkeauthor=P.+Mondelliniauthor=J.+Leylandauthor=M.+A.+Pierottiauthor=J.+Whittakerauthor=S.+S.+Taylorauthor=I.+Bongarzoneauthor=B.+A.+Ponder&title=RET+is+constitutively+activated+by+novel+tandem+mutations+that+alter+the+active+site+resulting+in+multiple+endocrine+neoplasia+type+2B&doi=10.1158%2F0008-5472.CAN-06-0884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0884%26sid%3Dliteratum%253Aachs%26aulast%3DCranston%26aufirst%3DA.%2BN.%26aulast%3DCarniti%26aufirst%3DC.%26aulast%3DOakhill%26aufirst%3DK.%26aulast%3DRadzio-Andzelm%26aufirst%3DE.%26aulast%3DStone%26aufirst%3DE.%2BA.%26aulast%3DMcCallion%26aufirst%3DA.%2BS.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DMondellini%26aufirst%3DP.%26aulast%3DLeyland%26aufirst%3DJ.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DWhittaker%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DBongarzone%26aufirst%3DI.%26aulast%3DPonder%26aufirst%3DB.%2BA.%26atitle%3DRET%2520is%2520constitutively%2520activated%2520by%2520novel%2520tandem%2520mutations%2520that%2520alter%2520the%2520active%2520site%2520resulting%2520in%2520multiple%2520endocrine%2520neoplasia%2520type%25202B%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D10179%26epage%3D10187%26doi%3D10.1158%2F0008-5472.CAN-06-0884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Romei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span> </span><span class="NLM_article-title">RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma</span> <span class="citation_source-journal">Front. Endocrinol. (Lausanne, Switz.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.3389/fendo.2012.00054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.3389%2Ffendo.2012.00054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=22649402" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1-8&author=C.+Romeiauthor=R.+Elisei&title=RET%2FPTC+Translocations+and+Clinico-Pathological+Features+in+Human+Papillary+Thyroid+Carcinoma&doi=10.3389%2Ffendo.2012.00054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2012.00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2012.00054%26sid%3Dliteratum%253Aachs%26aulast%3DRomei%26aufirst%3DC.%26aulast%3DElisei%26aufirst%3DR.%26atitle%3DRET%252FPTC%2520Translocations%2520and%2520Clinico-Pathological%2520Features%2520in%2520Human%2520Papillary%2520Thyroid%2520Carcinoma%26jtitle%3DFront.%2520Endocrinol.%2520%2528Lausanne%252C%2520Switz.%2529%26date%3D2012%26volume%3D3%26spage%3D1%26epage%3D8%26doi%3D10.3389%2Ffendo.2012.00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Song, M.</span><span> </span><span class="NLM_article-title">Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3672</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span><span class="refDoi"> DOI: 10.1021/jm501464c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501464c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2isbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3672-3681&author=M.+Song&title=Progress+in+Discovery+of+KIF5B-RET+Kinase+Inhibitors+for+the+Treatment+of+Non-Small-Cell+Lung+Cancer&doi=10.1021%2Fjm501464c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Song, Minsoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3672-3681</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1-2% of lung adenocarcinomas (LADCs) in late 2011.  Several related clin. trials for non-small-cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as lenvatinib, vandetanib, sunitinib, ponatinib, cabozantinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene.  Anti-RET activity and the status of clin. development of these known RET tyrosine kinase inhibitors (TKIs) for KIF5B-RET fusion-pos. NSCLC are discussed.  A kinase inhibitor that can target a driver mutation specifically may lead to a superior clin. benefit compared with broad-spectrum kinase inhibitors.  In this regard, an anal. of the structure of RET kinase and its complex with known RET inhibitors are also briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAOaAhnoMFVLVg90H21EOLACvtfcHk0liTqL3FMPFiLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2isbc%253D&md5=9420c8894295f711ca3a490dee790860</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm501464c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501464c%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DM.%26atitle%3DProgress%2520in%2520Discovery%2520of%2520KIF5B-RET%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3672%26epage%3D3681%26doi%3D10.1021%2Fjm501464c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Mulligan, L. M.</span><span> </span><span class="NLM_article-title">RET revisited: expanding the oncogenic portfolio</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span><span class="refDoi"> DOI: 10.1038/nrc3680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2Fnrc3680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=24561444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=173-186&author=L.+M.+Mulligan&title=RET+revisited%3A+expanding+the+oncogenic+portfolio&doi=10.1038%2Fnrc3680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">RET revisited: expanding the oncogenic portfolio</span></div><div class="casAuthors">Mulligan, Lois M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-186</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RET receptor tyrosine kinase is crucial for normal development but also contributes to pathologies that reflect both the loss and the gain of RET function.  Activation of RET occurs via oncogenic mutations in familial and sporadic cancers - most notably, those of the thyroid and the lung.  RET has also recently been implicated in the progression of breast and pancreatic tumors, among others, which makes it an attractive target for small-mol. kinase inhibitors as therapeutics.  However, the complex roles of RET in homeostasis and survival of neural lineages and in tumor-assocd. inflammation might also suggest potential long-term pitfalls of broadly targeting RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohwDQSALnEwbVg90H21EOLACvtfcHk0liTqL3FMPFiLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D&md5=665dae74c8f7a1df0e413ca15ca86440</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc3680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3680%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26atitle%3DRET%2520revisited%253A%2520expanding%2520the%2520oncogenic%2520portfolio%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D173%26epage%3D186%26doi%3D10.1038%2Fnrc3680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Diner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alao, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soderlund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunnerhagen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotli, M.</span><span> </span><span class="NLM_article-title">Preparation of 3-Substituted-1-Isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET Kinase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4876</span><span class="refDoi"> DOI: 10.1021/jm3003944</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003944" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4872-4876&author=P.+Dinerauthor=J.+P.+Alaoauthor=J.+Soderlundauthor=P.+Sunnerhagenauthor=M.+Grotli&title=Preparation+of+3-Substituted-1-Isopropyl-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-amines+as+RET+Kinase+Inhibitors&doi=10.1021%2Fjm3003944"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm3003944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003944%26sid%3Dliteratum%253Aachs%26aulast%3DDiner%26aufirst%3DP.%26aulast%3DAlao%26aufirst%3DJ.%2BP.%26aulast%3DSoderlund%26aufirst%3DJ.%26aulast%3DSunnerhagen%26aufirst%3DP.%26aulast%3DGrotli%26aufirst%3DM.%26atitle%3DPreparation%2520of%25203-Substituted-1-Isopropyl-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amines%2520as%2520RET%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4872%26epage%3D4876%26doi%3D10.1021%2Fjm3003944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anaganti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6056</span><span class="NLM_x">–</span> <span class="NLM_lpage">6063</span><span class="refDoi"> DOI: 10.1038/sj.onc.1207810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2Fsj.onc.1207810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=15184865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVKlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6056-6063&author=F.+Carlomagnoauthor=T.+Guidaauthor=S.+Anagantiauthor=G.+Vecchioauthor=A.+Fuscoauthor=A.+J.+Ryanauthor=M.+Billaudauthor=M.+Santoro&title=Disease+associated+mutations+at+valine+804+in+the+RET+receptor+tyrosine+kinase+confer+resistance+to+selective+kinase+inhibitors&doi=10.1038%2Fsj.onc.1207810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors</span></div><div class="casAuthors">Carlomagno, Francesca; Guida, Teresa; Anaganti, Suresh; Vecchio, Giancarlo; Fusco, Alfredo; Ryan, Anderson J.; Billaud, Marc; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6056-6063</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC50≤100 nM) towards constitutively active oncogenic RET kinases.  Here, we show that most oncogenic MEN2-assocd. RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition.  In contrast, MEN2-assocd. swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compds.  Substitution of valine 804 with the small amino- acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC50: 20 nM) than the wild-type kinase.  Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJql666y5D-bVg90H21EOLACvtfcHk0liTqL3FMPFiLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVKlt7c%253D&md5=39ec0aa2550048d7cd9a5536a6180fc0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207810%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DGuida%26aufirst%3DT.%26aulast%3DAnaganti%26aufirst%3DS.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DBillaud%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DDisease%2520associated%2520mutations%2520at%2520valine%2520804%2520in%2520the%2520RET%2520receptor%2520tyrosine%2520kinase%2520confer%2520resistance%2520to%2520selective%2520kinase%2520inhibitors%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6056%26epage%3D6063%26doi%3D10.1038%2Fsj.onc.1207810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Romei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariotti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fugazzola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taccaliti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opocher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">degli Uberti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccherini, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cremonini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seregni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferolla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puxeddu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosci, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottici, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verga, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscaro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zatelli, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faggiano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinchera, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Network, I.</span><span> </span><span class="NLM_article-title">Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes</span> <span class="citation_source-journal">Eur. J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1530/EJE-10-0333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1530%2FEJE-10-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=20516206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSksrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2010&pages=301-308&author=C.+Romeiauthor=S.+Mariottiauthor=L.+Fugazzolaauthor=A.+Taccalitiauthor=F.+Paciniauthor=G.+Opocherauthor=C.+Mianauthor=M.+Castellanoauthor=E.+degli+Ubertiauthor=I.+Ceccheriniauthor=N.+Cremoniniauthor=E.+Seregniauthor=F.+Orlandiauthor=P.+Ferollaauthor=E.+Puxedduauthor=F.+Giorginoauthor=A.+Colaoauthor=P.+Loliauthor=F.+Bondiauthor=B.+Cosciauthor=V.+Botticiauthor=A.+Cappaiauthor=G.+Pinnaauthor=L.+Persaniauthor=U.+Vergaauthor=M.+Boscaroauthor=M.+G.+Castagnaauthor=C.+Cappelliauthor=M.+C.+Zatelliauthor=A.+Faggianoauthor=G.+Franciaauthor=M.+L.+Brandiauthor=A.+Falchettiauthor=A.+Pincheraauthor=R.+Eliseiauthor=I.+Network&title=Multiple+endocrine+neoplasia+type+2+syndromes+%28MEN+2%29%3A+results+from+the+ItaMEN+network+analysis+on+the+prevalence+of+different+genotypes+and+phenotypes&doi=10.1530%2FEJE-10-0333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes</span></div><div class="casAuthors">Romei, Cristina; Mariotti, Stefano; Fugazzola, Laura; Taccaliti, Augusto; Pacini, Furio; Opocher, Giuseppe; Mian, Caterina; Castellano, Maurizio; Uberti, Ettore Degli; Ceccherini, Isabella; Cremonini, Nadia; Seregni, Ettore; Orlandi, Fabio; Ferolla, Piero; Puxeddu, Efisio; Giorgino, Francesco; Colao, Annamaria; Loli, Paola; Bondi, Fabio; Cosci, Barbara; Bottici, Valeria; Cappai, Antonello; Pinna, Giovanni; Persani, Luca; Uberta, Verga; Boscaro, Marco; Castagna, Maria Grazia; Cappelli, Carlo; Zatelli, Maria Chiara; Faggiano, Antongiulio; Francia, Giuseppe; Brandi, Maria Luisa; Falchetti, Alberto; Pinchera, Aldo; Elisei, Rossella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-308</span>CODEN:
                <span class="NLM_cas:coden">EJOEEP</span>;
        ISSN:<span class="NLM_cas:issn">0804-4643</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Objective: Multiple endocrine neoplasia type 2 (MEN 2) is a genetic disease characterized by medullary thyroid carcinoma (MTC) assocd. (MEN 2A and 2B) or not familial MTC (FMTC) with other endocrine neoplasia due to germline RET gene mutations.  The prevalence of these rare genetic diseases and their corresponding RET mutations are unknown due to the small size of the study population.  Methods: We collected data on germline RET mutations of 250 families with hereditary MTC followed in 20 different Italian centers.  Results and conclusions: The most frequent RET amino acid substitution was Val804Met (19.6%) followed by Cys634Arg (13.6%).  A total of 40 different germline RET mutations were present.  Six families (2.4%) were neg. for germline RET mutations.  The comparison of the prevalence of RET germline mutations in the present study with those published by other European studies showed a higher prevalence of Val804Met and Ser891Ala mutations and a lower prevalence of Leu790Phe and Tyr791Phe (P < 0.0001).  A statistically significant higher prevalence of mutations affecting non-cysteine codons was also found (P < 0.0001).  Furthermore, the phenotype data collection showed an unexpected higher prevalence of FMTC (57.6%) with respect to other MEN 2 syndromes (34% MEN 2A and 6.8% of MEN 2B).  In conclusion, we obsd. a statistically significant different pattern of RET mutations in Italian MEN 2 families with respect to other European studies and a higher prevalence of FMTC phenotype.  The different ethnic origins of the patients and the particular attention given to analyzing apparently sporadic MTC for RET germline mutations may explain these findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8RiQLPgS4X7Vg90H21EOLACvtfcHk0li6Bb9k9m95dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSksrjL&md5=58ad8f2df324963e1c91988500be5fcc</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1530%2FEJE-10-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FEJE-10-0333%26sid%3Dliteratum%253Aachs%26aulast%3DRomei%26aufirst%3DC.%26aulast%3DMariotti%26aufirst%3DS.%26aulast%3DFugazzola%26aufirst%3DL.%26aulast%3DTaccaliti%26aufirst%3DA.%26aulast%3DPacini%26aufirst%3DF.%26aulast%3DOpocher%26aufirst%3DG.%26aulast%3DMian%26aufirst%3DC.%26aulast%3DCastellano%26aufirst%3DM.%26aulast%3Ddegli%2BUberti%26aufirst%3DE.%26aulast%3DCeccherini%26aufirst%3DI.%26aulast%3DCremonini%26aufirst%3DN.%26aulast%3DSeregni%26aufirst%3DE.%26aulast%3DOrlandi%26aufirst%3DF.%26aulast%3DFerolla%26aufirst%3DP.%26aulast%3DPuxeddu%26aufirst%3DE.%26aulast%3DGiorgino%26aufirst%3DF.%26aulast%3DColao%26aufirst%3DA.%26aulast%3DLoli%26aufirst%3DP.%26aulast%3DBondi%26aufirst%3DF.%26aulast%3DCosci%26aufirst%3DB.%26aulast%3DBottici%26aufirst%3DV.%26aulast%3DCappai%26aufirst%3DA.%26aulast%3DPinna%26aufirst%3DG.%26aulast%3DPersani%26aufirst%3DL.%26aulast%3DVerga%26aufirst%3DU.%26aulast%3DBoscaro%26aufirst%3DM.%26aulast%3DCastagna%26aufirst%3DM.%2BG.%26aulast%3DCappelli%26aufirst%3DC.%26aulast%3DZatelli%26aufirst%3DM.%2BC.%26aulast%3DFaggiano%26aufirst%3DA.%26aulast%3DFrancia%26aufirst%3DG.%26aulast%3DBrandi%26aufirst%3DM.%2BL.%26aulast%3DFalchetti%26aufirst%3DA.%26aulast%3DPinchera%26aufirst%3DA.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DNetwork%26aufirst%3DI.%26atitle%3DMultiple%2520endocrine%2520neoplasia%2520type%25202%2520syndromes%2520%2528MEN%25202%2529%253A%2520results%2520from%2520the%2520ItaMEN%2520network%2520analysis%2520on%2520the%2520prevalence%2520of%2520different%2520genotypes%2520and%2520phenotypes%26jtitle%3DEur.%2520J.%2520Endocrinol.%26date%3D2010%26volume%3D163%26spage%3D301%26epage%3D308%26doi%3D10.1530%2FEJE-10-0333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pinna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orgiana, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcassi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariotti, S.</span><span> </span><span class="NLM_article-title">RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype</span> <span class="citation_source-journal">Thyroid</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1089/thy.2006.0198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1089%2Fthy.2006.0198" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=101-104&author=G.+Pinnaauthor=G.+Orgianaauthor=A.+Riolaauthor=M.+Ghianiauthor=M.+L.+Laiauthor=C.+Carcassiauthor=S.+Mariotti&title=RET+proto-oncogene+in+Sardinia%3A+V804M+is+the+most+frequent+mutation+and+may+be+associated+with+FMTC%2FMEN-2A+phenotype&doi=10.1089%2Fthy.2006.0198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1089%2Fthy.2006.0198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fthy.2006.0198%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DG.%26aulast%3DOrgiana%26aufirst%3DG.%26aulast%3DRiola%26aufirst%3DA.%26aulast%3DGhiani%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DM.%2BL.%26aulast%3DCarcassi%26aufirst%3DC.%26aulast%3DMariotti%26aufirst%3DS.%26atitle%3DRET%2520proto-oncogene%2520in%2520Sardinia%253A%2520V804M%2520is%2520the%2520most%2520frequent%2520mutation%2520and%2520may%2520be%2520associated%2520with%2520FMTC%252FMEN-2A%2520phenotype%26jtitle%3DThyroid%26date%3D2007%26volume%3D17%26spage%3D101%26epage%3D104%26doi%3D10.1089%2Fthy.2006.0198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1016/S1535-6108(02)00096-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia&doi=10.1016%2FS1535-6108%2802%2900096-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0li6Bb9k9m95dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125%26doi%3D10.1016%2FS1535-6108%2802%2900096-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breeden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span><span class="refDoi"> DOI: 10.1182/blood-2007-11-123950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1182%2Fblood-2007-11-123950" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=53-55&author=E.+Jabbourauthor=H.+Kantarjianauthor=D.+Jonesauthor=M.+Breedenauthor=G.+Garcia-Maneroauthor=S.+O%E2%80%99Brienauthor=F.+Ravandiauthor=G.+Borthakurauthor=J.+Cortes&title=Characteristics+and+outcomes+of+patients+with+chronic+myeloid+leukemia+and+T315I+mutation+following+failure+of+imatinib+mesylate+therapy&doi=10.1182%2Fblood-2007-11-123950"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-11-123950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-11-123950%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DBreeden%26aufirst%3DM.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DCharacteristics%2520and%2520outcomes%2520of%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520and%2520T315I%2520mutation%2520following%2520failure%2520of%2520imatinib%2520mesylate%2520therapy%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D53%26epage%3D55%26doi%3D10.1182%2Fblood-2007-11-123950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Giaccone, G.</span><span> </span><span class="NLM_article-title">EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1038/ncponc0200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2Fncponc0200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=16264986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A280%3ADC%252BD2Mros1Wnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=296-297&author=G.+Giaccone&title=EGFR+point+mutation+confers+resistance+to+gefitinib+in+a+patient+with+non-small-cell+lung+cancer&doi=10.1038%2Fncponc0200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer</span></div><div class="casAuthors">Giaccone Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature clinical practice. Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">296-7</span>
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1T0RPlFKPxLFU0A1HOshhfW6udTcc2eatFj9jZI2Cprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mros1Wnsg%253D%253D&md5=ce9b6b319dc5bb04664ba6474f8882c5</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1038%2Fncponc0200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0200%26sid%3Dliteratum%253Aachs%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DEGFR%2520point%2520mutation%2520confers%2520resistance%2520to%2520gefitinib%2520in%2520a%2520patient%2520with%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2005%26volume%3D2%26spage%3D296%26epage%3D297%26doi%3D10.1038%2Fncponc0200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljm4h0I6Eb3iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span> </span><span class="NLM_article-title">Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2910</span><span class="NLM_x">–</span> <span class="NLM_lpage">2918</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1158%2F1535-7163.MCT-14-0274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=25349307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCju7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2910-2918&author=T.+Kodamaauthor=T.+Tsukaguchiauthor=Y.+Satohauthor=M.+Yoshidaauthor=Y.+Watanabeauthor=O.+Kondohauthor=H.+Sakamoto&title=Alectinib+shows+potent+antitumor+activity+against+RET-rearranged+non-small+cell+lung+cancer&doi=10.1158%2F1535-7163.MCT-14-0274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Kodama, Tatsushi; Tsukaguchi, Toshiyuki; Satoh, Yasuko; Yoshida, Miyuki; Watanabe, Yoshiaki; Kondoh, Osamu; Sakamoto, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2910-2918</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Alectinib/CH5424802 is a known inhibitor of anaplastic lymphoma kinase (ALK) and is being evaluated in clin. trials for the treatment of ALK fusion-pos. non-small cell lung cancer (NSCLC).  Recently, some RET and ROS1 fusion genes have been implicated as driver oncogenes in NSCLC and have become mol. targets for antitumor agents.  This study aims to explore addnl. target indications of alectinib by testing its ability to inhibit the activity of kinases other than ALK.  We newly verified that alectinib inhibited RET kinase activity and the growth of RET fusion-pos. cells by suppressing RET phosphorylation.  In contrast, alectinib hardly inhibited ROS1 kinase activity unlike other ALK/ROS1 inhibitors such as crizotinib and LDK378.  It also showed antitumor activity in mouse models of tumors driven by the RET fusion.  In addn., alectinib showed kinase inhibitory activity against RET gatekeeper mutations (RET V804L and V804M) and blocked cell growth driven by the KIF5B-RET V804L and V804M.  Our results suggest that alectinib is effective against RET fusion-pos. tumors.  Thus, alectinib might be a therapeutic option for patients with RET fusion-pos. NSCLC.  Mol Cancer Ther; 13(12); 2910-8. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoydfltWoZlIrVg90H21EOLACvtfcHk0ljm4h0I6Eb3iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCju7vF&md5=c7e0003e2906707cbec875c8ca9c9e39</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0274%26sid%3Dliteratum%253Aachs%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DSakamoto%26aufirst%3DH.%26atitle%3DAlectinib%2520shows%2520potent%2520antitumor%2520activity%2520against%2520RET-rearranged%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2910%26epage%3D2918%26doi%3D10.1158%2F1535-7163.MCT-14-0274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza-Menacho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1016/j.mce.2013.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1016%2Fj.mce.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=23811235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2013&pages=1-6&author=L.+Mologniauthor=S.+Redaelliauthor=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+Gambacorti-Passerini&title=Ponatinib+is+a+potent+inhibitor+of+wild-type+and+drug-resistant+gatekeeper+mutant+RET+kinase&doi=10.1016%2Fj.mce.2013.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span></div><div class="casAuthors">Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon cancer, and has been validated as a mol. target in these tumors.  Vandetanib was recently approved for the treatment of medullary thyroid cancer.  However, vandetanib is ineffective in vitro against RET mutants carrying bulky aminoacids at position 804, the gatekeeper residue, similarly to drug-resistant BCR-ABL mutants in chronic myeloid leukemia.  Ponatinib is a multi-target kinase inhibitor that was recently approved for treatment-refractory Philadelphia-pos. leukemia.  We show here potent inhibition of oncogenic RET by ponatinib, including the drug-insensitive V804M/L mutants.  Ponatinib inhibited the growth of RET+ and BCR-ABL+ cells with similar potency, while not affecting RET-neg. cells.  Both in biochem. and in cellular assays ponatinib compared favorably with known RET inhibitors, such as vandetanib, cabozantinib, sorafenib, sunitinib and motesanib, used as ref. compds.  We suggest that ponatinib should be considered for the treatment of RET+ tumors, in particular those expressing vandetanib-resistant V804M/L mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1KRyhCS6ULVg90H21EOLACvtfcHk0litiJd5CbyBjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP&md5=f08de33f80af574f3ec843d26269ed98</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DPonatinib%2520is%2520a%2520potent%2520inhibitor%2520of%2520wild-type%2520and%2520drug-resistant%2520gatekeeper%2520mutant%2520RET%2520kinase%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D377%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.mce.2013.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Falco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonocore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torregrossa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">E811</span><span class="NLM_x">–</span> <span class="NLM_lpage">E819</span><span class="refDoi"> DOI: 10.1210/jc.2012-2672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1210%2Fjc.2012-2672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=23526464" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=E811-E819&author=V.+De+Falcoauthor=P.+Buonocoreauthor=M.+Muthuauthor=L.+Torregrossaauthor=F.+Basoloauthor=F.+Billaudauthor=J.+M.+Gozgitauthor=F.+Carlomagnoauthor=M.+Santoro&title=Ponatinib+%28AP24534%29+Is+a+Novel+Potent+Inhibitor+of+Oncogenic+RET+Mutants+Associated+With+Thyroid+Cancer&doi=10.1210%2Fjc.2012-2672"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1210%2Fjc.2012-2672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2012-2672%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DBuonocore%26aufirst%3DP.%26aulast%3DMuthu%26aufirst%3DM.%26aulast%3DTorregrossa%26aufirst%3DL.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DBillaud%26aufirst%3DF.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DPonatinib%2520%2528AP24534%2529%2520Is%2520a%2520Novel%2520Potent%2520Inhibitor%2520of%2520Oncogenic%2520RET%2520Mutants%2520Associated%2520With%2520Thyroid%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3DE811%26epage%3DE819%26doi%3D10.1210%2Fjc.2012-2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Frett, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moccia, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brescia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Falco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Admire, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. Y.</span><span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8717</span><span class="NLM_x">–</span> <span class="NLM_lpage">8721</span><span class="refDoi"> DOI: 10.1002/anie.201501104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1002%2Fanie.201501104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8717-8721&author=B.+Frettauthor=F.+Carlomagnoauthor=M.+L.+Mocciaauthor=A.+Bresciaauthor=G.+Federicoauthor=V.+De+Falcoauthor=B.+Admireauthor=Z.+Z.+Chenauthor=W.+Q.+Qiauthor=M.+Santoroauthor=H.+Y.+Li&title=Fragment-Based+Discovery+of+a+Dual+pan-RET%2FVEGFR2+Kinase+Inhibitor+Optimized+for+Single-Agent+Polypharmacology&doi=10.1002%2Fanie.201501104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span></div><div class="casAuthors">Frett, Brendan; Carlomagno, Francesca; Moccia, Maria Luisa; Brescia, Annalisa; Federico, Giorgia; De Falco, Valentina; Admire, Brittany; Chen, Zhongzhu; Qi, Wenqing; Santoro, Massimo; Li, Hong-yu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8717-8721</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is assocd. with several cancers.  A fragment-based chem. screen led to the identification of a novel RET inhibitor, Pz-1.  Modeling and kinetic anal. identified Pz-1 as a type II tyrosine kinase inhibitor that is able to bind the "DFG-out" conformation of the kinase.  Importantly, from a single-agent polypharmacol. standpoint, Pz-1 was shown to be active on VEGFR2, which can block the blood supply required for RET-stimulated growth.  In cell-based assays, 1.0 nM of Pz-1 strongly inhibited phosphorylation of all tested RET oncoproteins.  At 1.0 mg kg-1 day-1 per os, Pz-1 abrogated the formation of tumors induced by RET-mutant fibroblasts and blocked the phosphorylation of both RET and VEGFR2 in tumor tissue.  Pz-1 featured no detectable toxicity at concns. of up to 100.0 mg kg-1, which indicates a large therapeutic window.  This study validates the effectiveness and usefulness of a medicinal chem./polypharmacol. approach to obtain an inhibitor capable of targeting multiple oncogenic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcoWkpO70i7rVg90H21EOLACvtfcHk0litiJd5CbyBjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtLnL&md5=05039c7074e7375de3884e0550d8c7ff</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fanie.201501104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201501104%26sid%3Dliteratum%253Aachs%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DMoccia%26aufirst%3DM.%2BL.%26aulast%3DBrescia%26aufirst%3DA.%26aulast%3DFederico%26aufirst%3DG.%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DAdmire%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%2BZ.%26aulast%3DQi%26aufirst%3DW.%2BQ.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%2BY.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Dual%2520pan-RET%252FVEGFR2%2520Kinase%2520Inhibitor%2520Optimized%2520for%2520Single-Agent%2520Polypharmacology%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D8717%26epage%3D8721%26doi%3D10.1002%2Fanie.201501104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span> </span><span class="NLM_article-title">Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e30353</span><span class="refDoi"> DOI: 10.1371/journal.pone.0030353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1371%2Fjournal.pone.0030353" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e30353&author=J.+J.+Zangauthor=S.+Q.+Wuauthor=L.+Tangauthor=X.+D.+Xuauthor=J.+Baiauthor=C.+C.+Dingauthor=Y.+Changauthor=L.+Yueauthor=E.+M.+Kangauthor=J.+He&title=Incidence+and+Risk+of+QTc+Interval+Prolongation+among+Cancer+Patients+Treated+with+Vandetanib%3A+A+Systematic+Review+and+Meta-analysis&doi=10.1371%2Fjournal.pone.0030353"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0030353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0030353%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%2BJ.%26aulast%3DWu%26aufirst%3DS.%2BQ.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DX.%2BD.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DC.%2BC.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DYue%26aufirst%3DL.%26aulast%3DKang%26aufirst%3DE.%2BM.%26aulast%3DHe%26aufirst%3DJ.%26atitle%3DIncidence%2520and%2520Risk%2520of%2520QTc%2520Interval%2520Prolongation%2520among%2520Cancer%2520Patients%2520Treated%2520with%2520Vandetanib%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-analysis%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De30353%26doi%3D10.1371%2Fjournal.pone.0030353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhang, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H. Q.</span><span> </span><span class="NLM_article-title">Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e90135</span><span class="refDoi"> DOI: 10.1371/journal.pone.0090135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1371%2Fjournal.pone.0090135" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e90135&author=Z.+F.+Zhangauthor=T.+Wangauthor=L.+H.+Liuauthor=H.+Q.+Guo&title=Risks+of+Proteinuria+Associated+with+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors+in+Cancer+Patients%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1371%2Fjournal.pone.0090135"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0090135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0090135%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DL.%2BH.%26aulast%3DGuo%26aufirst%3DH.%2BQ.%26atitle%3DRisks%2520of%2520Proteinuria%2520Associated%2520with%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Cancer%2520Patients%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De90135%26doi%3D10.1371%2Fjournal.pone.0090135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Qi, W. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span> </span><span class="NLM_article-title">Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">919</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04417.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1111%2Fj.1365-2125.2012.04417.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=22882307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFOgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=919-930&author=W.+X.+Qiauthor=Z.+Shenauthor=F.+Linauthor=Y.+J.+Sunauthor=D.+L.+Minauthor=L.+N.+Tangauthor=A.+N.+Heauthor=Y.+Yao&title=Incidence+and+risk+of+hypertension+with+vandetanib+in+cancer+patients%3A+a+systematic+review+and+meta-analysis+of+clinical+trials&doi=10.1111%2Fj.1365-2125.2012.04417.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials</span></div><div class="casAuthors">Qi, Wei-Xiang; Shen, Zan; Lin, Feng; Sun, Yuan-jue; Min, Da-liu; Tang, Li-Na; He, Ai-Na; Yao, Yang</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">919-930</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : To perform a systematic review and meta-anal. of published clin. trials to det. incidence rate and overall risk of hypertension with vandetanib in cancer patients.  Methods : A comprehensive literature search for studies published up to March 2012 was performed.  Summary incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calcd. employing fixed- or random-effects models depending on the heterogeneity of the included trials.  Results : A total of 11 trials with 3154 patients were included for the meta-anal.  The summary incidences of all-grade and high-grade hypertension in patients with cancer were 24.2% [95% confidence interval (CI), 18.1-30.2%] and 6.4% (95% CI, 3.3-9.5%), resp.  Subgroup anal. demonstrated that the pooled incidences of all-grade and high-grade hypertension were 21.8% [95% CI, 15-30.5%] and 7.6% (95% CI, 2.8-18.8%), resp., among non-small-cell lung cancer (NSCLC) patients, and 32.1% (95% CI: 27.3-37.3%) and 8.8% (5.9%-12.9%), resp., among MTC patients, and 15.4 (95% CI: 3.2-33.7%) and 3.4% (95% CI: 1%-11.1%) resp., among non-MTC/NSCLC tumors patients.  Furthermore, vandetanib was assocd. with a significant increased risk of all-grade hypertension (RR 5.1, 95% CI: 3.76-6.92, P = 0.000) and high-grade hypertension (RR 8.06, 95% CI: 3.41-19.04, P = 0.000) in comparison with controls.  Conclusions : There is a significant risk of developing hypertension in cancer patients receiving vandetanib.  Appropriate monitoring and treatment is strongly recommended to prevent cardiovascular complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmpi83QcuIBbVg90H21EOLACvtfcHk0liabMbB_qDWKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFOgsb4%253D&md5=fa30d2837fd2da42742862f644c19d0c</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04417.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04417.x%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%2BX.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DY.%2BJ.%26aulast%3DMin%26aufirst%3DD.%2BL.%26aulast%3DTang%26aufirst%3DL.%2BN.%26aulast%3DHe%26aufirst%3DA.%2BN.%26aulast%3DYao%26aufirst%3DY.%26atitle%3DIncidence%2520and%2520risk%2520of%2520hypertension%2520with%2520vandetanib%2520in%2520cancer%2520patients%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520clinical%2520trials%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D919%26epage%3D930%26doi%3D10.1111%2Fj.1365-2125.2012.04417.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaelin, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutcher, J. P.</span><span> </span><span class="NLM_article-title">A phase I study of cabozantinib (XL184) in patients with renal cell cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1608</span><span class="refDoi"> DOI: 10.1093/annonc/mdu184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1093%2Fannonc%2Fmdu184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=24827131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A280%3ADC%252BC2cjislyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1603-1608&author=T.+K.+Choueiriauthor=S.+K.+Palauthor=D.+F.+McDermottauthor=S.+Morrisseyauthor=K.+C.+Fergusonauthor=J.+Hollandauthor=W.+G.+Kaelinauthor=J.+P.+Dutcher&title=A+phase+I+study+of+cabozantinib+%28XL184%29+in+patients+with+renal+cell+cancer&doi=10.1093%2Fannonc%2Fmdu184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19dR"><div class="casContent"><span class="casTitleNuber">19d</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of cabozantinib (XL184) in patients with renal cell cancer</span></div><div class="casAuthors">Choueiri T K; Morrissey S; Kaelin W G; Pal S K; McDermott D F; Ferguson K C; Holland J; Dutcher J P</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1603-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are important drug targets in renal cell carcinoma (RCC).  PATIENTS AND METHODS:  This single-arm open-label phase I trial evaluated the safety and tolerability of cabozantinib in heavily pretreated patients with metastatic clear cell RCC.  RESULTS:  The study enrolled 25 RCC patients for whom standard therapy had failed.  Patients received a median of two prior systemic agents, and most patients had previously received at least one VEGF pathway inhibiting therapy (22 patients [88%]).  Common adverse events included fatigue, diarrhea, nausea, proteinuria, appetite decreased, palmar-plantar erythrodysesthesia, and vomiting.  Partial response was reported in seven patients (28%).  Median progression-free survival was 12.9 months, and median overall survival was 15.0 months.  CONCLUSION:  Cabozantinib demonstrates preliminary anti-tumor activity and a safety profile similar to that seen with other multitargeted VEGFR tyrosine kinase inhibitors in advanced RCC patients.  Further evaluation of cabozantinib in RCC is warranted.  ClinicalTrials.gov identifier: NCT01100619.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsk4Vjqyl9wdHxxy173TfNfW6udTcc2eZv28Qh412mHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjislyisQ%253D%253D&md5=08d0408e4b6c33c7bcca1ebdcf624d51</span></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu184%26sid%3Dliteratum%253Aachs%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DMorrissey%26aufirst%3DS.%26aulast%3DFerguson%26aufirst%3DK.%2BC.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26aulast%3DDutcher%26aufirst%3DJ.%2BP.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520cabozantinib%2520%2528XL184%2529%2520in%2520patients%2520with%2520renal%2520cell%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1603%26epage%3D1608%26doi%3D10.1093%2Fannonc%2Fmdu184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Jawalekar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reubsaet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutjes, F. P. J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Delft, F. L.</span><span> </span><span class="NLM_article-title">Synthesis of isoxazoles by hypervalent iodine-induced cycloaddition of nitrile oxides to alkynes</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3198</span><span class="NLM_x">–</span> <span class="NLM_lpage">3200</span><span class="refDoi"> DOI: 10.1039/c0cc04646a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1039%2Fc0cc04646a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=21286620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1ertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=3198-3200&author=A.+M.+Jawalekarauthor=E.+Reubsaetauthor=F.+P.+J.+T.+Rutjesauthor=F.+L.+van+Delft&title=Synthesis+of+isoxazoles+by+hypervalent+iodine-induced+cycloaddition+of+nitrile+oxides+to+alkynes&doi=10.1039%2Fc0cc04646a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of isoxazoles by hypervalent iodine-induced cycloaddition of nitrile oxides to alkynes</span></div><div class="casAuthors">Jawalekar, Anup M.; Reubsaet, Erik; Rutjes, Floris P. J. T.; van Delft, Floris L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3198-3200</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Treatment of oximes with hypervalent iodine leads to substituted isoxazoles via rapid formation of nitrile oxides.  Reaction with terminal alkynes led to a series of 3,5-disubstituted isoxazoles with complete regioselectivity and high yield, in a procedure mild enough to prep. a range of nucleoside and peptide conjugates.  Exceptionally high reaction rates were found for the formation of 3,4,5-trisubstituted isoxazoles from a cyclic alkyne.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRG9XOcr5E7Vg90H21EOLACvtfcHk0lihrYJWQCDg9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1ertLc%253D&md5=dbc1ab6da96fd068d45581ba9fc1e129</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc0cc04646a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0cc04646a%26sid%3Dliteratum%253Aachs%26aulast%3DJawalekar%26aufirst%3DA.%2BM.%26aulast%3DReubsaet%26aufirst%3DE.%26aulast%3DRutjes%26aufirst%3DF.%2BP.%2BJ.%2BT.%26aulast%3Dvan%2BDelft%26aufirst%3DF.%2BL.%26atitle%3DSynthesis%2520of%2520isoxazoles%2520by%2520hypervalent%2520iodine-induced%2520cycloaddition%2520of%2520nitrile%2520oxides%2520to%2520alkynes%26jtitle%3DChem.%2520Commun.%26date%3D2011%26volume%3D47%26spage%3D3198%26epage%3D3200%26doi%3D10.1039%2Fc0cc04646a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvatore, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defranciscis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panariello, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colantuoni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span> </span><span class="NLM_article-title">Point Mutation of the Ret Protooncogene in the Tt Human Medullary-Thyroid Carcinoma Cell-Line</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">207</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span><span class="refDoi"> DOI: 10.1006/bbrc.1995.1287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1006%2Fbbrc.1995.1287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=1995&pages=1022-1028&author=F.+Carlomagnoauthor=D.+Salvatoreauthor=M.+Santoroauthor=V.+Defranciscisauthor=L.+Quadroauthor=L.+Panarielloauthor=V.+Colantuoniauthor=A.+Fusco&title=Point+Mutation+of+the+Ret+Protooncogene+in+the+Tt+Human+Medullary-Thyroid+Carcinoma+Cell-Line&doi=10.1006%2Fbbrc.1995.1287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1995.1287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1995.1287%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSalvatore%26aufirst%3DD.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DDefranciscis%26aufirst%3DV.%26aulast%3DQuadro%26aufirst%3DL.%26aulast%3DPanariello%26aufirst%3DL.%26aulast%3DColantuoni%26aufirst%3DV.%26aulast%3DFusco%26aufirst%3DA.%26atitle%3DPoint%2520Mutation%2520of%2520the%2520Ret%2520Protooncogene%2520in%2520the%2520Tt%2520Human%2520Medullary-Thyroid%2520Carcinoma%2520Cell-Line%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D207%26spage%3D1022%26epage%3D1028%26doi%3D10.1006%2Fbbrc.1995.1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licitra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medvedev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreissl, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3639</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span><span class="refDoi"> DOI: 10.1200/JCO.2012.48.4659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3946&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+Mullerauthor=P.+Schoffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0lihrYJWQCDg9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DMuller%26aufirst%3DS.%2BP.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3946%26doi%3D10.1200%2FJCO.2012.48.4659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimono, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakumo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span> </span><span class="NLM_article-title">Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4469</span><span class="NLM_x">–</span> <span class="NLM_lpage">4475</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2Fsj.onc.1203799" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=4469-4475&author=H.+Hayashiauthor=M.+Ichiharaauthor=T.+Iwashitaauthor=H.+Murakamiauthor=Y.+Shimonoauthor=K.+Kawaiauthor=K.+Kurokawaauthor=Y.+Murakumoauthor=T.+Imaiauthor=H.+Funahashiauthor=A.+Nakaoauthor=M.+Takahashi&title=Characterization+of+intracellular+signals+via+tyrosine+1062+in+RET+activated+by+glial+cell+line-derived+neurotrophic+factor&doi=10.1038%2Fsj.onc.1203799"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203799%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DH.%26aulast%3DIchihara%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DShimono%26aufirst%3DY.%26aulast%3DKawai%26aufirst%3DK.%26aulast%3DKurokawa%26aufirst%3DK.%26aulast%3DMurakumo%26aufirst%3DY.%26aulast%3DImai%26aufirst%3DT.%26aulast%3DFunahashi%26aufirst%3DH.%26aulast%3DNakao%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520intracellular%2520signals%2520via%2520tyrosine%25201062%2520in%2520RET%2520activated%2520by%2520glial%2520cell%2520line-derived%2520neurotrophic%2520factor%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D4469%26epage%3D4475%26doi%3D10.1038%2Fsj.onc.1203799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Iwashita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyauchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span> </span><span class="NLM_article-title">A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">804</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span><span class="refDoi"> DOI: 10.1006/bbrc.2000.2227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1006%2Fbbrc.2000.2227" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2000&pages=804-808&author=T.+Iwashitaauthor=H.+Murakamiauthor=K.+Kurokawaauthor=K.+Kawaiauthor=A.+Miyauchiauthor=H.+Futamiauthor=S.+Qiaoauthor=M.+Ichiharaauthor=M.+Takahashi&title=A+two-hit+model+for+development+of+multiple+endocrine+neoplasia+type+2B+by+RET+mutations&doi=10.1006%2Fbbrc.2000.2227"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.2000.2227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.2000.2227%26sid%3Dliteratum%253Aachs%26aulast%3DIwashita%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DKurokawa%26aufirst%3DK.%26aulast%3DKawai%26aufirst%3DK.%26aulast%3DMiyauchi%26aufirst%3DA.%26aulast%3DFutami%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DS.%26aulast%3DIchihara%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DM.%26atitle%3DA%2520two-hit%2520model%2520for%2520development%2520of%2520multiple%2520endocrine%2520neoplasia%2520type%25202B%2520by%2520RET%2520mutations%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2000%26volume%3D268%26spage%3D804%26epage%3D808%26doi%3D10.1006%2Fbbrc.2000.2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Segouffin-Cariou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, M.</span><span> </span><span class="NLM_article-title">Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">3568</span><span class="NLM_x">–</span> <span class="NLM_lpage">3576</span><span class="refDoi"> DOI: 10.1074/jbc.275.5.3568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1074%2Fjbc.275.5.3568" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=3568-3576&author=C.+Segouffin-Cariouauthor=M.+Billaud&title=Transforming+ability+of+MEN2A-RET+requires+activation+of+the+phosphatidylinositol+3-kinase%2FAKT+signaling+pathway&doi=10.1074%2Fjbc.275.5.3568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.5.3568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.5.3568%26sid%3Dliteratum%253Aachs%26aulast%3DSegouffin-Cariou%26aufirst%3DC.%26aulast%3DBillaud%26aufirst%3DM.%26atitle%3DTransforming%2520ability%2520of%2520MEN2A-RET%2520requires%2520activation%2520of%2520the%2520phosphatidylinositol%25203-kinase%252FAKT%2520signaling%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D3568%26epage%3D3576%26doi%3D10.1074%2Fjbc.275.5.3568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Boulay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuleux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The Ret receptor tyrosine kinase pathway functionally interacts with the ER alpha pathway in breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3743</span><span class="NLM_x">–</span> <span class="NLM_lpage">3751</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1158%2F0008-5472.CAN-07-5100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3743-3751&author=A.+Boulayauthor=M.+Breuleuxauthor=C.+Stephanauthor=C.+Fuxauthor=C.+Briskenauthor=M.+Ficheauthor=M.+Wartmannauthor=M.+Stummauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+Ret+receptor+tyrosine+kinase+pathway+functionally+interacts+with+the+ER+alpha+pathway+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-07-5100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5100%26sid%3Dliteratum%253Aachs%26aulast%3DBoulay%26aufirst%3DA.%26aulast%3DBreuleux%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DFux%26aufirst%3DC.%26aulast%3DBrisken%26aufirst%3DC.%26aulast%3DFiche%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520Ret%2520receptor%2520tyrosine%2520kinase%2520pathway%2520functionally%2520interacts%2520with%2520the%2520ER%2520alpha%2520pathway%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3743%26epage%3D3751%26doi%3D10.1158%2F0008-5472.CAN-07-5100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjaer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibanez, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span> </span><span class="NLM_article-title">Structure and chemical inhibition of the RET tyrosine kinase domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">33577</span><span class="NLM_x">–</span> <span class="NLM_lpage">33587</span><span class="refDoi"> DOI: 10.1074/jbc.M605604200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kjaerauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ibanezauthor=N.+Q.+McDonald&title=Structure+and+chemical+inhibition+of+the+RET+tyrosine+kinase+domain&doi=10.1074%2Fjbc.M605604200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0lilLzgnyhlsWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIbanez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520chemical%2520inhibition%2520of%2520the%2520RET%2520tyrosine%2520kinase%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587%26doi%3D10.1074%2Fjbc.M605604200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1158%2F0008-5472.CAN-08-4889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=19808973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+W.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+Tumor+Cell+Growth%2C+Invasion%2C+and+Metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+Novel+Inhibitor+of+HGF+and+VEGF+Receptor+Tyrosine+Kinases&doi=10.1158%2F0008-5472.CAN-08-4889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span></div><div class="casAuthors">Qian, Fawn; Engst, Stefan; Yamaguchi, Kyoko; Yu, Peiwen; Won, Kwang-Ai; Mock, Lillian; Lou, Tracy; Tan, Jenny; Li, Connie; Tam, Danny; Lougheed, Julie; Yakes, F. Michael; Bentzien, Frauke; Xu, Wei; Zaks, Tal; Wooster, Richard; Greshock, Joel; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8009-8016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies.  Vascular endothelial growth factor (VEGF) receptors are expressed on the surface of vascular endothelial cells and cooperate with Met to induce tumor invasion and vascularization.  EXEL-2880 (XL880, GSK1363089) is a small-mol. kinase inhibitor that targets members of the HGF and VEGF receptor tyrosine kinase families, with addnl. inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor β, and Tie-2.  Binding of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consistent with X-ray crystallog. data showing that the inhibitor is deeply bound in the Met kinase active site cleft.  EXEL-2880 inhibits cellular HGF-induced Met phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells.  In addn., EXEL-2880 prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions.  In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an exptl. model of lung metastasis.  Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoviVE_HZ5p_bVg90H21EOLACvtfcHk0ligo7Xf1gW15w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF&md5=f3bf5b432ee42b164d23b690828e3c78</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4889%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%2BW.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520Tumor%2520Cell%2520Growth%252C%2520Invasion%252C%2520and%2520Metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520Novel%2520Inhibitor%2520of%2520HGF%2520and%2520VEGF%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.CAN-08-4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b'],'ref15':['cit15a','cit15b'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c','cit19d'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b','cit23c'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 23 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Virginia Spanò, Roberta Rocca, Marilia Barreca, Daniele Giallombardo, Alessandra Montalbano, Anna Carbone, Maria Valeria Raimondi, Eugenio Gaudio, Roberta Bortolozzi, Ruoli Bai, Pierfrancesco Tassone, Stefano Alcaro, Ernest Hamel, Giampietro Viola, Francesco Bertoni, <span class="NLM_string-name hlFld-ContribAuthor">Paola Barraja</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 12023-12042. <a href="https://doi.org/10.1021/acs.jmedchem.0c01315" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01315%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrrolo%25255B2%2525E2%252580%2525B2%25252C3%2525E2%252580%2525B2%25253A3%25252C4%25255Dcyclohepta%25255B1%25252C2-d%25255D%25255B1%25252C2%25255Doxazoles%25252C%252Ba%252BNew%252BClass%252Bof%252BAntimitotic%252BAgents%252BActive%252Bagainst%252BMultiple%252BMalignant%252BCell%252BTypes%26aulast%3DSpan%25C3%25B2%26aufirst%3DVirginia%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29072020%26date%3D12102020%26date%3D28092020%26volume%3D63%26issue%3D20%26spage%3D12023%26epage%3D12042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rebecca Newton, Bohdan Waszkowycz, Chitra Seewooruthun, Daniel Burschowsky, Mark Richards, Samantha Hitchin, Habiba Begum, Amanda Watson, Eleanor French, Niall Hamilton, Stuart Jones, Li-Ying Lin, Ian Waddell, Aude Echalier, Richard Bayliss, Allan M. Jordan, <span class="NLM_string-name hlFld-ContribAuthor">Donald Ogilvie</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RETV804M Kinase. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (4)
                                     , 497-505. <a href="https://doi.org/10.1021/acsmedchemlett.9b00615" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00615</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00615%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252BOptimization%252Bof%252Bwt-RET%25252FKDR-Selective%252BInhibitors%252Bof%252BRETV804M%252BKinase%26aulast%3DNewton%26aufirst%3DRebecca%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D17122019%26date%3D28022020%26date%3D06032020%26date%3D28022020%26volume%3D11%26issue%3D4%26spage%3D497%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hanna Cho, Injae Shin, Eunhye Ju, Seunghye Choi, Wooyoung Hur, Haelee Kim, Eunmi Hong, Nam Doo Kim, Hwan Geun Choi, Nathanael S. Gray, <span class="NLM_string-name hlFld-ContribAuthor">Taebo Sim</span>. </span><span class="cited-content_cbyCitation_article-title">First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (18)
                                     , 8353-8373. <a href="https://doi.org/10.1021/acs.jmedchem.8b00882" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00882%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFirst%252BSAR%252BStudy%252Bfor%252BOverriding%252BNRAS%252BMutant%252BDriven%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DCho%26aufirst%3DHanna%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04062018%26date%3D11092018%26date%3D28082018%26volume%3D61%26issue%3D18%26spage%3D8353%26epage%3D8373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Carra</span>, <span class="hlFld-ContribAuthor ">Germano  Gaudenzi</span>, <span class="hlFld-ContribAuthor ">Alessandra  Dicitore</span>, <span class="hlFld-ContribAuthor ">Davide  Saronni</span>, <span class="hlFld-ContribAuthor ">Maria Celeste  Cantone</span>, <span class="hlFld-ContribAuthor ">Alice  Plebani</span>, <span class="hlFld-ContribAuthor ">Anna  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Maria Orietta  Borghi</span>, <span class="hlFld-ContribAuthor ">Leo J.  Hofland</span>, <span class="hlFld-ContribAuthor ">Luca  Persani</span>, <span class="hlFld-ContribAuthor ">Giovanni  Vitale</span>. </span><span class="cited-content_cbyCitation_article-title">Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (6)
                                     , 3031. <a href="https://doi.org/10.3390/ijms22063031" title="DOI URL">https://doi.org/10.3390/ijms22063031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22063031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22063031%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DVandetanib%252Bversus%252BCabozantinib%252Bin%252BMedullary%252BThyroid%252BCarcinoma%25253A%252BA%252BFocus%252Bon%252BAnti-Angiogenic%252BEffects%252Bin%252BZebrafish%252BModel%26aulast%3DCarra%26aufirst%3DSilvia%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D6%26spage%3D3031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Swapnil P.  Bhujbal</span>, <span class="hlFld-ContribAuthor ">Seketoulie  Keretsu</span>, <span class="hlFld-ContribAuthor ">Seung Joo  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (3)
                                     , 691. <a href="https://doi.org/10.3390/molecules26030691" title="DOI URL">https://doi.org/10.3390/molecules26030691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26030691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26030691%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DMolecular%252BModelling%252BStudies%252Bon%252BPyrazole%252BDerivatives%252Bfor%252Bthe%252BDesign%252Bof%252BPotent%252BRearranged%252Bduring%252BTransfection%252BKinase%252BInhibitors%26aulast%3DBhujbal%26aufirst%3DSwapnil%2BP.%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D3%26spage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cong-Cong  Jia</span>, <span class="hlFld-ContribAuthor ">Wang  Chen</span>, <span class="hlFld-ContribAuthor ">Zi-Li  Feng</span>, <span class="hlFld-ContribAuthor ">Zhao-Peng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     , 45-62. <a href="https://doi.org/10.4155/fmc-2020-0170" title="DOI URL">https://doi.org/10.4155/fmc-2020-0170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0170%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bof%252BRET%252Bprotein%252Bkinase%252Binhibitors%252Bwith%252Bdiverse%252Bscaffolds%252Bas%252Bhinge%252Bbinders%26aulast%3DJia%26aufirst%3DCong-Cong%26date%3D2021%26volume%3D13%26issue%3D1%26spage%3D45%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eddie L  Myers</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5–6 Systems: Other Four Heteroatoms 2:2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00056-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00056-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00056-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00056-1%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5%2525E2%252580%2525936%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25253A2%26aulast%3DMyers%26aufirst%3DEddie%2BL%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyang  Li</span>, <span class="hlFld-ContribAuthor ">Jingyi  Su</span>, <span class="hlFld-ContribAuthor ">Yanru  Yang</span>, <span class="hlFld-ContribAuthor ">Wenhua  Lian</span>, <span class="hlFld-ContribAuthor ">Zhou  Deng</span>, <span class="hlFld-ContribAuthor ">Zaiyou  Yang</span>, <span class="hlFld-ContribAuthor ">Guyue  Chen</span>, <span class="hlFld-ContribAuthor ">Baoding  Zhang</span>, <span class="hlFld-ContribAuthor ">Chao  Dong</span>, <span class="hlFld-ContribAuthor ">Xueyan  Liu</span>, <span class="hlFld-ContribAuthor ">Li  Li</span>, <span class="hlFld-ContribAuthor ">Zheng  Wang</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Hu</span>, <span class="hlFld-ContribAuthor ">Qingyan  Xu</span>, <span class="hlFld-ContribAuthor ">Xianming  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112755. <a href="https://doi.org/10.1016/j.ejmech.2020.112755" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112755</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112755%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-methyl-N-%2525284-%252528%2525284-methylpiperazin-%252B1-yl%252529methyl%252529-3-%252528trifluoromethyl%252529phenyl%252529-3-%252528%2525286-%252528pyridin-3-yl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-yl%252529-oxy%252529benzamide%252Bas%252Ba%252Bpotent%252Binhibitor%252Bof%252BRET%252Band%252Bits%252Bgatekeeper%252Bmutant%26aulast%3DLi%26aufirst%3DXiaoyang%26date%3D2020%26volume%3D207%26spage%3D112755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mehwash  Zia</span>, <span class="hlFld-ContribAuthor ">Shahid  Hameed</span>, <span class="hlFld-ContribAuthor ">Iqbal  Ahmad</span>, <span class="hlFld-ContribAuthor ">Nida  Tabassum</span>, <span class="hlFld-ContribAuthor ">Sammer  Yousuf</span>. </span><span class="cited-content_cbyCitation_article-title">Regio-isomeric isoxazole sulfonates: Synthesis, characterization, electrochemical studies and DNA binding activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1220 </em>, 128635. <a href="https://doi.org/10.1016/j.molstruc.2020.128635" title="DOI URL">https://doi.org/10.1016/j.molstruc.2020.128635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2020.128635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2020.128635%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DRegio-isomeric%252Bisoxazole%252Bsulfonates%25253A%252BSynthesis%25252C%252Bcharacterization%25252C%252Belectrochemical%252Bstudies%252Band%252BDNA%252Bbinding%252Bactivity%26aulast%3DZia%26aufirst%3DMehwash%26date%3D2020%26volume%3D1220%26spage%3D128635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunju  Nam</span>, <span class="hlFld-ContribAuthor ">Dongkeun  Hwang</span>, <span class="hlFld-ContribAuthor ">Namdoo  Kim</span>, <span class="hlFld-ContribAuthor ">Hong-Seog  Seo</span>, <span class="hlFld-ContribAuthor ">Khalid B.  Selim</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of 1
              H
              -pyrazolo[3,4-b]pyridine derivatives as potent ALK-L1196M inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 1426-1438. <a href="https://doi.org/10.1080/14756366.2019.1639694" title="DOI URL">https://doi.org/10.1080/14756366.2019.1639694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2019.1639694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2019.1639694%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252B1%252BH%252B-pyrazolo%25255B3%25252C4-b%25255Dpyridine%252Bderivatives%252Bas%252Bpotent%252BALK-L1196M%252Binhibitors%26aulast%3DNam%26aufirst%3DYunju%26date%3D2019%26date%3D2019%26volume%3D34%26issue%3D1%26spage%3D1426%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pablo E.  Guzmán</span>, <span class="hlFld-ContribAuthor ">Rosario C.  Sausa</span>, <span class="hlFld-ContribAuthor ">Leah A.  Wingard</span>, <span class="hlFld-ContribAuthor ">Rose A.  Pesce‐Rodriguez</span>, <span class="hlFld-ContribAuthor ">Jesse J.  Sabatini</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of Isoxazole‐Based Energetic Plasticizer Candidates EEIN and IDN. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>2018 </em>
                                    (47)
                                     , 6724-6728. <a href="https://doi.org/10.1002/ejoc.201801285" title="DOI URL">https://doi.org/10.1002/ejoc.201801285</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201801285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201801285%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252BIsoxazole%2525E2%252580%252590Based%252BEnergetic%252BPlasticizer%252BCandidates%252BEEIN%252Band%252BIDN%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DPablo%2BE.%26date%3D2018%26date%3D2018%26volume%3D2018%26issue%3D47%26spage%3D6724%26epage%3D6728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parthasarathi  Subramanian</span>, <span class="hlFld-ContribAuthor ">Krishna P.  Kaliappan</span>. </span><span class="cited-content_cbyCitation_article-title">Transition-Metal-Free Multicomponent Approach to Stereoenriched Cyclopentyl-isoxazoles through C−C Bond Cleavage. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - An Asian Journal</span><span> <strong>2018,</strong> <em>13 </em>
                                    (16)
                                     , 2031-2039. <a href="https://doi.org/10.1002/asia.201800608" title="DOI URL">https://doi.org/10.1002/asia.201800608</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.201800608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.201800608%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520An%2520Asian%2520Journal%26atitle%3DTransition-Metal-Free%252BMulticomponent%252BApproach%252Bto%252BStereoenriched%252BCyclopentyl-isoxazoles%252Bthrough%252BC%2525E2%252588%252592C%252BBond%252BCleavage%26aulast%3DSubramanian%26aufirst%3DParthasarathi%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D16%26spage%3D2031%26epage%3D2039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Zhu</span>, <span class="hlFld-ContribAuthor ">Jun  Mo</span>, <span class="hlFld-ContribAuthor ">Hong-zhi  Lin</span>, <span class="hlFld-ContribAuthor ">Yao  Chen</span>, <span class="hlFld-ContribAuthor ">Hao-peng  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">The recent progress of isoxazole in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (12)
                                     , 3065-3075. <a href="https://doi.org/10.1016/j.bmc.2018.05.013" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.05.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.05.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Brecent%252Bprogress%252Bof%252Bisoxazole%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DZhu%26aufirst%3DJie%26date%3D2018%26volume%3D26%26issue%3D12%26spage%3D3065%26epage%3D3075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sara  Redaelli</span>, <span class="hlFld-ContribAuthor ">Ivan  Plaza-Menacho</span>, <span class="hlFld-ContribAuthor ">Luca  Mologni</span>. </span><span class="cited-content_cbyCitation_article-title">Novel targeted therapeutics for MEN2. </span><span class="cited-content_cbyCitation_journal-name">Endocrine-Related Cancer</span><span> <strong>2018,</strong> <em>25 </em>
                                    (2)
                                     , T53-T68. <a href="https://doi.org/10.1530/ERC-17-0297" title="DOI URL">https://doi.org/10.1530/ERC-17-0297</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1530/ERC-17-0297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1530%2FERC-17-0297%26sid%3Dliteratum%253Aachs%26jtitle%3DEndocrine-Related%2520Cancer%26atitle%3DNovel%252Btargeted%252Btherapeutics%252Bfor%252BMEN2%26aulast%3DRedaelli%26aufirst%3DSara%26date%3D2018%26volume%3D25%26issue%3D2%26spage%3DT53%26epage%3DT68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiao  Yang</span>, <span class="hlFld-ContribAuthor ">Kai  Chen</span>, <span class="hlFld-ContribAuthor ">Guo  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiu-Yuan  Yang</span>, <span class="hlFld-ContribAuthor ">Yue-Shan  Li</span>, <span class="hlFld-ContribAuthor ">Shen-Zhen  Huang</span>, <span class="hlFld-ContribAuthor ">Yan-Lin  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Xiao-Juan  Jiang</span>, <span class="hlFld-ContribAuthor ">Heng-Xiu  Yan</span>, <span class="hlFld-ContribAuthor ">Jing-Qiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Rong  Xiang</span>, <span class="hlFld-ContribAuthor ">You-Fu  Luo</span>, <span class="hlFld-ContribAuthor ">Wei-Min  Li</span>, <span class="hlFld-ContribAuthor ">Yu-Quan  Wei</span>, <span class="hlFld-ContribAuthor ">Lin-Li  Li</span>, <span class="hlFld-ContribAuthor ">Sheng-Yong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1148-1164. <a href="https://doi.org/10.1016/j.ejmech.2017.09.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Band%252Bstructure-activity%252Brelationship%252Bstudies%252Bof%252BN-phenyl-7%25252C8-dihydro-6H-pyrimido%25255B5%25252C4-b%25255D%25255B1%25252C4%25255Doxazin-4-amine%252Bderivatives%252Bas%252Ba%252Bnew%252Bclass%252Bof%252Binhibitors%252Bof%252BRET%252Band%252Bits%252Bdrug%252Bresistance%252Bmutants%26aulast%3DYang%26aufirst%3DJiao%26date%3D2018%26volume%3D143%26spage%3D1148%26epage%3D1164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Swapnil P.  Bhujbal</span>, <span class="hlFld-ContribAuthor ">Pavithra K.  Balasubramanian</span>, <span class="hlFld-ContribAuthor ">Seung  Joo Cho</span>. </span><span class="cited-content_cbyCitation_article-title">In silico studies on 2-substituted phenol quinazoline derivatives as RET receptor tyrosine kinase antagonists. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2017,</strong> <em>26 </em>
                                    (12)
                                     , 3228-3239. <a href="https://doi.org/10.1007/s00044-017-2016-5" title="DOI URL">https://doi.org/10.1007/s00044-017-2016-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-017-2016-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-017-2016-5%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DIn%252Bsilico%252Bstudies%252Bon%252B2-substituted%252Bphenol%252Bquinazoline%252Bderivatives%252Bas%252BRET%252Breceptor%252Btyrosine%252Bkinase%252Bantagonists%26aulast%3DBhujbal%26aufirst%3DSwapnil%2BP.%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D12%26spage%3D3228%26epage%3D3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fen  Xu</span>, <span class="hlFld-ContribAuthor ">Wei-Fen  Kang</span>, <span class="hlFld-ContribAuthor ">Xiao-Ning  Wang</span>, <span class="hlFld-ContribAuthor ">Ying-Ying  Zhu</span>, <span class="hlFld-ContribAuthor ">San-Xu  Chen</span>, <span class="hlFld-ContribAuthor ">Yue-Jie  Kong</span>, <span class="hlFld-ContribAuthor ">Shao-Ming  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Hypervalent iodine-induced formation of 3,5-disubstituted isoxazoles via [3 + 2] cycloaddition of diynes with aldoximes. </span><span class="cited-content_cbyCitation_journal-name">Monatshefte für Chemie - Chemical Monthly</span><span> <strong>2017,</strong> <em>148 </em>
                                    (6)
                                     , 1109-1116. <a href="https://doi.org/10.1007/s00706-016-1907-3" title="DOI URL">https://doi.org/10.1007/s00706-016-1907-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00706-016-1907-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00706-016-1907-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMonatshefte%2520f%25C3%25BCr%2520Chemie%2520-%2520Chemical%2520Monthly%26atitle%3DHypervalent%252Biodine-induced%252Bformation%252Bof%252B3%25252C5-disubstituted%252Bisoxazoles%252Bvia%252B%25255B3%2525C2%2525A0%25252B%2525C2%2525A02%25255D%252Bcycloaddition%252Bof%252Bdiynes%252Bwith%252Baldoximes%26aulast%3DXu%26aufirst%3DFen%26date%3D2017%26date%3D2017%26volume%3D148%26issue%3D6%26spage%3D1109%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentina  De Falco</span>, <span class="hlFld-ContribAuthor ">Francesca  Carlomagno</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>, <span class="hlFld-ContribAuthor ">Massimo  Santoro</span>. </span><span class="cited-content_cbyCitation_article-title">The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. </span><span class="cited-content_cbyCitation_journal-name">Best Practice & Research Clinical Endocrinology & Metabolism</span><span> <strong>2017,</strong> <em>31 </em>
                                    (3)
                                     , 307-318. <a href="https://doi.org/10.1016/j.beem.2017.04.013" title="DOI URL">https://doi.org/10.1016/j.beem.2017.04.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.beem.2017.04.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.beem.2017.04.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBest%2520Practice%2520%2526%2520Research%2520Clinical%2520Endocrinology%2520%2526%2520Metabolism%26atitle%3DThe%252Bmolecular%252Bbasis%252Bfor%252BRET%252Btyrosine-kinase%252Binhibitors%252Bin%252Bthyroid%252Bcancer%26aulast%3DDe%2BFalco%26aufirst%3DValentina%26date%3D2017%26volume%3D31%26issue%3D3%26spage%3D307%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengyan  Wang</span>, <span class="hlFld-ContribAuthor ">Hongchun  Liu</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Li  Xing</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Xisheng  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure–activity relationship study of pyrazolo[3,4- d ]pyrimidines as tyrosine kinase RET inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (11)
                                     , 2544-2548. <a href="https://doi.org/10.1016/j.bmcl.2017.03.088" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.03.088</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.03.088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.03.088%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bstudy%252Bof%252Bpyrazolo%25255B3%25252C4-%252Bd%252B%25255Dpyrimidines%252Bas%252Btyrosine%252Bkinase%252BRET%252Binhibitors%26aulast%3DWang%26aufirst%3DChengyan%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2544%26epage%3D2548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hojong  Yoon</span>, <span class="hlFld-ContribAuthor ">Injae  Shin</span>, <span class="hlFld-ContribAuthor ">Yunju  Nam</span>, <span class="hlFld-ContribAuthor ">Nam Doo  Kim</span>, <span class="hlFld-ContribAuthor ">Kyung-Bok  Lee</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>125 </em>, 1145-1155. <a href="https://doi.org/10.1016/j.ejmech.2016.10.050" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.10.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.10.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.10.050%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Ba%252Bnovel%252B5-amino-3-%2525285-cyclopropylisoxazol-3-yl%252529-1-isopropyl-1H-pyrazole-4-carboxamide%252Bas%252Ba%252Bspecific%252BRET%252Bkinase%252Binhibitor%26aulast%3DYoon%26aufirst%3DHojong%26date%3D2017%26volume%3D125%26spage%3D1145%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Virginia  Spanò</span>, <span class="hlFld-ContribAuthor ">Marzia  Pennati</span>, <span class="hlFld-ContribAuthor ">Barbara  Parrino</span>, <span class="hlFld-ContribAuthor ">Anna  Carbone</span>, <span class="hlFld-ContribAuthor ">Alessandra  Montalbano</span>, <span class="hlFld-ContribAuthor ">Alessia  Lopergolo</span>, <span class="hlFld-ContribAuthor ">Valentina  Zuco</span>, <span class="hlFld-ContribAuthor ">Denis  Cominetti</span>, <span class="hlFld-ContribAuthor ">Patrizia  Diana</span>, <span class="hlFld-ContribAuthor ">Girolamo  Cirrincione</span>, <span class="hlFld-ContribAuthor ">Nadia  Zaffaroni</span>, <span class="hlFld-ContribAuthor ">Paola  Barraja</span>. </span><span class="cited-content_cbyCitation_article-title">[1,2]Oxazolo[5,4- e ]isoindoles as promising tubulin polymerization inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>124 </em>, 840-851. <a href="https://doi.org/10.1016/j.ejmech.2016.09.013" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.09.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.09.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.09.013%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%25255B1%25252C2%25255DOxazolo%25255B5%25252C4-%252Be%252B%25255Disoindoles%252Bas%252Bpromising%252Btubulin%252Bpolymerization%252Binhibitors%26aulast%3DSpan%25C3%25B2%26aufirst%3DVirginia%26date%3D2016%26volume%3D124%26spage%3D840%26epage%3D851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taiki  Morita</span>, <span class="hlFld-ContribAuthor ">Shinichiro  Fuse</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Nakamura</span>. </span><span class="cited-content_cbyCitation_article-title">Generation of an 4-Isoxazolyl Anion Species: Facile Access to Multifunctionalized Isoxazoles. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2016,</strong> <em>128 </em>
                                    (43)
                                     , 13778-13782. <a href="https://doi.org/10.1002/ange.201608039" title="DOI URL">https://doi.org/10.1002/ange.201608039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201608039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201608039%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DGeneration%252Bof%252Ban%252B4-Isoxazolyl%252BAnion%252BSpecies%25253A%252BFacile%252BAccess%252Bto%252BMultifunctionalized%252BIsoxazoles%26aulast%3DMorita%26aufirst%3DTaiki%26date%3D2016%26date%3D2016%26volume%3D128%26issue%3D43%26spage%3D13778%26epage%3D13782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taiki  Morita</span>, <span class="hlFld-ContribAuthor ">Shinichiro  Fuse</span>, <span class="hlFld-ContribAuthor ">Hiroyuki  Nakamura</span>. </span><span class="cited-content_cbyCitation_article-title">Generation of an 4-Isoxazolyl Anion Species: Facile Access to Multifunctionalized Isoxazoles. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2016,</strong> <em>55 </em>
                                    (43)
                                     , 13580-13584. <a href="https://doi.org/10.1002/anie.201608039" title="DOI URL">https://doi.org/10.1002/anie.201608039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201608039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201608039%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DGeneration%252Bof%252Ban%252B4-Isoxazolyl%252BAnion%252BSpecies%25253A%252BFacile%252BAccess%252Bto%252BMultifunctionalized%252BIsoxazoles%26aulast%3DMorita%26aufirst%3DTaiki%26date%3D2016%26date%3D2016%26volume%3D55%26issue%3D43%26spage%3D13580%26epage%3D13584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Representative RET inhibitors. (B) Rational design of novel isoxazole-containing RET inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Inhibitors <b>5a</b>–<b>b</b>, <b>6a</b>–<b>l</b>, and <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagent and condition: (a) 2-bromopropane, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 69%; (b) tributyl(vinyl)tin, Pd(PPh<sub>3</sub>)<sub>4</sub>, toluene, reflux, 82%; (c) (i) OsO<sub>4</sub>, NMO, THF/H<sub>2</sub>O, 0 °C to rt; (ii) NaIO<sub>4</sub>, THF/H<sub>2</sub>O, 0 °C to rt; (d) hydroxylamine hydrochloride or benzyloxyamine hydrochloride, NaOAc, EtOH, rt, 72–89% over two steps; (e) styrene or various acetylenes, phenyliodine bis(trifluoroacetate), MeOH/H<sub>2</sub>O, rt, 17–32%; (f) <b>6l</b>, CsF, MeCN/EtOH, rt, 43%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Inhibitors <b>16</b> and <b>17a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagent and condition: (a) diethyl oxalate, NaH, THF, 0 °C to rt, 92%; (b) hydroxylamine hydrochloride, MeOH, reflux, 88%; (c) NaOH, EtOH, rt, 100%; (d) oxalyl chloride, cat. DMF, CH<sub>2</sub>Cl<sub>2</sub>, rt; (e) malononitrile, DIPEA, THF, 0 °C; (f) dimethylsulfate, THF, reflux, 63% over three steps; (g) hydrazine dihydrochloride, TEA, EtOH, rt, 72%; (h) formamide, 160 °C, 82%; (g) a) R<sub>2</sub>-X (X = Br, I) or 2,2-dimethoxyoxirane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C or b) R<sub>2</sub>–OH, DIAD, PPh<sub>3</sub>, THF, rt, 32–81%.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking models of (A,B) <b>6i</b>, (C,D) <b>7a</b>, and (E,F) cabozantinib bound to RET kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV">2IVV</a> for <b>6i</b> and <b>7a</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8">3LQ8</a> for cabozantinib). Hydrogen bonds are depicted as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) KinomeScanTreeSpot description of the <b>6i</b> selectivity profile. <b>6i</b> was screened against a 332 kinase panel at a concentration of 1 μM. Scores for primary screen hits are reported as a percent of the DMSO control (% control). (B) Biochemical IC<sub>50</sub>s of <b>6i</b> measured with selected kinases.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Autophosphorylation of RET and its downstream signaling are blocked by <b>6i</b>. The effect of <b>6i</b> on autophosphorylation of RET in (A) RET-WT Ba/F3, (B) RET-S891A Ba/F3, (C) RET-V804L Ba/F3, and (D) RET-V804M Ba/F3. (A–D) Ba/F3 cells, stably transformed with the indicated constructs, were treated for 1 h with gradually increasing concentrations of <b>7a</b>, cabozantinib, and <b>6i</b> (0–10 μM) and then lysed. Protein extracts were immunoblotted with antibodies specific for the Y905 and Y1062 phosphorylated forms of RET. Actin was used as loading control. (E) TT cells were treated with <b>6i</b> (0.1, 1, and 10 μM), cabozantinib, and <b>7a</b> (1 and 10 μM) for 4 h. Cell lysates were immunoblotted with the indicated antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>6i</b> induces apoptosis in TT cells but not in Nthy ori-3-1. Effects of <b>7a</b>, <b>6i</b>, and cabozantinib on cell cycle arrest of (A) TT cells and (B) Nthy ori-3-1 cells. TT cells and Nthy ori-3-1 cells were incubated with the indicated compounds for 48 and 24 h, respectively. Cells, fixed with 70% ethanol, were stained with propidium iodide and analyzed by using flow cytometry. (A,B) The left panel contains a representative image obtained from the flow cytometric analysis of cell cycle arrest. Bar graphs in the right panel contain means ± SDs for three independent experiments on Nthy ori-3-1 cells and for two independent sets on TT cells. Effects of <b>7a</b>, <b>6i</b>, and cabozantinib on apoptosis of (C) TT cells and (D) Nthy ori-3-1 cells. The indicated concentrations of the compounds were incubated with TT cells for 96 h and Nthy ori-3-1 cells for 48 h. Cells were harvested and incubated in a binding buffer containing propidium iodide and annexin V and then analyzed by using flow cytometry. (C,D) The left panel contains a representative image of the flow cytometric analysis of apoptosis. In the right panel are bar graphs that indicate the mean ± SDs for three independent experiments. **<i>p</i> < 0.01, ***<i>p</i> < 0.001, one way ANOVA tested. (E) Treatment with <b>6i</b> for 96 h induces cleavage of PARP1/2, while increasing the expression of PUMA in TT cells. Actin was used as the loading control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/medium/jm-2015-01522e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Anchorage independent growth of TT cells is suppressed by treatment with <b>6i</b>. (A–G) Effects of <b>7a</b>, <b>6i</b>, and cabozantinib on anchorage-independent growth of TT cells in soft agar. (A–F) A representative colony under each indicated condition was photographed after crystal violet staining at 400× magnification. Bar = 0.2 mm. (G) Soft agar assays were performed three times. Total colonies in each well were automatically counted using ImageJ software. The average number of colonies (<i>n</i> = 3) are presented with ± SD, ***<i>p</i> < 0.001, one way ANOVA tested.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01522/20160113/images/large/jm-2015-01522e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01522&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64630" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64630" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 26 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Attie-Bitach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abitbol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delezoide, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachnis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munnich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vekemans, M.</span><span> </span><span class="NLM_article-title">Expression of the RET proto-oncogene in human embryos</span> <span class="citation_source-journal">Am. J. Med. Genet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">486</span><span class="refDoi"> DOI: 10.1002/(SICI)1096-8628(19981228)80:5<481::AID-AJMG8>3.0.CO;2-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1002%2F%28SICI%291096-8628%2819981228%2980%3A5%3C481%3A%3AAID-AJMG8%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=9880212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A280%3ADyaK1M%252FpsVyhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1998&pages=481-486&issue=5&author=T.+Attie-Bitachauthor=M.+Abitbolauthor=M.+Gerardauthor=A.+L.+Delezoideauthor=J.+Augeauthor=A.+Peletauthor=J.+Amielauthor=V.+Pachnisauthor=A.+Munnichauthor=S.+Lyonnetauthor=M.+Vekemans&title=Expression+of+the+RET+proto-oncogene+in+human+embryos&doi=10.1002%2F%28SICI%291096-8628%2819981228%2980%3A5%3C481%3A%3AAID-AJMG8%3E3.0.CO%3B2-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the RET proto-oncogene in human embryos</span></div><div class="casAuthors">Attie-Bitach T; Abitbol M; Gerard M; Delezoide A L; Auge J; Pelet A; Amiel J; Pachnis V; Munnich A; Lyonnet S; Vekemans M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-6</span>
        ISSN:<span class="NLM_cas:issn">0148-7299</span>.
    </div><div class="casAbstract">The patterns of RET proto-oncogene expression in mouse, rat, and chicken and the anomalies observed in targeted RET mutants suggest that RET plays a major role in development of mouse enteric nervous system and in kidney organogenesis.  Here, we report on in situ hybridization studies describing the pattern of RET proto-oncogene expression during early development of human embryos between 23 and 42 days.  We show that the RET gene is expressed in the developing kidney (nephric duct, mesonephric tubules, and ureteric bud), the presumptive enteric neuroblasts of the developing enteric nervous system, cranial ganglia (VII+VIII, IX, and X) and in the presumptive motor neurons of the spinal cord.  Yet, despite the high level of RET gene expression in the kidney and in the motor neurons of the developing central nervous system in human embryos, only rare cases with renal agenesis have been reported in Hirschsprung disease patients, and no clinical evidence of spinal cord involvement has been shown in patients carrying RET germline mutations (i.e., multiple endocrine neoplasia syndromes and Hirschsprung disease).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA7WHZRXiaJQxyojvcjibhfW6udTcc2eapCMQqp_bi_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FpsVyhsw%253D%253D&md5=b290f70327e19be3290d83f6fe2a19c7</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-8628%2819981228%2980%3A5%3C481%3A%3AAID-AJMG8%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-8628%252819981228%252980%253A5%253C481%253A%253AAID-AJMG8%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DAttie-Bitach%26aufirst%3DT.%26aulast%3DAbitbol%26aufirst%3DM.%26aulast%3DGerard%26aufirst%3DM.%26aulast%3DDelezoide%26aufirst%3DA.%2BL.%26aulast%3DAuge%26aufirst%3DJ.%26aulast%3DPelet%26aufirst%3DA.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DPachnis%26aufirst%3DV.%26aulast%3DMunnich%26aufirst%3DA.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DVekemans%26aufirst%3DM.%26atitle%3DExpression%2520of%2520the%2520RET%2520proto-oncogene%2520in%2520human%2520embryos%26jtitle%3DAm.%2520J.%2520Med.%2520Genet%26date%3D1998%26volume%3D80%26issue%3D5%26spage%3D481%26epage%3D486%26doi%3D10.1002%2F%28SICI%291096-8628%2819981228%2980%3A5%3C481%3A%3AAID-AJMG8%3E3.0.CO%3B2-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Durbec, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LarssonBlomberg, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchardt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costantini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pachnis, V.</span><span> </span><span class="NLM_article-title">Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts</span> <span class="citation_source-journal">Development</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">349</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=1996&pages=349-358&author=P.+L.+Durbecauthor=L.+B.+LarssonBlombergauthor=A.+Schuchardtauthor=F.+Costantiniauthor=V.+Pachnis&title=Common+origin+and+developmental+dependence+on+c-ret+of+subsets+of+enteric+and+sympathetic+neuroblasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDurbec%26aufirst%3DP.%2BL.%26aulast%3DLarssonBlomberg%26aufirst%3DL.%2BB.%26aulast%3DSchuchardt%26aufirst%3DA.%26aulast%3DCostantini%26aufirst%3DF.%26aulast%3DPachnis%26aufirst%3DV.%26atitle%3DCommon%2520origin%2520and%2520developmental%2520dependence%2520on%2520c-ret%2520of%2520subsets%2520of%2520enteric%2520and%2520sympathetic%2520neuroblasts%26jtitle%3DDevelopment%26date%3D1996%26volume%3D122%26spage%3D349%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Arighi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borrello, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sariola, H.</span><span> </span><span class="NLM_article-title">RET tyrosine kinase signaling in development and cancer</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1016/j.cytogfr.2005.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1016%2Fj.cytogfr.2005.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=15982921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvVCnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=441-467&author=E.+Arighiauthor=M.+G.+Borrelloauthor=H.+Sariola&title=RET+tyrosine+kinase+signaling+in+development+and+cancer&doi=10.1016%2Fj.cytogfr.2005.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">RET tyrosine kinase signaling in development and cancer</span></div><div class="casAuthors">Arighi, Elena; Borrello, Maria Grazia; Sariola, Hannu</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4-5</span>),
    <span class="NLM_cas:pages">441-467</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The variety of diseases caused by mutations in RET receptor tyrosine kinase provides a classic example of phenotypic heterogeneity.  Gain-of-function mutations of RET are assocd. with human cancer.  Gene rearrangements juxtaposing the tyrosine kinase domain to heterologous gene partners have been found in sporadic papillary carcinomas of the thyroid (PTC).  These rearrangements generate chimeric RET/PTC oncogenes.  In the germline, point mutations of RET are responsible for multiple endocrine neoplasia type 2 (MEN 2A and 2B) and familial medullary thyroid carcinoma (FMTC).  Both MEN 2 mutations and PTC gene rearrangements potentiate the intrinsic tyrosine kinase activity of RET and, ultimately, activate the RET downstream targets.  Loss-of-function mutations of RET cause Hirschsprung's disease (HSCR) or colonic aganglionosis.  A deeper understanding of the mol. signaling of normal vs. abnormal RET activity in cancer will enable the development of potential new treatments for patients with sporadic and inherited thyroid cancer or MEN 2 syndrome.  We now review the role and mechanisms of RET signaling in development and carcinogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozw_crTv66LbVg90H21EOLACvtfcHk0lisRULVfQPGUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvVCnu7s%253D&md5=8f664352542b6034d0ca001b9c1c4f16</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2005.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2005.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DArighi%26aufirst%3DE.%26aulast%3DBorrello%26aufirst%3DM.%2BG.%26aulast%3DSariola%26aufirst%3DH.%26atitle%3DRET%2520tyrosine%2520kinase%2520signaling%2520in%2520development%2520and%2520cancer%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2005%26volume%3D16%26spage%3D441%26epage%3D467%26doi%3D10.1016%2Fj.cytogfr.2005.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jain, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Encinas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milbrandt, J.</span><span> </span><span class="NLM_article-title">Critical and distinct roles for key RET tyrosine docking sites in renal development</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">321</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.1101/gad.1387206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1101%2Fgad.1387206" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2006&pages=321-333&author=S.+Jainauthor=M.+Encinasauthor=E.+M.+Johnsonauthor=J.+Milbrandt&title=Critical+and+distinct+roles+for+key+RET+tyrosine+docking+sites+in+renal+development&doi=10.1101%2Fgad.1387206"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1101%2Fgad.1387206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.1387206%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DS.%26aulast%3DEncinas%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DMilbrandt%26aufirst%3DJ.%26atitle%3DCritical%2520and%2520distinct%2520roles%2520for%2520key%2520RET%2520tyrosine%2520docking%2520sites%2520in%2520renal%2520development%26jtitle%3DGenes%2520Dev.%26date%3D2006%26volume%3D20%26spage%3D321%26epage%3D333%26doi%3D10.1101%2Fgad.1387206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lundgren, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakahata, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebellato, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlen, P.</span><span> </span><span class="NLM_article-title">RET PLCgamma phosphotyrosine binding domain regulates Ca2+ signaling and neocortical neuronal migration</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e31258</span><span class="refDoi"> DOI: 10.1371/journal.pone.0031258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1371%2Fjournal.pone.0031258" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e31258&author=T.+K.+Lundgrenauthor=K.+Nakahataauthor=N.+Fritzauthor=P.+Rebellatoauthor=S.+Zhangauthor=P.+Uhlen&title=RET+PLCgamma+phosphotyrosine+binding+domain+regulates+Ca2%2B+signaling+and+neocortical+neuronal+migration&doi=10.1371%2Fjournal.pone.0031258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0031258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0031258%26sid%3Dliteratum%253Aachs%26aulast%3DLundgren%26aufirst%3DT.%2BK.%26aulast%3DNakahata%26aufirst%3DK.%26aulast%3DFritz%26aufirst%3DN.%26aulast%3DRebellato%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DUhlen%26aufirst%3DP.%26atitle%3DRET%2520PLCgamma%2520phosphotyrosine%2520binding%2520domain%2520regulates%2520Ca2%252B%2520signaling%2520and%2520neocortical%2520neuronal%2520migration%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De31258%26doi%3D10.1371%2Fjournal.pone.0031258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Mulligan, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwok, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healey, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsdon, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mole, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papi, L.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">458</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span><span class="refDoi"> DOI: 10.1038/363458a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2F363458a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=1993&pages=458-460&author=L.+M.+Mulliganauthor=J.+B.+Kwokauthor=C.+S.+Healeyauthor=M.+J.+Elsdonauthor=C.+Engauthor=E.+Gardnerauthor=D.+R.+Loveauthor=S.+E.+Moleauthor=J.+K.+Mooreauthor=L.+Papi&title=Germ-line+mutations+of+the+RET+proto-oncogene+in+multiple+endocrine+neoplasia+type+2A&doi=10.1038%2F363458a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F363458a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F363458a0%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26aulast%3DKwok%26aufirst%3DJ.%2BB.%26aulast%3DHealey%26aufirst%3DC.%2BS.%26aulast%3DElsdon%26aufirst%3DM.%2BJ.%26aulast%3DEng%26aufirst%3DC.%26aulast%3DGardner%26aufirst%3DE.%26aulast%3DLove%26aufirst%3DD.%2BR.%26aulast%3DMole%26aufirst%3DS.%2BE.%26aulast%3DMoore%26aufirst%3DJ.%2BK.%26aulast%3DPapi%26aufirst%3DL.%26atitle%3DGerm-line%2520mutations%2520of%2520the%2520RET%2520proto-oncogene%2520in%2520multiple%2520endocrine%2520neoplasia%2520type%25202A%26jtitle%3DNature%26date%3D1993%26volume%3D363%26spage%3D458%26epage%3D460%26doi%3D10.1038%2F363458a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Eng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuffenecker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenoir, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Amstel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lips, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishisho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takai, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank-Raue, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raue, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noll, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zedenius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordenskjold, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komminoth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hendy, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulligan, L. M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">1575</span><span class="NLM_x">–</span> <span class="NLM_lpage">1579</span><span class="refDoi"> DOI: 10.1001/jama.276.19.1575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1001%2Fjama.276.19.1575" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1996&pages=1575-1579&author=C.+Engauthor=D.+Claytonauthor=I.+Schuffeneckerauthor=G.+Lenoirauthor=G.+Coteauthor=R.+F.+Gagelauthor=H.+K.+van+Amstelauthor=C.+J.+Lipsauthor=I.+Nishishoauthor=S.+I.+Takaiauthor=D.+J.+Marshauthor=B.+G.+Robinsonauthor=K.+Frank-Raueauthor=F.+Raueauthor=F.+Xueauthor=W.+W.+Nollauthor=C.+Romeiauthor=F.+Paciniauthor=M.+Finkauthor=B.+Niederleauthor=J.+Zedeniusauthor=M.+Nordenskjoldauthor=P.+Komminothauthor=G.+N.+Hendyauthor=L.+M.+Mulligan&title=The+relationship+between+specific+RET+proto-oncogene+mutations+and+disease+phenotype+in+multiple+endocrine+neoplasia+type+2.+International+RET+mutation+consortium+analysis&doi=10.1001%2Fjama.276.19.1575"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1001%2Fjama.276.19.1575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.276.19.1575%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DC.%26aulast%3DClayton%26aufirst%3DD.%26aulast%3DSchuffenecker%26aufirst%3DI.%26aulast%3DLenoir%26aufirst%3DG.%26aulast%3DCote%26aufirst%3DG.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3Dvan%2BAmstel%26aufirst%3DH.%2BK.%26aulast%3DLips%26aufirst%3DC.%2BJ.%26aulast%3DNishisho%26aufirst%3DI.%26aulast%3DTakai%26aufirst%3DS.%2BI.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DFrank-Raue%26aufirst%3DK.%26aulast%3DRaue%26aufirst%3DF.%26aulast%3DXue%26aufirst%3DF.%26aulast%3DNoll%26aufirst%3DW.%2BW.%26aulast%3DRomei%26aufirst%3DC.%26aulast%3DPacini%26aufirst%3DF.%26aulast%3DFink%26aufirst%3DM.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DZedenius%26aufirst%3DJ.%26aulast%3DNordenskjold%26aufirst%3DM.%26aulast%3DKomminoth%26aufirst%3DP.%26aulast%3DHendy%26aufirst%3DG.%2BN.%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26atitle%3DThe%2520relationship%2520between%2520specific%2520RET%2520proto-oncogene%2520mutations%2520and%2520disease%2520phenotype%2520in%2520multiple%2520endocrine%2520neoplasia%2520type%25202.%2520International%2520RET%2520mutation%2520consortium%2520analysis%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D1996%26volume%3D276%26spage%3D1575%26epage%3D1579%26doi%3D10.1001%2Fjama.276.19.1575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Mulligan, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuffenecker, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zedenius, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lips, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takai, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noll, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fink, M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium</span> <span class="citation_source-journal">J. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">238</span><span class="NLM_x">, </span> <span class="NLM_fpage">343</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span><span class="refDoi"> DOI: 10.1111/j.1365-2796.1995.tb01208.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1111%2Fj.1365-2796.1995.tb01208.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=7595170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A280%3ADyaK28%252FmvFKmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=238&publication_year=1995&pages=343-346&author=L.+M.+Mulliganauthor=D.+J.+Marshauthor=B.+G.+Robinsonauthor=I.+Schuffeneckerauthor=J.+Zedeniusauthor=C.+J.+Lipsauthor=R.+F.+Gagelauthor=S.+I.+Takaiauthor=W.+W.+Nollauthor=M.+Fink&title=Genotype-phenotype+correlation+in+multiple+endocrine+neoplasia+type+2%3A+report+of+the+International+RET+Mutation+Consortium&doi=10.1111%2Fj.1365-2796.1995.tb01208.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium</span></div><div class="casAuthors">Mulligan L M; Marsh D J; Robinson B G; Schuffenecker I; Zedenius J; Lips C J; Gagel R F; Takai S I; Noll W W; Fink M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of internal medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">238</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">343-6</span>
        ISSN:<span class="NLM_cas:issn">0954-6820</span>.
    </div><div class="casAbstract">The International RET Mutation Consortium was first convened as part of the Fifth International Workshop on Multiple Endocrine Neoplasia, Stockholm, Sweden, in an attempt to analyse the relationship of RET mutation and disease phenotype in the autosomal dominantly inherited multiple endocrine neoplasia type 2 (MEN 2) syndromes.  Out of 361 families studied, 41% had MEN 2A, 17.7% MEN 2B, 6.4% FMTC and the remaining subjects were unclassified.  RET mutations were detected in 87.3% of families overall.  Over 93% of MEN 2B families had the RET 918 ATG-->ACG mutation, while the most frequent mutation detected in MEN 2A families was cysteine codon 634 (87% of all mutations).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS24qPZJh1PEmGmni0r9GoKfW6udTcc2ebikhJYj246mbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FmvFKmsg%253D%253D&md5=7f0c721ba5775850ba95d9cd00b5c67b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2796.1995.tb01208.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2796.1995.tb01208.x%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26aulast%3DMarsh%26aufirst%3DD.%2BJ.%26aulast%3DRobinson%26aufirst%3DB.%2BG.%26aulast%3DSchuffenecker%26aufirst%3DI.%26aulast%3DZedenius%26aufirst%3DJ.%26aulast%3DLips%26aufirst%3DC.%2BJ.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DTakai%26aufirst%3DS.%2BI.%26aulast%3DNoll%26aufirst%3DW.%2BW.%26aulast%3DFink%26aufirst%3DM.%26atitle%3DGenotype-phenotype%2520correlation%2520in%2520multiple%2520endocrine%2520neoplasia%2520type%25202%253A%2520report%2520of%2520the%2520International%2520RET%2520Mutation%2520Consortium%26jtitle%3DJ.%2520Intern.%2520Med.%26date%3D1995%26volume%3D238%26spage%3D343%26epage%3D346%26doi%3D10.1111%2Fj.1365-2796.1995.tb01208.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Cranston, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carniti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakhill, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radzio-Andzelm, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallion, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hodgson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mondellini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leyland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierotti, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bongarzone, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ponder, B. A.</span><span> </span><span class="NLM_article-title">RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">10179</span><span class="NLM_x">–</span> <span class="NLM_lpage">10187</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-0884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1158%2F0008-5472.CAN-06-0884" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=10179-10187&author=A.+N.+Cranstonauthor=C.+Carnitiauthor=K.+Oakhillauthor=E.+Radzio-Andzelmauthor=E.+A.+Stoneauthor=A.+S.+McCallionauthor=S.+Hodgsonauthor=S.+Clarkeauthor=P.+Mondelliniauthor=J.+Leylandauthor=M.+A.+Pierottiauthor=J.+Whittakerauthor=S.+S.+Taylorauthor=I.+Bongarzoneauthor=B.+A.+Ponder&title=RET+is+constitutively+activated+by+novel+tandem+mutations+that+alter+the+active+site+resulting+in+multiple+endocrine+neoplasia+type+2B&doi=10.1158%2F0008-5472.CAN-06-0884"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-0884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-0884%26sid%3Dliteratum%253Aachs%26aulast%3DCranston%26aufirst%3DA.%2BN.%26aulast%3DCarniti%26aufirst%3DC.%26aulast%3DOakhill%26aufirst%3DK.%26aulast%3DRadzio-Andzelm%26aufirst%3DE.%26aulast%3DStone%26aufirst%3DE.%2BA.%26aulast%3DMcCallion%26aufirst%3DA.%2BS.%26aulast%3DHodgson%26aufirst%3DS.%26aulast%3DClarke%26aufirst%3DS.%26aulast%3DMondellini%26aufirst%3DP.%26aulast%3DLeyland%26aufirst%3DJ.%26aulast%3DPierotti%26aufirst%3DM.%2BA.%26aulast%3DWhittaker%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DBongarzone%26aufirst%3DI.%26aulast%3DPonder%26aufirst%3DB.%2BA.%26atitle%3DRET%2520is%2520constitutively%2520activated%2520by%2520novel%2520tandem%2520mutations%2520that%2520alter%2520the%2520active%2520site%2520resulting%2520in%2520multiple%2520endocrine%2520neoplasia%2520type%25202B%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D10179%26epage%3D10187%26doi%3D10.1158%2F0008-5472.CAN-06-0884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Romei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span> </span><span class="NLM_article-title">RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma</span> <span class="citation_source-journal">Front. Endocrinol. (Lausanne, Switz.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.3389/fendo.2012.00054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.3389%2Ffendo.2012.00054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=22649402" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1-8&author=C.+Romeiauthor=R.+Elisei&title=RET%2FPTC+Translocations+and+Clinico-Pathological+Features+in+Human+Papillary+Thyroid+Carcinoma&doi=10.3389%2Ffendo.2012.00054"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2012.00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2012.00054%26sid%3Dliteratum%253Aachs%26aulast%3DRomei%26aufirst%3DC.%26aulast%3DElisei%26aufirst%3DR.%26atitle%3DRET%252FPTC%2520Translocations%2520and%2520Clinico-Pathological%2520Features%2520in%2520Human%2520Papillary%2520Thyroid%2520Carcinoma%26jtitle%3DFront.%2520Endocrinol.%2520%2528Lausanne%252C%2520Switz.%2529%26date%3D2012%26volume%3D3%26spage%3D1%26epage%3D8%26doi%3D10.3389%2Ffendo.2012.00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Song, M.</span><span> </span><span class="NLM_article-title">Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3672</span><span class="NLM_x">–</span> <span class="NLM_lpage">3681</span><span class="refDoi"> DOI: 10.1021/jm501464c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501464c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2isbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3672-3681&author=M.+Song&title=Progress+in+Discovery+of+KIF5B-RET+Kinase+Inhibitors+for+the+Treatment+of+Non-Small-Cell+Lung+Cancer&doi=10.1021%2Fjm501464c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Song, Minsoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3672-3681</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1-2% of lung adenocarcinomas (LADCs) in late 2011.  Several related clin. trials for non-small-cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as lenvatinib, vandetanib, sunitinib, ponatinib, cabozantinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene.  Anti-RET activity and the status of clin. development of these known RET tyrosine kinase inhibitors (TKIs) for KIF5B-RET fusion-pos. NSCLC are discussed.  A kinase inhibitor that can target a driver mutation specifically may lead to a superior clin. benefit compared with broad-spectrum kinase inhibitors.  In this regard, an anal. of the structure of RET kinase and its complex with known RET inhibitors are also briefly discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAOaAhnoMFVLVg90H21EOLACvtfcHk0ljUFbG9RbHdKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2isbc%253D&md5=9420c8894295f711ca3a490dee790860</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm501464c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501464c%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DM.%26atitle%3DProgress%2520in%2520Discovery%2520of%2520KIF5B-RET%2520Kinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3672%26epage%3D3681%26doi%3D10.1021%2Fjm501464c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Mulligan, L. M.</span><span> </span><span class="NLM_article-title">RET revisited: expanding the oncogenic portfolio</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span><span class="refDoi"> DOI: 10.1038/nrc3680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2Fnrc3680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=24561444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=173-186&author=L.+M.+Mulligan&title=RET+revisited%3A+expanding+the+oncogenic+portfolio&doi=10.1038%2Fnrc3680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">RET revisited: expanding the oncogenic portfolio</span></div><div class="casAuthors">Mulligan, Lois M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-186</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RET receptor tyrosine kinase is crucial for normal development but also contributes to pathologies that reflect both the loss and the gain of RET function.  Activation of RET occurs via oncogenic mutations in familial and sporadic cancers - most notably, those of the thyroid and the lung.  RET has also recently been implicated in the progression of breast and pancreatic tumors, among others, which makes it an attractive target for small-mol. kinase inhibitors as therapeutics.  However, the complex roles of RET in homeostasis and survival of neural lineages and in tumor-assocd. inflammation might also suggest potential long-term pitfalls of broadly targeting RET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohwDQSALnEwbVg90H21EOLACvtfcHk0ljUFbG9RbHdKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFalsLc%253D&md5=665dae74c8f7a1df0e413ca15ca86440</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc3680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3680%26sid%3Dliteratum%253Aachs%26aulast%3DMulligan%26aufirst%3DL.%2BM.%26atitle%3DRET%2520revisited%253A%2520expanding%2520the%2520oncogenic%2520portfolio%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D173%26epage%3D186%26doi%3D10.1038%2Fnrc3680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Diner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alao, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soderlund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunnerhagen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotli, M.</span><span> </span><span class="NLM_article-title">Preparation of 3-Substituted-1-Isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET Kinase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4872</span><span class="NLM_x">–</span> <span class="NLM_lpage">4876</span><span class="refDoi"> DOI: 10.1021/jm3003944</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003944" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4872-4876&author=P.+Dinerauthor=J.+P.+Alaoauthor=J.+Soderlundauthor=P.+Sunnerhagenauthor=M.+Grotli&title=Preparation+of+3-Substituted-1-Isopropyl-1H-pyrazolo%5B3%2C4-d%5Dpyrimidin-4-amines+as+RET+Kinase+Inhibitors&doi=10.1021%2Fjm3003944"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm3003944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003944%26sid%3Dliteratum%253Aachs%26aulast%3DDiner%26aufirst%3DP.%26aulast%3DAlao%26aufirst%3DJ.%2BP.%26aulast%3DSoderlund%26aufirst%3DJ.%26aulast%3DSunnerhagen%26aufirst%3DP.%26aulast%3DGrotli%26aufirst%3DM.%26atitle%3DPreparation%2520of%25203-Substituted-1-Isopropyl-1H-pyrazolo%255B3%252C4-d%255Dpyrimidin-4-amines%2520as%2520RET%2520Kinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4872%26epage%3D4876%26doi%3D10.1021%2Fjm3003944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anaganti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vecchio, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6056</span><span class="NLM_x">–</span> <span class="NLM_lpage">6063</span><span class="refDoi"> DOI: 10.1038/sj.onc.1207810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2Fsj.onc.1207810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=15184865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmsVKlt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=6056-6063&author=F.+Carlomagnoauthor=T.+Guidaauthor=S.+Anagantiauthor=G.+Vecchioauthor=A.+Fuscoauthor=A.+J.+Ryanauthor=M.+Billaudauthor=M.+Santoro&title=Disease+associated+mutations+at+valine+804+in+the+RET+receptor+tyrosine+kinase+confer+resistance+to+selective+kinase+inhibitors&doi=10.1038%2Fsj.onc.1207810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors</span></div><div class="casAuthors">Carlomagno, Francesca; Guida, Teresa; Anaganti, Suresh; Vecchio, Giancarlo; Fusco, Alfredo; Ryan, Anderson J.; Billaud, Marc; Santoro, Massimo</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6056-6063</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC50≤100 nM) towards constitutively active oncogenic RET kinases.  Here, we show that most oncogenic MEN2-assocd. RET kinase mutants are highly susceptible to PP1, PP2 and ZD6474 inhibition.  In contrast, MEN2-assocd. swap of bulky hydrophobic leucine or methionine residues for valine 804 in the RET kinase domain causes resistance to the three compds.  Substitution of valine 804 with the small amino- acid glycine renders the RET kinase even more susceptible to inhibition (ZD6474 IC50: 20 nM) than the wild-type kinase.  Our data identify valine 804 of RET as a structural determinant mediating resistance to pyrazolopyrimidines and 4-anilinoquinazolines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJql666y5D-bVg90H21EOLACvtfcHk0ljUFbG9RbHdKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmsVKlt7c%253D&md5=39ec0aa2550048d7cd9a5536a6180fc0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207810%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DGuida%26aufirst%3DT.%26aulast%3DAnaganti%26aufirst%3DS.%26aulast%3DVecchio%26aufirst%3DG.%26aulast%3DFusco%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DA.%2BJ.%26aulast%3DBillaud%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DDisease%2520associated%2520mutations%2520at%2520valine%2520804%2520in%2520the%2520RET%2520receptor%2520tyrosine%2520kinase%2520confer%2520resistance%2520to%2520selective%2520kinase%2520inhibitors%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D6056%26epage%3D6063%26doi%3D10.1038%2Fsj.onc.1207810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Romei, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariotti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fugazzola, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taccaliti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Opocher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mian, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castellano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">degli Uberti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccherini, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cremonini, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seregni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferolla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puxeddu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgino, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosci, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottici, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verga, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boscaro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagna, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappelli, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zatelli, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faggiano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchetti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinchera, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Network, I.</span><span> </span><span class="NLM_article-title">Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes</span> <span class="citation_source-journal">Eur. J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">308</span><span class="refDoi"> DOI: 10.1530/EJE-10-0333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1530%2FEJE-10-0333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=20516206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFSksrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2010&pages=301-308&author=C.+Romeiauthor=S.+Mariottiauthor=L.+Fugazzolaauthor=A.+Taccalitiauthor=F.+Paciniauthor=G.+Opocherauthor=C.+Mianauthor=M.+Castellanoauthor=E.+degli+Ubertiauthor=I.+Ceccheriniauthor=N.+Cremoniniauthor=E.+Seregniauthor=F.+Orlandiauthor=P.+Ferollaauthor=E.+Puxedduauthor=F.+Giorginoauthor=A.+Colaoauthor=P.+Loliauthor=F.+Bondiauthor=B.+Cosciauthor=V.+Botticiauthor=A.+Cappaiauthor=G.+Pinnaauthor=L.+Persaniauthor=U.+Vergaauthor=M.+Boscaroauthor=M.+G.+Castagnaauthor=C.+Cappelliauthor=M.+C.+Zatelliauthor=A.+Faggianoauthor=G.+Franciaauthor=M.+L.+Brandiauthor=A.+Falchettiauthor=A.+Pincheraauthor=R.+Eliseiauthor=I.+Network&title=Multiple+endocrine+neoplasia+type+2+syndromes+%28MEN+2%29%3A+results+from+the+ItaMEN+network+analysis+on+the+prevalence+of+different+genotypes+and+phenotypes&doi=10.1530%2FEJE-10-0333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes</span></div><div class="casAuthors">Romei, Cristina; Mariotti, Stefano; Fugazzola, Laura; Taccaliti, Augusto; Pacini, Furio; Opocher, Giuseppe; Mian, Caterina; Castellano, Maurizio; Uberti, Ettore Degli; Ceccherini, Isabella; Cremonini, Nadia; Seregni, Ettore; Orlandi, Fabio; Ferolla, Piero; Puxeddu, Efisio; Giorgino, Francesco; Colao, Annamaria; Loli, Paola; Bondi, Fabio; Cosci, Barbara; Bottici, Valeria; Cappai, Antonello; Pinna, Giovanni; Persani, Luca; Uberta, Verga; Boscaro, Marco; Castagna, Maria Grazia; Cappelli, Carlo; Zatelli, Maria Chiara; Faggiano, Antongiulio; Francia, Giuseppe; Brandi, Maria Luisa; Falchetti, Alberto; Pinchera, Aldo; Elisei, Rossella</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-308</span>CODEN:
                <span class="NLM_cas:coden">EJOEEP</span>;
        ISSN:<span class="NLM_cas:issn">0804-4643</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Objective: Multiple endocrine neoplasia type 2 (MEN 2) is a genetic disease characterized by medullary thyroid carcinoma (MTC) assocd. (MEN 2A and 2B) or not familial MTC (FMTC) with other endocrine neoplasia due to germline RET gene mutations.  The prevalence of these rare genetic diseases and their corresponding RET mutations are unknown due to the small size of the study population.  Methods: We collected data on germline RET mutations of 250 families with hereditary MTC followed in 20 different Italian centers.  Results and conclusions: The most frequent RET amino acid substitution was Val804Met (19.6%) followed by Cys634Arg (13.6%).  A total of 40 different germline RET mutations were present.  Six families (2.4%) were neg. for germline RET mutations.  The comparison of the prevalence of RET germline mutations in the present study with those published by other European studies showed a higher prevalence of Val804Met and Ser891Ala mutations and a lower prevalence of Leu790Phe and Tyr791Phe (P < 0.0001).  A statistically significant higher prevalence of mutations affecting non-cysteine codons was also found (P < 0.0001).  Furthermore, the phenotype data collection showed an unexpected higher prevalence of FMTC (57.6%) with respect to other MEN 2 syndromes (34% MEN 2A and 6.8% of MEN 2B).  In conclusion, we obsd. a statistically significant different pattern of RET mutations in Italian MEN 2 families with respect to other European studies and a higher prevalence of FMTC phenotype.  The different ethnic origins of the patients and the particular attention given to analyzing apparently sporadic MTC for RET germline mutations may explain these findings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8RiQLPgS4X7Vg90H21EOLACvtfcHk0li9SamTJpg_Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFSksrjL&md5=58ad8f2df324963e1c91988500be5fcc</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1530%2FEJE-10-0333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FEJE-10-0333%26sid%3Dliteratum%253Aachs%26aulast%3DRomei%26aufirst%3DC.%26aulast%3DMariotti%26aufirst%3DS.%26aulast%3DFugazzola%26aufirst%3DL.%26aulast%3DTaccaliti%26aufirst%3DA.%26aulast%3DPacini%26aufirst%3DF.%26aulast%3DOpocher%26aufirst%3DG.%26aulast%3DMian%26aufirst%3DC.%26aulast%3DCastellano%26aufirst%3DM.%26aulast%3Ddegli%2BUberti%26aufirst%3DE.%26aulast%3DCeccherini%26aufirst%3DI.%26aulast%3DCremonini%26aufirst%3DN.%26aulast%3DSeregni%26aufirst%3DE.%26aulast%3DOrlandi%26aufirst%3DF.%26aulast%3DFerolla%26aufirst%3DP.%26aulast%3DPuxeddu%26aufirst%3DE.%26aulast%3DGiorgino%26aufirst%3DF.%26aulast%3DColao%26aufirst%3DA.%26aulast%3DLoli%26aufirst%3DP.%26aulast%3DBondi%26aufirst%3DF.%26aulast%3DCosci%26aufirst%3DB.%26aulast%3DBottici%26aufirst%3DV.%26aulast%3DCappai%26aufirst%3DA.%26aulast%3DPinna%26aufirst%3DG.%26aulast%3DPersani%26aufirst%3DL.%26aulast%3DVerga%26aufirst%3DU.%26aulast%3DBoscaro%26aufirst%3DM.%26aulast%3DCastagna%26aufirst%3DM.%2BG.%26aulast%3DCappelli%26aufirst%3DC.%26aulast%3DZatelli%26aufirst%3DM.%2BC.%26aulast%3DFaggiano%26aufirst%3DA.%26aulast%3DFrancia%26aufirst%3DG.%26aulast%3DBrandi%26aufirst%3DM.%2BL.%26aulast%3DFalchetti%26aufirst%3DA.%26aulast%3DPinchera%26aufirst%3DA.%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DNetwork%26aufirst%3DI.%26atitle%3DMultiple%2520endocrine%2520neoplasia%2520type%25202%2520syndromes%2520%2528MEN%25202%2529%253A%2520results%2520from%2520the%2520ItaMEN%2520network%2520analysis%2520on%2520the%2520prevalence%2520of%2520different%2520genotypes%2520and%2520phenotypes%26jtitle%3DEur.%2520J.%2520Endocrinol.%26date%3D2010%26volume%3D163%26spage%3D301%26epage%3D308%26doi%3D10.1530%2FEJE-10-0333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pinna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orgiana, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carcassi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariotti, S.</span><span> </span><span class="NLM_article-title">RET proto-oncogene in Sardinia: V804M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype</span> <span class="citation_source-journal">Thyroid</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">101</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span><span class="refDoi"> DOI: 10.1089/thy.2006.0198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1089%2Fthy.2006.0198" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=101-104&author=G.+Pinnaauthor=G.+Orgianaauthor=A.+Riolaauthor=M.+Ghianiauthor=M.+L.+Laiauthor=C.+Carcassiauthor=S.+Mariotti&title=RET+proto-oncogene+in+Sardinia%3A+V804M+is+the+most+frequent+mutation+and+may+be+associated+with+FMTC%2FMEN-2A+phenotype&doi=10.1089%2Fthy.2006.0198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1089%2Fthy.2006.0198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fthy.2006.0198%26sid%3Dliteratum%253Aachs%26aulast%3DPinna%26aufirst%3DG.%26aulast%3DOrgiana%26aufirst%3DG.%26aulast%3DRiola%26aufirst%3DA.%26aulast%3DGhiani%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DM.%2BL.%26aulast%3DCarcassi%26aufirst%3DC.%26aulast%3DMariotti%26aufirst%3DS.%26atitle%3DRET%2520proto-oncogene%2520in%2520Sardinia%253A%2520V804M%2520is%2520the%2520most%2520frequent%2520mutation%2520and%2520may%2520be%2520associated%2520with%2520FMTC%252FMEN-2A%2520phenotype%26jtitle%3DThyroid%26date%3D2007%26volume%3D17%26spage%3D101%26epage%3D104%26doi%3D10.1089%2Fthy.2006.0198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicoll, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorre, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquette, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1016/S1535-6108(02)00096-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1016%2FS1535-6108%2802%2900096-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=12204532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=117-125&author=N.+P.+Shahauthor=J.+M.+Nicollauthor=B.+Nagarauthor=M.+E.+Gorreauthor=R.+L.+Paquetteauthor=J.+Kuriyanauthor=C.+L.+Sawyers&title=Multiple+BCR-ABL+kinase+domain+mutations+confer+polyclonal+resistance+to+the+tyrosine+kinase+inhibitor+imatinib+%28STI571%29+in+chronic+phase+and+blast+crisis+chronic+myeloid+leukemia&doi=10.1016%2FS1535-6108%2802%2900096-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia</span></div><div class="casAuthors">Shah, Neil P.; Nicoll, John M.; Nagar, Bhushan; Gorre, Mercedes E.; Paquette, Ronald L.; Kuriyan, John; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-125</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Through sequencing anal. of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib.  Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found.  Mutations fell into two groups-those that alter amino acids that directly contact imatinib and those postulated to prevent BCR-ABL from achieving the inactive conformational state required for imatinib binding.  Distinct mutations conferred varying degrees of imatinib resistance.  Mutations detected in a subset of patients with stable chronic phase disease correlated with subsequent disease progression.  Multiple independent mutant clones were detected in a subset of relapsed cases.  Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpUVEO266u7Vg90H21EOLACvtfcHk0li9SamTJpg_Vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslSks7c%253D&md5=2edcdc31ccc39ccc495e5eddeb4856e1</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2FS1535-6108%2802%2900096-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-6108%252802%252900096-X%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DNicoll%26aufirst%3DJ.%2BM.%26aulast%3DNagar%26aufirst%3DB.%26aulast%3DGorre%26aufirst%3DM.%2BE.%26aulast%3DPaquette%26aufirst%3DR.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DMultiple%2520BCR-ABL%2520kinase%2520domain%2520mutations%2520confer%2520polyclonal%2520resistance%2520to%2520the%2520tyrosine%2520kinase%2520inhibitor%2520imatinib%2520%2528STI571%2529%2520in%2520chronic%2520phase%2520and%2520blast%2520crisis%2520chronic%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Cell%26date%3D2002%26volume%3D2%26spage%3D117%26epage%3D125%26doi%3D10.1016%2FS1535-6108%2802%2900096-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breeden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span><span class="refDoi"> DOI: 10.1182/blood-2007-11-123950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1182%2Fblood-2007-11-123950" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2008&pages=53-55&author=E.+Jabbourauthor=H.+Kantarjianauthor=D.+Jonesauthor=M.+Breedenauthor=G.+Garcia-Maneroauthor=S.+O%E2%80%99Brienauthor=F.+Ravandiauthor=G.+Borthakurauthor=J.+Cortes&title=Characteristics+and+outcomes+of+patients+with+chronic+myeloid+leukemia+and+T315I+mutation+following+failure+of+imatinib+mesylate+therapy&doi=10.1182%2Fblood-2007-11-123950"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-11-123950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-11-123950%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DBreeden%26aufirst%3DM.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DCharacteristics%2520and%2520outcomes%2520of%2520patients%2520with%2520chronic%2520myeloid%2520leukemia%2520and%2520T315I%2520mutation%2520following%2520failure%2520of%2520imatinib%2520mesylate%2520therapy%26jtitle%3DBlood%26date%3D2008%26volume%3D112%26spage%3D53%26epage%3D55%26doi%3D10.1182%2Fblood-2007-11-123950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Giaccone, G.</span><span> </span><span class="NLM_article-title">EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Clin. Pract. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">296</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1038/ncponc0200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2Fncponc0200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=16264986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A280%3ADC%252BD2Mros1Wnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=296-297&author=G.+Giaccone&title=EGFR+point+mutation+confers+resistance+to+gefitinib+in+a+patient+with+non-small-cell+lung+cancer&doi=10.1038%2Fncponc0200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15aR"><div class="casContent"><span class="casTitleNuber">15a</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer</span></div><div class="casAuthors">Giaccone Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature clinical practice. Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">296-7</span>
        ISSN:<span class="NLM_cas:issn">1743-4254</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ1T0RPlFKPxLFU0A1HOshhfW6udTcc2eYRgV01WNCcUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mros1Wnsg%253D%253D&md5=ce9b6b319dc5bb04664ba6474f8882c5</span></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1038%2Fncponc0200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncponc0200%26sid%3Dliteratum%253Aachs%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DEGFR%2520point%2520mutation%2520confers%2520resistance%2520to%2520gefitinib%2520in%2520a%2520patient%2520with%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Clin.%2520Pract.%2520Oncol.%26date%3D2005%26volume%3D2%26spage%3D296%26epage%3D297%26doi%3D10.1038%2Fncponc0200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljW_ZMJzkPNkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakamoto, H.</span><span> </span><span class="NLM_article-title">Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2910</span><span class="NLM_x">–</span> <span class="NLM_lpage">2918</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1158%2F1535-7163.MCT-14-0274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=25349307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCju7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2910-2918&author=T.+Kodamaauthor=T.+Tsukaguchiauthor=Y.+Satohauthor=M.+Yoshidaauthor=Y.+Watanabeauthor=O.+Kondohauthor=H.+Sakamoto&title=Alectinib+shows+potent+antitumor+activity+against+RET-rearranged+non-small+cell+lung+cancer&doi=10.1158%2F1535-7163.MCT-14-0274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Kodama, Tatsushi; Tsukaguchi, Toshiyuki; Satoh, Yasuko; Yoshida, Miyuki; Watanabe, Yoshiaki; Kondoh, Osamu; Sakamoto, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2910-2918</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Alectinib/CH5424802 is a known inhibitor of anaplastic lymphoma kinase (ALK) and is being evaluated in clin. trials for the treatment of ALK fusion-pos. non-small cell lung cancer (NSCLC).  Recently, some RET and ROS1 fusion genes have been implicated as driver oncogenes in NSCLC and have become mol. targets for antitumor agents.  This study aims to explore addnl. target indications of alectinib by testing its ability to inhibit the activity of kinases other than ALK.  We newly verified that alectinib inhibited RET kinase activity and the growth of RET fusion-pos. cells by suppressing RET phosphorylation.  In contrast, alectinib hardly inhibited ROS1 kinase activity unlike other ALK/ROS1 inhibitors such as crizotinib and LDK378.  It also showed antitumor activity in mouse models of tumors driven by the RET fusion.  In addn., alectinib showed kinase inhibitory activity against RET gatekeeper mutations (RET V804L and V804M) and blocked cell growth driven by the KIF5B-RET V804L and V804M.  Our results suggest that alectinib is effective against RET fusion-pos. tumors.  Thus, alectinib might be a therapeutic option for patients with RET fusion-pos. NSCLC.  Mol Cancer Ther; 13(12); 2910-8. 2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoydfltWoZlIrVg90H21EOLACvtfcHk0lhb3aPlDN9TRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCju7vF&md5=c7e0003e2906707cbec875c8ca9c9e39</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0274%26sid%3Dliteratum%253Aachs%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DSatoh%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DKondoh%26aufirst%3DO.%26aulast%3DSakamoto%26aufirst%3DH.%26atitle%3DAlectinib%2520shows%2520potent%2520antitumor%2520activity%2520against%2520RET-rearranged%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2910%26epage%3D2918%26doi%3D10.1158%2F1535-7163.MCT-14-0274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mologni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redaelli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morandi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plaza-Menacho, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gambacorti-Passerini, C.</span><span> </span><span class="NLM_article-title">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">377</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1016/j.mce.2013.06.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1016%2Fj.mce.2013.06.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=23811235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2013&pages=1-6&author=L.+Mologniauthor=S.+Redaelliauthor=A.+Morandiauthor=I.+Plaza-Menachoauthor=C.+Gambacorti-Passerini&title=Ponatinib+is+a+potent+inhibitor+of+wild-type+and+drug-resistant+gatekeeper+mutant+RET+kinase&doi=10.1016%2Fj.mce.2013.06.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase</span></div><div class="casAuthors">Mologni, Luca; Redaelli, Sara; Morandi, Andrea; Plaza-Menacho, Ivan; Gambacorti-Passerini, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon cancer, and has been validated as a mol. target in these tumors.  Vandetanib was recently approved for the treatment of medullary thyroid cancer.  However, vandetanib is ineffective in vitro against RET mutants carrying bulky aminoacids at position 804, the gatekeeper residue, similarly to drug-resistant BCR-ABL mutants in chronic myeloid leukemia.  Ponatinib is a multi-target kinase inhibitor that was recently approved for treatment-refractory Philadelphia-pos. leukemia.  We show here potent inhibition of oncogenic RET by ponatinib, including the drug-insensitive V804M/L mutants.  Ponatinib inhibited the growth of RET+ and BCR-ABL+ cells with similar potency, while not affecting RET-neg. cells.  Both in biochem. and in cellular assays ponatinib compared favorably with known RET inhibitors, such as vandetanib, cabozantinib, sorafenib, sunitinib and motesanib, used as ref. compds.  We suggest that ponatinib should be considered for the treatment of RET+ tumors, in particular those expressing vandetanib-resistant V804M/L mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA1KRyhCS6ULVg90H21EOLACvtfcHk0lhb3aPlDN9TRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1GmurfP&md5=f08de33f80af574f3ec843d26269ed98</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.06.025%26sid%3Dliteratum%253Aachs%26aulast%3DMologni%26aufirst%3DL.%26aulast%3DRedaelli%26aufirst%3DS.%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DGambacorti-Passerini%26aufirst%3DC.%26atitle%3DPonatinib%2520is%2520a%2520potent%2520inhibitor%2520of%2520wild-type%2520and%2520drug-resistant%2520gatekeeper%2520mutant%2520RET%2520kinase%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D377%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.mce.2013.06.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">De Falco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buonocore, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torregrossa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basolo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozgit, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span> </span><span class="NLM_article-title">Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer</span> <span class="citation_source-journal">J. Clin. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">E811</span><span class="NLM_x">–</span> <span class="NLM_lpage">E819</span><span class="refDoi"> DOI: 10.1210/jc.2012-2672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1210%2Fjc.2012-2672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=23526464" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2013&pages=E811-E819&author=V.+De+Falcoauthor=P.+Buonocoreauthor=M.+Muthuauthor=L.+Torregrossaauthor=F.+Basoloauthor=F.+Billaudauthor=J.+M.+Gozgitauthor=F.+Carlomagnoauthor=M.+Santoro&title=Ponatinib+%28AP24534%29+Is+a+Novel+Potent+Inhibitor+of+Oncogenic+RET+Mutants+Associated+With+Thyroid+Cancer&doi=10.1210%2Fjc.2012-2672"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1210%2Fjc.2012-2672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2012-2672%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DBuonocore%26aufirst%3DP.%26aulast%3DMuthu%26aufirst%3DM.%26aulast%3DTorregrossa%26aufirst%3DL.%26aulast%3DBasolo%26aufirst%3DF.%26aulast%3DBillaud%26aufirst%3DF.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DM.%26atitle%3DPonatinib%2520%2528AP24534%2529%2520Is%2520a%2520Novel%2520Potent%2520Inhibitor%2520of%2520Oncogenic%2520RET%2520Mutants%2520Associated%2520With%2520Thyroid%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2013%26volume%3D98%26spage%3DE811%26epage%3DE819%26doi%3D10.1210%2Fjc.2012-2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Frett, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moccia, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brescia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Falco, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Admire, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, W. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H. Y.</span><span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8717</span><span class="NLM_x">–</span> <span class="NLM_lpage">8721</span><span class="refDoi"> DOI: 10.1002/anie.201501104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1002%2Fanie.201501104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=8717-8721&author=B.+Frettauthor=F.+Carlomagnoauthor=M.+L.+Mocciaauthor=A.+Bresciaauthor=G.+Federicoauthor=V.+De+Falcoauthor=B.+Admireauthor=Z.+Z.+Chenauthor=W.+Q.+Qiauthor=M.+Santoroauthor=H.+Y.+Li&title=Fragment-Based+Discovery+of+a+Dual+pan-RET%2FVEGFR2+Kinase+Inhibitor+Optimized+for+Single-Agent+Polypharmacology&doi=10.1002%2Fanie.201501104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology</span></div><div class="casAuthors">Frett, Brendan; Carlomagno, Francesca; Moccia, Maria Luisa; Brescia, Annalisa; Federico, Giorgia; De Falco, Valentina; Admire, Brittany; Chen, Zhongzhu; Qi, Wenqing; Santoro, Massimo; Li, Hong-yu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">8717-8721</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is assocd. with several cancers.  A fragment-based chem. screen led to the identification of a novel RET inhibitor, Pz-1.  Modeling and kinetic anal. identified Pz-1 as a type II tyrosine kinase inhibitor that is able to bind the "DFG-out" conformation of the kinase.  Importantly, from a single-agent polypharmacol. standpoint, Pz-1 was shown to be active on VEGFR2, which can block the blood supply required for RET-stimulated growth.  In cell-based assays, 1.0 nM of Pz-1 strongly inhibited phosphorylation of all tested RET oncoproteins.  At 1.0 mg kg-1 day-1 per os, Pz-1 abrogated the formation of tumors induced by RET-mutant fibroblasts and blocked the phosphorylation of both RET and VEGFR2 in tumor tissue.  Pz-1 featured no detectable toxicity at concns. of up to 100.0 mg kg-1, which indicates a large therapeutic window.  This study validates the effectiveness and usefulness of a medicinal chem./polypharmacol. approach to obtain an inhibitor capable of targeting multiple oncogenic pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcoWkpO70i7rVg90H21EOLACvtfcHk0lhb3aPlDN9TRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWgtLnL&md5=05039c7074e7375de3884e0550d8c7ff</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1002%2Fanie.201501104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201501104%26sid%3Dliteratum%253Aachs%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DMoccia%26aufirst%3DM.%2BL.%26aulast%3DBrescia%26aufirst%3DA.%26aulast%3DFederico%26aufirst%3DG.%26aulast%3DDe%2BFalco%26aufirst%3DV.%26aulast%3DAdmire%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%2BZ.%26aulast%3DQi%26aufirst%3DW.%2BQ.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DH.%2BY.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Dual%2520pan-RET%252FVEGFR2%2520Kinase%2520Inhibitor%2520Optimized%2520for%2520Single-Agent%2520Polypharmacology%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D8717%26epage%3D8721%26doi%3D10.1002%2Fanie.201501104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span> </span><span class="NLM_article-title">Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e30353</span><span class="refDoi"> DOI: 10.1371/journal.pone.0030353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1371%2Fjournal.pone.0030353" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e30353&author=J.+J.+Zangauthor=S.+Q.+Wuauthor=L.+Tangauthor=X.+D.+Xuauthor=J.+Baiauthor=C.+C.+Dingauthor=Y.+Changauthor=L.+Yueauthor=E.+M.+Kangauthor=J.+He&title=Incidence+and+Risk+of+QTc+Interval+Prolongation+among+Cancer+Patients+Treated+with+Vandetanib%3A+A+Systematic+Review+and+Meta-analysis&doi=10.1371%2Fjournal.pone.0030353"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0030353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0030353%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DJ.%2BJ.%26aulast%3DWu%26aufirst%3DS.%2BQ.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DX.%2BD.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DC.%2BC.%26aulast%3DChang%26aufirst%3DY.%26aulast%3DYue%26aufirst%3DL.%26aulast%3DKang%26aufirst%3DE.%2BM.%26aulast%3DHe%26aufirst%3DJ.%26atitle%3DIncidence%2520and%2520Risk%2520of%2520QTc%2520Interval%2520Prolongation%2520among%2520Cancer%2520Patients%2520Treated%2520with%2520Vandetanib%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-analysis%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De30353%26doi%3D10.1371%2Fjournal.pone.0030353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Zhang, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H. Q.</span><span> </span><span class="NLM_article-title">Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e90135</span><span class="refDoi"> DOI: 10.1371/journal.pone.0090135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1371%2Fjournal.pone.0090135" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=e90135&author=Z.+F.+Zhangauthor=T.+Wangauthor=L.+H.+Liuauthor=H.+Q.+Guo&title=Risks+of+Proteinuria+Associated+with+Vascular+Endothelial+Growth+Factor+Receptor+Tyrosine+Kinase+Inhibitors+in+Cancer+Patients%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1371%2Fjournal.pone.0090135"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0090135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0090135%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DL.%2BH.%26aulast%3DGuo%26aufirst%3DH.%2BQ.%26atitle%3DRisks%2520of%2520Proteinuria%2520Associated%2520with%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor%2520Tyrosine%2520Kinase%2520Inhibitors%2520in%2520Cancer%2520Patients%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26spage%3De90135%26doi%3D10.1371%2Fjournal.pone.0090135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Qi, W. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span> </span><span class="NLM_article-title">Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">919</span><span class="NLM_x">–</span> <span class="NLM_lpage">930</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2012.04417.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1111%2Fj.1365-2125.2012.04417.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=22882307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFOgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2013&pages=919-930&author=W.+X.+Qiauthor=Z.+Shenauthor=F.+Linauthor=Y.+J.+Sunauthor=D.+L.+Minauthor=L.+N.+Tangauthor=A.+N.+Heauthor=Y.+Yao&title=Incidence+and+risk+of+hypertension+with+vandetanib+in+cancer+patients%3A+a+systematic+review+and+meta-analysis+of+clinical+trials&doi=10.1111%2Fj.1365-2125.2012.04417.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials</span></div><div class="casAuthors">Qi, Wei-Xiang; Shen, Zan; Lin, Feng; Sun, Yuan-jue; Min, Da-liu; Tang, Li-Na; He, Ai-Na; Yao, Yang</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">919-930</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim : To perform a systematic review and meta-anal. of published clin. trials to det. incidence rate and overall risk of hypertension with vandetanib in cancer patients.  Methods : A comprehensive literature search for studies published up to March 2012 was performed.  Summary incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calcd. employing fixed- or random-effects models depending on the heterogeneity of the included trials.  Results : A total of 11 trials with 3154 patients were included for the meta-anal.  The summary incidences of all-grade and high-grade hypertension in patients with cancer were 24.2% [95% confidence interval (CI), 18.1-30.2%] and 6.4% (95% CI, 3.3-9.5%), resp.  Subgroup anal. demonstrated that the pooled incidences of all-grade and high-grade hypertension were 21.8% [95% CI, 15-30.5%] and 7.6% (95% CI, 2.8-18.8%), resp., among non-small-cell lung cancer (NSCLC) patients, and 32.1% (95% CI: 27.3-37.3%) and 8.8% (5.9%-12.9%), resp., among MTC patients, and 15.4 (95% CI: 3.2-33.7%) and 3.4% (95% CI: 1%-11.1%) resp., among non-MTC/NSCLC tumors patients.  Furthermore, vandetanib was assocd. with a significant increased risk of all-grade hypertension (RR 5.1, 95% CI: 3.76-6.92, P = 0.000) and high-grade hypertension (RR 8.06, 95% CI: 3.41-19.04, P = 0.000) in comparison with controls.  Conclusions : There is a significant risk of developing hypertension in cancer patients receiving vandetanib.  Appropriate monitoring and treatment is strongly recommended to prevent cardiovascular complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmpi83QcuIBbVg90H21EOLACvtfcHk0limJ_Snwt2zQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFOgsb4%253D&md5=fa30d2837fd2da42742862f644c19d0c</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2012.04417.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2012.04417.x%26sid%3Dliteratum%253Aachs%26aulast%3DQi%26aufirst%3DW.%2BX.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DY.%2BJ.%26aulast%3DMin%26aufirst%3DD.%2BL.%26aulast%3DTang%26aufirst%3DL.%2BN.%26aulast%3DHe%26aufirst%3DA.%2BN.%26aulast%3DYao%26aufirst%3DY.%26atitle%3DIncidence%2520and%2520risk%2520of%2520hypertension%2520with%2520vandetanib%2520in%2520cancer%2520patients%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%2520of%2520clinical%2520trials%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2013%26volume%3D75%26spage%3D919%26epage%3D930%26doi%3D10.1111%2Fj.1365-2125.2012.04417.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaelin, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutcher, J. P.</span><span> </span><span class="NLM_article-title">A phase I study of cabozantinib (XL184) in patients with renal cell cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1603</span><span class="NLM_x">–</span> <span class="NLM_lpage">1608</span><span class="refDoi"> DOI: 10.1093/annonc/mdu184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1093%2Fannonc%2Fmdu184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=24827131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A280%3ADC%252BC2cjislyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=1603-1608&author=T.+K.+Choueiriauthor=S.+K.+Palauthor=D.+F.+McDermottauthor=S.+Morrisseyauthor=K.+C.+Fergusonauthor=J.+Hollandauthor=W.+G.+Kaelinauthor=J.+P.+Dutcher&title=A+phase+I+study+of+cabozantinib+%28XL184%29+in+patients+with+renal+cell+cancer&doi=10.1093%2Fannonc%2Fmdu184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19dR"><div class="casContent"><span class="casTitleNuber">19d</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of cabozantinib (XL184) in patients with renal cell cancer</span></div><div class="casAuthors">Choueiri T K; Morrissey S; Kaelin W G; Pal S K; McDermott D F; Ferguson K C; Holland J; Dutcher J P</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1603-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are important drug targets in renal cell carcinoma (RCC).  PATIENTS AND METHODS:  This single-arm open-label phase I trial evaluated the safety and tolerability of cabozantinib in heavily pretreated patients with metastatic clear cell RCC.  RESULTS:  The study enrolled 25 RCC patients for whom standard therapy had failed.  Patients received a median of two prior systemic agents, and most patients had previously received at least one VEGF pathway inhibiting therapy (22 patients [88%]).  Common adverse events included fatigue, diarrhea, nausea, proteinuria, appetite decreased, palmar-plantar erythrodysesthesia, and vomiting.  Partial response was reported in seven patients (28%).  Median progression-free survival was 12.9 months, and median overall survival was 15.0 months.  CONCLUSION:  Cabozantinib demonstrates preliminary anti-tumor activity and a safety profile similar to that seen with other multitargeted VEGFR tyrosine kinase inhibitors in advanced RCC patients.  Further evaluation of cabozantinib in RCC is warranted.  ClinicalTrials.gov identifier: NCT01100619.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsk4Vjqyl9wdHxxy173TfNfW6udTcc2eaJhl25M7S1F7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cjislyisQ%253D%253D&md5=08d0408e4b6c33c7bcca1ebdcf624d51</span></div><a href="/servlet/linkout?suffix=cit19d&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdu184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdu184%26sid%3Dliteratum%253Aachs%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DPal%26aufirst%3DS.%2BK.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DMorrissey%26aufirst%3DS.%26aulast%3DFerguson%26aufirst%3DK.%2BC.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DKaelin%26aufirst%3DW.%2BG.%26aulast%3DDutcher%26aufirst%3DJ.%2BP.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520cabozantinib%2520%2528XL184%2529%2520in%2520patients%2520with%2520renal%2520cell%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2014%26volume%3D25%26spage%3D1603%26epage%3D1608%26doi%3D10.1093%2Fannonc%2Fmdu184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Jawalekar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reubsaet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutjes, F. P. J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Delft, F. L.</span><span> </span><span class="NLM_article-title">Synthesis of isoxazoles by hypervalent iodine-induced cycloaddition of nitrile oxides to alkynes</span> <span class="citation_source-journal">Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">3198</span><span class="NLM_x">–</span> <span class="NLM_lpage">3200</span><span class="refDoi"> DOI: 10.1039/c0cc04646a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1039%2Fc0cc04646a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=21286620" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3MXis1ertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=3198-3200&author=A.+M.+Jawalekarauthor=E.+Reubsaetauthor=F.+P.+J.+T.+Rutjesauthor=F.+L.+van+Delft&title=Synthesis+of+isoxazoles+by+hypervalent+iodine-induced+cycloaddition+of+nitrile+oxides+to+alkynes&doi=10.1039%2Fc0cc04646a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of isoxazoles by hypervalent iodine-induced cycloaddition of nitrile oxides to alkynes</span></div><div class="casAuthors">Jawalekar, Anup M.; Reubsaet, Erik; Rutjes, Floris P. J. T.; van Delft, Floris L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3198-3200</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Treatment of oximes with hypervalent iodine leads to substituted isoxazoles via rapid formation of nitrile oxides.  Reaction with terminal alkynes led to a series of 3,5-disubstituted isoxazoles with complete regioselectivity and high yield, in a procedure mild enough to prep. a range of nucleoside and peptide conjugates.  Exceptionally high reaction rates were found for the formation of 3,4,5-trisubstituted isoxazoles from a cyclic alkyne.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRG9XOcr5E7Vg90H21EOLACvtfcHk0ljISs5fbczy6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXis1ertLc%253D&md5=dbc1ab6da96fd068d45581ba9fc1e129</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc0cc04646a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0cc04646a%26sid%3Dliteratum%253Aachs%26aulast%3DJawalekar%26aufirst%3DA.%2BM.%26aulast%3DReubsaet%26aufirst%3DE.%26aulast%3DRutjes%26aufirst%3DF.%2BP.%2BJ.%2BT.%26aulast%3Dvan%2BDelft%26aufirst%3DF.%2BL.%26atitle%3DSynthesis%2520of%2520isoxazoles%2520by%2520hypervalent%2520iodine-induced%2520cycloaddition%2520of%2520nitrile%2520oxides%2520to%2520alkynes%26jtitle%3DChem.%2520Commun.%26date%3D2011%26volume%3D47%26spage%3D3198%26epage%3D3200%26doi%3D10.1039%2Fc0cc04646a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Carlomagno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvatore, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Defranciscis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quadro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panariello, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colantuoni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fusco, A.</span><span> </span><span class="NLM_article-title">Point Mutation of the Ret Protooncogene in the Tt Human Medullary-Thyroid Carcinoma Cell-Line</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">207</span><span class="NLM_x">, </span> <span class="NLM_fpage">1022</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span><span class="refDoi"> DOI: 10.1006/bbrc.1995.1287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1006%2Fbbrc.1995.1287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=1995&pages=1022-1028&author=F.+Carlomagnoauthor=D.+Salvatoreauthor=M.+Santoroauthor=V.+Defranciscisauthor=L.+Quadroauthor=L.+Panarielloauthor=V.+Colantuoniauthor=A.+Fusco&title=Point+Mutation+of+the+Ret+Protooncogene+in+the+Tt+Human+Medullary-Thyroid+Carcinoma+Cell-Line&doi=10.1006%2Fbbrc.1995.1287"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1995.1287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1995.1287%26sid%3Dliteratum%253Aachs%26aulast%3DCarlomagno%26aufirst%3DF.%26aulast%3DSalvatore%26aufirst%3DD.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DDefranciscis%26aufirst%3DV.%26aulast%3DQuadro%26aufirst%3DL.%26aulast%3DPanariello%26aufirst%3DL.%26aulast%3DColantuoni%26aufirst%3DV.%26aulast%3DFusco%26aufirst%3DA.%26atitle%3DPoint%2520Mutation%2520of%2520the%2520Ret%2520Protooncogene%2520in%2520the%2520Tt%2520Human%2520Medullary-Thyroid%2520Carcinoma%2520Cell-Line%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D207%26spage%3D1022%26epage%3D1028%26doi%3D10.1006%2Fbbrc.1995.1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licitra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medvedev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreissl, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3639</span><span class="NLM_x">–</span> <span class="NLM_lpage">3946</span><span class="refDoi"> DOI: 10.1200/JCO.2012.48.4659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3946&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+Mullerauthor=P.+Schoffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0ljISs5fbczy6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DMuller%26aufirst%3DS.%2BP.%26aulast%3DSchoffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3946%26doi%3D10.1200%2FJCO.2012.48.4659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hayashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimono, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakumo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakao, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span> </span><span class="NLM_article-title">Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4469</span><span class="NLM_x">–</span> <span class="NLM_lpage">4475</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1038%2Fsj.onc.1203799" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=4469-4475&author=H.+Hayashiauthor=M.+Ichiharaauthor=T.+Iwashitaauthor=H.+Murakamiauthor=Y.+Shimonoauthor=K.+Kawaiauthor=K.+Kurokawaauthor=Y.+Murakumoauthor=T.+Imaiauthor=H.+Funahashiauthor=A.+Nakaoauthor=M.+Takahashi&title=Characterization+of+intracellular+signals+via+tyrosine+1062+in+RET+activated+by+glial+cell+line-derived+neurotrophic+factor&doi=10.1038%2Fsj.onc.1203799"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203799%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DH.%26aulast%3DIchihara%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DShimono%26aufirst%3DY.%26aulast%3DKawai%26aufirst%3DK.%26aulast%3DKurokawa%26aufirst%3DK.%26aulast%3DMurakumo%26aufirst%3DY.%26aulast%3DImai%26aufirst%3DT.%26aulast%3DFunahashi%26aufirst%3DH.%26aulast%3DNakao%26aufirst%3DA.%26aulast%3DTakahashi%26aufirst%3DM.%26atitle%3DCharacterization%2520of%2520intracellular%2520signals%2520via%2520tyrosine%25201062%2520in%2520RET%2520activated%2520by%2520glial%2520cell%2520line-derived%2520neurotrophic%2520factor%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D4469%26epage%3D4475%26doi%3D10.1038%2Fsj.onc.1203799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Iwashita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurokawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyauchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span> </span><span class="NLM_article-title">A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">804</span><span class="NLM_x">–</span> <span class="NLM_lpage">808</span><span class="refDoi"> DOI: 10.1006/bbrc.2000.2227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1006%2Fbbrc.2000.2227" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2000&pages=804-808&author=T.+Iwashitaauthor=H.+Murakamiauthor=K.+Kurokawaauthor=K.+Kawaiauthor=A.+Miyauchiauthor=H.+Futamiauthor=S.+Qiaoauthor=M.+Ichiharaauthor=M.+Takahashi&title=A+two-hit+model+for+development+of+multiple+endocrine+neoplasia+type+2B+by+RET+mutations&doi=10.1006%2Fbbrc.2000.2227"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.2000.2227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.2000.2227%26sid%3Dliteratum%253Aachs%26aulast%3DIwashita%26aufirst%3DT.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DKurokawa%26aufirst%3DK.%26aulast%3DKawai%26aufirst%3DK.%26aulast%3DMiyauchi%26aufirst%3DA.%26aulast%3DFutami%26aufirst%3DH.%26aulast%3DQiao%26aufirst%3DS.%26aulast%3DIchihara%26aufirst%3DM.%26aulast%3DTakahashi%26aufirst%3DM.%26atitle%3DA%2520two-hit%2520model%2520for%2520development%2520of%2520multiple%2520endocrine%2520neoplasia%2520type%25202B%2520by%2520RET%2520mutations%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2000%26volume%3D268%26spage%3D804%26epage%3D808%26doi%3D10.1006%2Fbbrc.2000.2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Segouffin-Cariou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billaud, M.</span><span> </span><span class="NLM_article-title">Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">3568</span><span class="NLM_x">–</span> <span class="NLM_lpage">3576</span><span class="refDoi"> DOI: 10.1074/jbc.275.5.3568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1074%2Fjbc.275.5.3568" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=3568-3576&author=C.+Segouffin-Cariouauthor=M.+Billaud&title=Transforming+ability+of+MEN2A-RET+requires+activation+of+the+phosphatidylinositol+3-kinase%2FAKT+signaling+pathway&doi=10.1074%2Fjbc.275.5.3568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23c&amp;dbid=16384&amp;doi=10.1074%2Fjbc.275.5.3568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.275.5.3568%26sid%3Dliteratum%253Aachs%26aulast%3DSegouffin-Cariou%26aufirst%3DC.%26aulast%3DBillaud%26aufirst%3DM.%26atitle%3DTransforming%2520ability%2520of%2520MEN2A-RET%2520requires%2520activation%2520of%2520the%2520phosphatidylinositol%25203-kinase%252FAKT%2520signaling%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D3568%26epage%3D3576%26doi%3D10.1074%2Fjbc.275.5.3568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Boulay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breuleux, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brisken, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiche, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wartmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, N. E.</span><span> </span><span class="NLM_article-title">The Ret receptor tyrosine kinase pathway functionally interacts with the ER alpha pathway in breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3743</span><span class="NLM_x">–</span> <span class="NLM_lpage">3751</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-5100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1158%2F0008-5472.CAN-07-5100" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3743-3751&author=A.+Boulayauthor=M.+Breuleuxauthor=C.+Stephanauthor=C.+Fuxauthor=C.+Briskenauthor=M.+Ficheauthor=M.+Wartmannauthor=M.+Stummauthor=H.+A.+Laneauthor=N.+E.+Hynes&title=The+Ret+receptor+tyrosine+kinase+pathway+functionally+interacts+with+the+ER+alpha+pathway+in+breast+cancer&doi=10.1158%2F0008-5472.CAN-07-5100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-5100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-5100%26sid%3Dliteratum%253Aachs%26aulast%3DBoulay%26aufirst%3DA.%26aulast%3DBreuleux%26aufirst%3DM.%26aulast%3DStephan%26aufirst%3DC.%26aulast%3DFux%26aufirst%3DC.%26aulast%3DBrisken%26aufirst%3DC.%26aulast%3DFiche%26aufirst%3DM.%26aulast%3DWartmann%26aufirst%3DM.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLane%26aufirst%3DH.%2BA.%26aulast%3DHynes%26aufirst%3DN.%2BE.%26atitle%3DThe%2520Ret%2520receptor%2520tyrosine%2520kinase%2520pathway%2520functionally%2520interacts%2520with%2520the%2520ER%2520alpha%2520pathway%2520in%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3743%26epage%3D3751%26doi%3D10.1158%2F0008-5472.CAN-07-5100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Knowles, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray-Rust, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kjaer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanrahan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibanez, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, N. Q.</span><span> </span><span class="NLM_article-title">Structure and chemical inhibition of the RET tyrosine kinase domain</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">33577</span><span class="NLM_x">–</span> <span class="NLM_lpage">33587</span><span class="refDoi"> DOI: 10.1074/jbc.M605604200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1074%2Fjbc.M605604200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=16928683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=33577-33587&author=P.+P.+Knowlesauthor=J.+Murray-Rustauthor=S.+Kjaerauthor=R.+P.+Scottauthor=S.+Hanrahanauthor=M.+Santoroauthor=C.+F.+Ibanezauthor=N.+Q.+McDonald&title=Structure+and+chemical+inhibition+of+the+RET+tyrosine+kinase+domain&doi=10.1074%2Fjbc.M605604200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain</span></div><div class="casAuthors">Knowles, Phillip P.; Murray-Rust, Judith; Kjaer, Svend; Scott, Rizaldy P.; Hanrahan, Sarah; Santoro, Massimo; Ibanez, Carlos F.; McDonald, Neil Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">33577-33587</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands.  Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.  We report here the biochem. characterization of the human RET tyrosine kinase domain and the structure detn. of the non-phosphorylated and phosphorylated forms.  Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status.  In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity.  Longer forms of RET contg. the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain.  Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity.  We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clin. relevant 4-anilinoquinazoline ZD6474.  These structures explain why certain multiple endocrine neoplasia 2-assocd. RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2p2bSJFNWxbVg90H21EOLACvtfcHk0lhvqCTWcNm-9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFegsb3K&md5=005ddc426f2c1a0a48bf7dc6c6083c88</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M605604200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M605604200%26sid%3Dliteratum%253Aachs%26aulast%3DKnowles%26aufirst%3DP.%2BP.%26aulast%3DMurray-Rust%26aufirst%3DJ.%26aulast%3DKjaer%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DR.%2BP.%26aulast%3DHanrahan%26aufirst%3DS.%26aulast%3DSantoro%26aufirst%3DM.%26aulast%3DIbanez%26aufirst%3DC.%2BF.%26aulast%3DMcDonald%26aufirst%3DN.%2BQ.%26atitle%3DStructure%2520and%2520chemical%2520inhibition%2520of%2520the%2520RET%2520tyrosine%2520kinase%2520domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D33577%26epage%3D33587%26doi%3D10.1074%2Fjbc.M605604200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=10.1158%2F0008-5472.CAN-08-4889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=19808973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+W.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+Tumor+Cell+Growth%2C+Invasion%2C+and+Metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+Novel+Inhibitor+of+HGF+and+VEGF+Receptor+Tyrosine+Kinases&doi=10.1158%2F0008-5472.CAN-08-4889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span></div><div class="casAuthors">Qian, Fawn; Engst, Stefan; Yamaguchi, Kyoko; Yu, Peiwen; Won, Kwang-Ai; Mock, Lillian; Lou, Tracy; Tan, Jenny; Li, Connie; Tam, Danny; Lougheed, Julie; Yakes, F. Michael; Bentzien, Frauke; Xu, Wei; Zaks, Tal; Wooster, Richard; Greshock, Joel; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8009-8016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies.  Vascular endothelial growth factor (VEGF) receptors are expressed on the surface of vascular endothelial cells and cooperate with Met to induce tumor invasion and vascularization.  EXEL-2880 (XL880, GSK1363089) is a small-mol. kinase inhibitor that targets members of the HGF and VEGF receptor tyrosine kinase families, with addnl. inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor β, and Tie-2.  Binding of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consistent with X-ray crystallog. data showing that the inhibitor is deeply bound in the Met kinase active site cleft.  EXEL-2880 inhibits cellular HGF-induced Met phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells.  In addn., EXEL-2880 prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions.  In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an exptl. model of lung metastasis.  Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoviVE_HZ5p_bVg90H21EOLACvtfcHk0lhvqCTWcNm-9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF&md5=f3bf5b432ee42b164d23b690828e3c78</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4889%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%2BW.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520Tumor%2520Cell%2520Growth%252C%2520Invasion%252C%2520and%2520Metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520Novel%2520Inhibitor%2520of%2520HGF%2520and%2520VEGF%2520Receptor%2520Tyrosine%2520Kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.CAN-08-4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2IVV','PDB','2IVV'); return false;">PDB: 2IVV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LQ8','PDB','3LQ8'); return false;">PDB: 3LQ8</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i62"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01522">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_61303"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01522">10.1021/acs.jmedchem.5b01522</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><i>In vitro</i> ADME and toxicity properties of <b>6i</b>; kinase selectivity profile of <b>6i</b>; inhibitory activity of <b>6i</b> against VEGFR2 Ba/F3 cell lines; inhibitory activity of <b>6i</b> against GDNF-induced phosphorylation of ERK1/2 in MCF-7 breast cancer cell lines; NMR spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01522/suppl_file/jm5b01522_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01522/suppl_file/jm5b01522_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01522/suppl_file/jm5b01522_si_001.pdf">jm5b01522_si_001.pdf (5.02 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01522/suppl_file/jm5b01522_si_002.csv">jm5b01522_si_002.csv (2.33 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01522&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01522%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-1%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01522" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679949891cf63cbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
